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ABSTRACT
The pocket proteins, through their interaction with the E2F transcription factors, ensure
the proper regulation of cell proliferation. By doing so, these protein complexes affect
other fundamental processes such as differentiation. Here we analyze the in vivo roles of
three proteins, pRb, E2F4, and p107, in murine embryonic development and in
differentiation in vitro. As Rb loss causes embryonic lethality due to placental defects,
we adopted a conditional knockout strategy to generate Rb-deficient embryos that survive
to birth. This approach allows us to assess a role for Rb in skeletal development. We
find that Rb-inactivation impairs the ossification of several bones. These bone defects
correlate with an inability of Rb-deficient osteoblasts to properly exit the cell cycle.
Similarly, we find that the mutation of E2f4 causes defects in embryonic ossification that
are accompanied by a significantly greater percentage of cycling cells compared to
controls. Overall, these findings indicate that both pRb and E2F4 are required in vivo for
proper cell cycle arrest of osteoblasts and, consequently, for the normal development of
bone. Furthermore, by expanding our analyses to in vitro studies, we show that Rb not
only regulates the cell cycle, but also the differentiation properties of the osteoblasts.
This correlates with a dramatic upregulation of pro-osteoblastic genes, including Bmp2,
Msx2, Runx2 and Osterix. By using the same strategy to conditionally delete Rb in
plO T0 embryos, we observe lethality at approximately e14.5 during development.
Analyzing embryos at e13.5, we find that the combined loss of pRb and p107 affects the
development of a variety of organs, including the central nervous system, limbs, blood
vessel endothelial cells, and heart. These data demonstrate novel, cooperative functions
for pRb and p107 in murine embryogenesis. Altogether, these studies provide evidence
of much broader and novel roles for pRb, p107, and E2F4 in the development and
differentiation of murine embryonic tissues.
Thesis Supervisor: Jacqueline A. Lees
Title: Professor of Biology
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Chapter 1
Introduction
Part 1: The Retinoblastoma Tumor Suppressor and Pocket Protein Family
A. Discovery of the retinoblastoma gene
The retinoblastoma gene was the first tumor suppressor to be cloned (Weinberg,
1992). Susceptibility to retinoblastoma was originally mapped to chromosome 13q14
through cytogenetic studies of retinoblastoma patients (Benedict et al., 1983; Dryja et al.,
1986; Sparkes et al., 1980). Subsequently, the human retinoblastoma gene, RB-1, was
cloned, and genetic alterations of RB-i were observed in retinoblastoma samples (Friend
et al., 1986; Fung et al., 1987; Lee et al., 1987). In addition, genetic mutations of RB-i
have been observed in many other tumor types, including osteosarcoma and small cell
lung carcinoma. Overall, the RB-i locus is estimated to be mutated or otherwise altered
in approximately one-third of all human tumors (Weinberg, 1992).
B. The retinoblastoma gene and cell cycle regulation
The initial finding that RB-1 is mutated in retinoblastoma and other tumor types
suggested a role for the retinoblastoma gene product, pRb, in cell cycle progression.
Subsequently, several reports demonstrated that pRb is a target of viral oncoproteins,
including adenovirus ElA, SV40 large T antigen, and the E7 protein of human
papillomaviruses (DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 1988).
Importantly, the interaction between the viral oncoproteins and pRb is required for
cellular transformation due to viral infection (Dyson et al., 1992; Ewen et al., 1989). In
addition, overexpression of pRb causes G1 arrest in cultured cells, while depletion of pRb
results in accelerated G1 progression (Herrera et al., 1996; Huang et al., 1988).
Together, these data strongly support a function for pRb in cell cycle regulation.
In accordance with a role in cell cycle control, the regulation of pRb follows a
specific cell cycle progression. Although pRb expression is relatively unchanged through
all phases of the cell cycle, its activity is governed via phosphorylation and
dephosphorylation events (Buchkovich et al., 1989; Trimarchi and Lees, 2002). In GO
and G1, pRb is hypophosphorylated. Mitogenic factors then cause the sequential
activation of two kinase complexes, Cdk4/6-cyclin D and Cdk2-cyclin E (Ewen et al.,
1993; Hatakeyama et al., 1994; Hinds et al., 1992; Kato et al., 1993; Lundberg and
Weinberg, 1998). These complexes phosphorylate pRb, which remains
hyperphosphorylated until mitosis, at which point pRb is dephosphorylated by protein
phosphatase 1 (Ludlow et al., 1993) and, under certain circumstances, protein
phosphatase 2A (Avni et al., 2003; Cicchillitti et al., 2003). In addition to the canonical
phosphorylation of pRb by the cyclin/Cdk complexes, recent work has found that ERK
and p38MAPK may also phosphorylate pRb (Garnovskaya et al., 2004; Nath et al., 2003;
Wang et al., 1999). However, these latter phosphorylation events may represent more
specialized functions of pRb, such as the release of E2F 1 to stimulate apoptosis (see Part
II).
The hypophosphorylated form of pRb correlates with its activated form. The
hypophosphorylated state of pRb has been shown to bind and inhibit the E2F family of
proteins, a group of transcription factors responsible for the induction of many Gl/S-
specific genes (Trimarchi and Lees, 2002). The phosphorylation of pRb due to mitogenic
signals causes the release of these E2Fs, thereby enabling G1/S cell cycle progression
(Buchkovich et al., 1989; Cooper and Shayman, 2001). With respect to the viral
oncoproteins, they bind to pRb and thereby disrupt the endogenous interactions of pRb
with E2F (Nevins, 1992). Such a disruption can easily account for the transformed nature
of the infected cells, as the free E2Fs are able to continuously induce cell cycle
progression uninhibited (E2F proteins will be described in more detail in Part II).
Recent studies have implicated roles for pRb in other aspects of the cell cycle
besides G1/S regulation. Senescence, the irreversible growth arrest induced by DNA
damage, cellular stress, or inappropriate gene expression, may require pRb. pRb is
typically in its active state in senescence, and forced expression of pRb can induce
senescence (Alexander and Hinds, 2001; Narita et al., 2003; Tiemann and Hinds, 1998;
Xu et al., 1997). pRb and heterochromatin-associated proteins are present at E2F
promoters in senescent but not quiescent cells (Narita et al., 2003). Finally, acute loss of
Rb (the murine retinoblastoma gene) in senescent cells is sufficient to allow re-entry into
the cell cycle (Sage et al., 2003).
pRb has also been implicated in the regulation of mitosis. pRb indirectly
mediates mitotic cyclin B degradation, suggesting a role in G2/M regulation (Lukas et al.,
1999). pRb-E2F can also regulate transcription of Mad2, a gene essential for proper
function of the mitotic spindle checkpoint (Hernando et al., 2004). In the absence of
pRb, it is implied that E2F1 and possibly other E2Fs induce transcription of Mad2,
resulting in aneuploidy and tumorigenesis in mice (Hernando et al., 2004; Sotillo et al.,
2007). Together, these studies suggest that pRb functions to regulate multiple aspects of
the cell cycle.
C. Mechanisms of cell cycle regulation
As discussed previously, the phosphorylation of pRb by the cyclin-Cdk
complexes in the GI and S phases of the cell cycle represent the canonical mechanism of
cell cycle regulation by pRb (Trimarchi and Lees, 2002). Hypophosphorylated pRb binds
to and inhibits the E2F transcriptional activators. The sequential activation of Cdk4/6-
cyclin D and Cdk2-cyclin E enables the phosphorylation of pRb, causing the release of
the E2F transcription factors and the subsequent induction of gene transcription required
for cell cycle progression through S phase.
In addition to inhibiting the "activating" E2Fs, pRb and the two related pocket
proteins (p107 and p130, discussed below) mediate cell cycle regulation by directly
repressing gene transcription through the "repressive" E2Fs (Trimarchi and Lees, 2002).
These pocket protein-E2F complexes recruit histone deacetylases (HDACs), resulting in
a restructuring of chromatin that represses transcription (Brehm et al., 1998; Luo et al.,
1998; Magnaghi-Jaulin et al., 1998). Furthermore, these complexes have been observed
at the promoters of the genes they repress, as demonstrated by chromatin
immunoprecipitation (Ferreira et al., 2001; Morrison et al., 2002; Rayman et al., 2002;
Takahashi et al., 2000). These complexes are typically observed during GO/G1 and
dissociate from E2F-promoter sites in late GI upon pocket protein phosphorylation
(Rayman et al., 2002; Takahashi et al., 2000; Taubert et al., 2004). Together, these data
suggest a model whereby pRb and the other pocket proteins bind to E2Fs in GO/G1 to
repress transcription and maintain a GO/GI state.
In addition to the E2Fs, pRb-mediated repression of transcription also occurs
through the recruitment of other proteins. For example, RBP1 binds to pRb and can
recruit HDACs to mediate transcriptional repression during growth arrest (Fattaey et al.,
1993; Lai et al., 1999a,b; Lai et al., 2001). A second related protein, RBP2, binds to pRb
and mediates repression via demethylation of a histone methylation site associated with
transcriptional activation (Christensen et al., 2007; Fattaey et al., 1993; Kim et al., 1994;
Klose et al., 2007). Conversely, other histone methylation sites are associated with
transcriptional repression. Through this mechanism, pRb can bind to SUV39H1, a
methyltransferase, at the cyclin E promoter and repress transcription (Nielsen et al.,
2001). Jumonji, which has structural homology to RBP2, interacts with pRb and
potentiates pRb-E2F regulation of the cell cycle through an unknown mechanism (Jung et
al., 2005; Takeuchi et al., 1995). JMJD2A, another protein similar to Jumonji and RBP2,
interacts with both pRb and HDACs and mediates pRb repression of cell cycle genes
(Gray et al., 2005). Overall, greater than 100 proteins have been reported to interact with
pRb, many of which directly or indirectly mediate pRb-associated transcriptional
repression (Frolov and Dyson, 2004; Morris and Dyson, 2001).
More generally, pRb may also affect transcription via nucleosome sliding and
assembly. pRb associates with Brahma (Brm) and Brm-related gene (BRG1),
components of the human SWI/SNF complex (Dunaief et al., 1994; Strober et al., 1996).
Through these associations, pRb is fully able to repress many E2F-responsive genes.
With respect to cyclin A, pRb and Brm are both required to properly mediate cyclin A
repression following serum starvation, and the repression is associated with Brm-
mediated nucleosome remodeling (Coisy et al., 2004; Philips et al., 1998). However,
since a physical association between pRb and Brm at the cyclin A locus has not been
demonstrated, the functional linkage between gene repression via nucleosome remodeling
and direct binding between pRb and Brm/BRG1 remains to be elucidated.
D. The role of pRb in differentiation and development
The first indication that pRb is involved in differentiation and development
originated from the phenotypes in the Rb - mouse. Rb - embryos die between embryonic
day (e) 13 and 15 with pronounced defects in erythroid, neuronal, and lens development
(Clarke et al, 1992; Jacks et al, 1992; Lee et al, 1992). These defects include abnormal
erythropoietic differentiation and ectopic proliferation and abnormal apoptosis in the
other affected tissues. Later studies demonstrated that the mid-gestational lethality is due
to reduced nutrient and gas exchange stemming from improper placental development,
and the presence of a wild-type placenta enables the Rb-deficient embryo to survive until
birth (de Bruin et al., 2003; Wu et al., 2003). Likewise, some of the apoptotic defects
have been determined to be cell non-autonomous phenotypes cause by the improper gas
and nutrient exchange (Lipinski et al., 2001; Maandag et al., 1994; MacPherson et al.,
2003; Williams et al., 1994b). However, the observed ectopic proliferation in the
aforementioned Rb-deficient cell types is a cell autonomous defect. These initial in vivo
studies implicate pRb as an important protein in differentiation and development.
The function of pRb in the differentiation of several cell types has been studied
more extensively since the generation and original publication of the germline Rb- mice.
The role of pRb in erythrocyte differentiation is one example. The original Rb - germline
knockout embryos display defects in erythrocyte development, such as abnormal nuclear
structure and incomplete enucleation. Subsequent studies indicate that this defect may
have been cell non-autonomous. For example, in Rb-depleted embryos with wild-type
placentas, it is reported that erythropoiesis is completely or almost completely normal (de
Bruin et al., 2003; Wu et al., 2003). Furthermore, Rb -/ - chimeric animals exhibit normal
red blood cells, including those that are Rb - (Maandag et al., 1994; Williams et al.,
1994b). However, the chimeric studies were performed primarily in adult mice. During
embryogenesis, at el 5.5 and el 6.5, a slight increase in nucleated red blood cells is
observed in Rb / chimeras, a phenotype that is no longer observed by e17.5 (Maandag et
al., 1994). Recent studies have expanded on this finding. Using an in vitro erythroid
differentiation culture system whereby erythrocyte progenitors are isolated from fetal
livers, acute deletion of pRb causes defects in cell cycle exit and terminal differentiation
(Clark et al., 2004; Spike et al., 2004). Furthermore, under stress conditions such as
drug-induced anemia, pRb is required to properly expand erythrocytes and promote
enucleation (Spike et al., 2004). These in vitro and in vivo studies clearly implicate a cell
autonomous role for pRb in erythrocyte differentiation.
In the lens, Rb - germline embryos display ectopic cell cycles and apoptosis.
Placental rescue experiments demonstrate that these defects are cell autonomous.
Furthermore, analysis of lens-specific genes indicates that late markers, such as filensin
and y-crystallin, are markedly decreased in the Rb - lens compared to the wild-type lens
(Liu and Zacksenhaus, 2000; Morgenbesser et al., 1994). Although the cause of the
impaired expression of late lens markers is not known, recent experiments suggest that
the defect is unrelated to the cell cycle exit defects of the cells in the Rb - lens (Liu and
Zacksenhaus, 2000).
Transgenic mice expressing low levels of Rb reveal a role for pRb in skeletal
muscle differentiation (Zacksenhaus et al., 1996). These embryos die at birth with
specific skeletal muscle defects, including increased apoptosis, increased numbers of
elongated nuclei that actively synthesize DNA, reduced muscle fibers, and reduced
expression of late muscle-specific genes. Placental rescue of Rb - embryos confirms
these in vivo findings (de Bruin et al., 2003; Wu et al., 2003). Furthermore, in vitro
studies corroborate the initial finding that the loss of pRb causes decreased expression of
late myogenic markers (Huh et al., 2004; Li et al., 2000; Novitch et al., 1996). Initial in
vitro experiments indicated that the inability of Rb / myocytes to properly differentiate
was due to a physical interaction between pRb and the muscle-specific transcription
factor MyoD that augmented the activity of MyoD (Gu et al., 1993). However, this
physical interaction has yet to be demonstrated in vivo (Li et al., 2000). Instead, the
defects in Rb- skeletal muscle differentiation appear to be due to the deregulation of the
cell cycle (Huh et al., 2004; Li et al., 2000; Zhang et al., 1999). Most recently,
conditional deletions of Rb in skeletal muscle cells in vivo and in vitro demonstrate that
pRb is required for proper cell cycle exit and the initiation of differentiation (Huh et al.,
2004). Moreover, without pRb myocytes do not downregulate early markers of
differentiation and hence fail to induce late stage, muscle-specific genes.
pRb is also important for the differentiation of several epithelial cell types. In the
intestinal epithelium, conditional loss of pRb causes a failure to exit the cell cycle in
several specific cell types within the intestine (Haigis et al., 2006; Yang and Hinds,
2007). These defects are accompanied by an increase in the expression of several genes
known to positively regulate cellular proliferation of the intestinal epithelium. In the
epidermis of the skin, conditional deletion of Rb causes increased proliferation and
aberrant expression of differentiation markers (Ruiz et al., 2004). Finally, lung epithelial
cells display increased proliferation upon lung-specific knockout of Rb (Wikenheiser-
Brokamp, 2004). The loss of pRb in the lung epithelium affects only the neuroendocrine
lineage, as the differentiation of other lung epithelial cell types, such as Clara cells and
ciliated cells, remain unchanged. Although it appears that the cell cycle regulatory role
of pRb is responsible for the lung neuroendocrine defect, as is the case for the
differentiation defects in the aforementioned epithelial tissues, more experiments are
required to determine the mechanistic origin of the lung defect.
pRb may also function in the maintenance of stem cell populations. As indicated
previously, Rb-null embryos have defective placentas that affect the survival of the
embryo (de Bruin et al., 2003; Wu et al., 2003). More recently it has been shown that the
loss of pRb in the placenta alone and not in the embryo proper results in embryonic
lethality by e15.5 (Wenzel et al., 2007). More specifically, Rb deletion in trophoblast
stem cells of the placenta causes an overexpansion of trophoblast cells, an increase in the
distribution of trophoblast markers, and a consequential disruption of placental
architecture (Wenzel et al., 2007; Wu et al., 2003). From these studies the authors
conclude that pRb plays a critical role in the maintenance of a mammalian stem cell
population. In support of such a conclusion, another group has demonstrated that pRb is
activated upon the differentiation of embryonic stem cells (White et al., 2005). Finally,
reduced expression of the pRb-related gene in Arabidopsis causes ectopic layers of stem
cells without affecting other mitotically dividing cells (Wildwater et al., 2005).
Conversely, overexpression of the pRb-related gene decreases the number of stem cells.
In fact, alterations to other members of the canonical pRb-E2F pathway similarly affect
the stem cells in the Arabidopsis plant. Together, these studies implicate pRb in the
regulation of stem cell populations.
The function of pRb in the differentiation of the various cell types above is, for
the most part, related to the role of pRb in cell cycle control and exit. However, studies
in other cell types have suggested cell cycle-independent roles of pRb in differentiation.
The best and most extensively studied example of this is the role of pRb in adipocyte
differentiation. pRb physically interacts with members of the CCAAT/enhancer-binding
protein (C/EBP) family, which are required for adipocyte differentiation. (Tanaka et al.,
1997). Moreover, pRb enhances the transcriptional activity of C/EBP[3 (Chen et al.,
1996). Finally, Rb - MEFs are unable to differentiate into adipocytes using the standard
adipogenic reagents for wild-type MEFs (Chen et al., 1996). Therefore, the inability of
Rb - MEFs to differentiate in vitro is believed to be due to their inability to adequately
activate the C/EBP adipocyte transcription factors. It was later found that the block in
differentiation due to the loss of pRb can be bypassed via the addition of a PPARy ligand
(Hansen et al., 1999). PPARy is an essential transcription factor for adipogenesis that is
induced by upstream adipogenic transcription factors such as C/EBP. One explanation
for this is that MEFs in culture express a PPARy isoform that can begin a transcriptional
cascade to induce the adipocyte-specific PPARy isoform (Hansen et al., 1999). Another
possibility is related to the finding that E2F1 transcribes PPARy during clonal expansion
(Fajas et al., 2002b). Therefore, in an Rb - setting, E2F1 may be uninhibited and can
upregulate PPARy. Hence, upon the addition of PPARy ligand, the block in adipocyte
differentiation is bypassed. Complicating matters, however, is the observation that pRb
can interact with HDAC3 and PPARy to repress the activity of PPARy (Fajas et al.,
2002a). Together, these data paint a complicated picture of the role of pRb in adipocyte
differentiation in vitro. On one hand, pRb promotes differentiation via C/EBP proteins,
while on the other hand, pRb represses PPARy transcription (via E2F 1 inhibition) and
activity. An explanation for this is that pRb may function to ultimately limit PPARy
activity in order to prevent uncontrolled adipocyte proliferation and differentiation. It is
unknown at this time the culture conditions that will allow the repressive function of pRb
on PPARy to prevail over the differentiation promoting activity of pRb on C/EBP in
wild-type MEFs. Regardless, these data implicate a cell cycle-independent function for
pRb in adipocyte differentiation in vitro.
Moreover, pRb has been implicated in the regulation of white versus brown fat
differentiation. In embryonic and neonatal mice, pRb is found in white adipocyte
precursors and not in brown fat precursors (Hansen et al., 2004). In adults, pRb is
observed to be hyperphosphorylated in brown fat after cold exposure, while pRb in white
fat remains unchanged (Hansen et al., 2004). In vitro, Rb - MEFs treated with PPARy
ligand differentiate into adipocytes, but they express markers of brown fat at levels
similar to that observed in brown adipose tissue taken from an adult mouse (Hansen et
al., 2004). Acute ablation of pRb in cultured, primary pre-adipocytes results in a similar
upregulation of brown fat-specific markers (Scime et al., 2005). Finally, mice expressing
large T antigen in adipocytes develop hibernomas (brown fat tumors) and display
conversion of white fat into brown fat (Ross et al., 1992). However, in this last example
it is unclear whether the phenotypes are due to the T antigen-mediated inactivation of
pRb or of p53, p300, CBP, or the other pocket proteins. Nevertheless, together these data
strongly implicate a role for pRb in the regulation of white versus brown adipocyte
differentiation.
A cell cycle-independent role for pRb in the differentiation pathway of several
other cell types has been suggested. In osteoblast differentiation in vitro, pRb physically
interacts with one of the essential transcription factors for osteogenic differentiation,
Runx2/CBFAl (Thomas et al., 2001). In addition, pRb associates with the promoter of
Runx2 target genes and acts as a transcriptional coactivator for Runx2 in vitro. Finally,
unlike wild-type MEFs, upon treatment with BMP2 Rb - MEFs do not differentiate or
secrete a mineralized matrix. In cultured neuronal cells, pRb binds to NRP/B, a protein
upregulated during neuronal differentiation and involved in neuronal process formation
(Kim et al., 1998). Furthermore, depletion of NRP/B decreases neuronal process
formation while overexpression facilitates differentiation in vitro. Relevant to this, other
markers of neuronal differentiation are decreased in the Rb-deficient embryos (Lee et al.,
1994). pRb may also function in cardiac development. When induced to differentiate in
culture, Rb - embryonic stem cells exhibit a significant delay in the expression of cardiac-
specific markers and terminal differentiation (Papadimou et al., 2005). Knockdown of
another gene, LEK], phenocopied the Rb - embryonic stem cell differentiation delay.
LEK1 is expressed in embryonic hearts and binds to pRb (Ashe et al., 2004; Goodwin et
al., 1999; Papadimou et al., 2005). However, a definitive and specific role for LEK1 in
heart development in vivo has yet to be demonstrated, and whether loss of pRb induces
cell cycle defects during cardiac differentiation has not been adequately ruled out.
Nevertheless, as with osteoblast and neuronal differentiation, these data suggest a cell
cycle-independent function for pRb in the differentiation of cardiomyocytes in vitro. It is
of interest to determine whether these differentiation-specific functions for pRb in vitro
are also observed and physiologically relevant during in vivo development.
E. The retinoblastoma gene in murine tumor formation and development
Unlike humans, mice heterozygous for Rb do not develop retinoblastomas. Mice
possessing conditional deletions of Rb in the retina or Rb- chimeric animals also do not
develop retinoblastomas (MacPherson et al., 2004; Robanus-Maandag et al., 1998;
Williams et al., 1994a). In a related manner, the Rb +' mice do not develop secondary
tumors such as osteosarcoma or small cell lung cancer as do humans carrying a mutation
in Rb. Instead, Rb' - mice and Rb- chimeric mice die within one year of age and are
predisposed to pituitary adenocarcinomas and C-cell-derived medullary thyroid tumors
with nearly 100% and 70% penetrance, respectively (Hu et al., 1994; Jacks et al., 1992;
Robanus-Maandag et al., 1998; Williams et al., 1994a,b).
Due to the high penetrance and lethality of pituitary and thyroid tumors in Rb +'
mice, it is difficult to ascertain whether the loss of pRb would lead to the development of
other tumor types commonly observed in humans with RB-1 loss. However, the use of
conditional deletions of Rb has facilitated the study of such tumors in the mouse. For
example, up to 60% of patients with prostate cancer exhibit loss of heterozygosity (LOH)
at RB-1. To analyze the effect of Rb loss in mice, Maddison et al. (2004) conditionally
deleted Rb in the prostate. By 52 weeks of age, the mice present a multifocal phenotype
closely resembling the clinical human disease. On the other hand, the use of Villin-Cre
in Rb conditional mice suggests that the loss of Rb alone is not sufficient to induce
tumorigenesis in the gastrointestinal tract or kidney of the mouse (Kucherlapati et al.,
2006).
Another method to facilitate the study of Rb loss in tumorigenesis is to introduce
another mutation into the Rb +- or Rb conditional mice. For example, several studies have
analyzed the effects of Rb loss in combination with deletions of the other pocket proteins
(discussed below). Others have analyzed the tumorigenic effects of the combined loss of
Rb and p53. Although 41% of Rb+-; p53- mice display retinal dysplasia, none develop
retinoblastoma. However, these mice do exhibit novel tumor types that are not observed
in either of the single mutant mouse models, such as islet cell carcinoma and
pinealblastoma (Harvey et al., 1995; Williams et al., 1994b). Conditional mouse models
of these genes have allowed for the study of other tumor types. For example, mutations
in RB-1 and p53 are frequently observed in human epithelial ovarian cancer. By
conditionally deleting Rb and p53 in the ovaries of mice, Flesken-Nikitin et al. (2003)
have created a mouse model for this tumor type that exhibits metastatic neoplasms
reminiscent of the human disease. Conditional deletion of Rb and p53 in the lungs of
mice cause the formation of lung tumors that are morphologically and
immunophenotypically similar to human small cell lung cancer (Meuwissen et al., 2003).
The use of Rb conditional mouse models for other tumor types will provide insight into
the oncogenic development and progression of the related human diseases.
F. The p107 and p130 pocket proteins and their cell cycle functions
The pocket protein family consists of pRb, p107, and p130. All three members
were originally discovered as targets bound to viral oncoproteins (Harlow et al., 1986;
Whyte et al., 1989). p107 and p130 are structurally similar to pRb, although they share
more homology to each other than they do to pRb (Ewen et al., 1991; Hannon et al.,
1993; Li et al., 1993). Also, the expression pattern of p107 or p130 is different than that
of pRb. While pRb is expressed throughout the cell cycle, p130 is most highly expressed
in GO/quiescent cells and p107 reaches its greatest expression during G1/S (Baldi et al.,
1995; Beijersbergen et al., 1995; Chen et al., 1989).
p107 and p130 possess roles in cell cycle control, similar to pRb. Upon
overexpression, p107 and p130 can induce G1 arrest in certain cell types (Classon and
Harlow, 2002). Additionally, they can interact with E2F family members and repress
transcription. Finally, they are phosphorylated by cyclin-dependent kinase complexes.
However, there are also significant differences between p107, p13 0 , and pRb. pRb is the
primary binding partner for the "activating" E2Fs, E2F1, E2F2, and E2F3 (discussed in
Part II). On the other hand, p107 and p130 bind to the "repressive" E2Fs, E2F4 and
E2F5. In accordance with this, p107 and p130 associate with HDAC1 at E2F-responsive
promoters in GO and GI (Ferreira et al., 1998; Rayman et al., 2002), and the loss of both
p 107 and p130 induces the expression of genes not observed upon the loss of pRb alone
(Herrera et al., 1996; Hurford et al., 1997). Additionally, p107 and p130 can inhibit CDK
function (Dynlacht et al., 1997; Zhu et al., 1995). Therefore, although p107 and p130
regulate the cell cycle along with pRb, these two pocket proteins do so predominantly
through direct repression of gene transcription and direct inhibition of CDKs in GO and
G1/S.
Although the pocket proteins possess distinct roles during cell cycle regulation, it
is apparent that they may also have overlapping functions and, furthermore, can
compensate for each other. Rb- - MEFs possess a shortened Gl phase of the cell cycle, a
phenotype that is exacerbated upon the additional deletion of p107 or p130 (Classon et
al., 2000; Dannenberg et al., 2000). Moreover, cells devoid of all three pocket proteins
do not respond to growth arrest signals (Dannenberg et al., 2000; Sage et al., 2000).
Compensation may account for the appearance of these stronger phenotypes in the
compound mutants, as levels of p107, for example, are upregulated in Rb- or p30 - cells
(Hurford et al., 1997; Mulligan et al., 1998; Sage et al., 2003). Similarly, in p130- T
lymphocytes, the typical p130-E2F protein complexes are replaced by p107-E2F
complexes (Mulligan et al., 1998). Lastly, acute depletion of pRb in GO/quiescent MEFs
induces cell cycle re-entry due to the delayed upregulation of p107 (Sage et al., 2003).
Functional compensation has also been implicated in vivo. The combinatorial deletion of
Rb and p107 causes embryonic death at el 1.5 and accelerated apoptosis in tissues,
including those of the central nervous system, indicating that pRb and p107 possess
overlapping functions and may compensate for each other in vivo (Lee et al., 1996).
G. The roles of p107 and p130 in differentiation, development, and tumorigenesis
Germline mutant mice ofpl07 and p130 have been generated using different
strain backgrounds leading to unique findings. On a C57B1/6 or 129/Sv background,
p107/ - and p]30-/- mice have no overt phenotypes (Cobrinik et al., 1996; Lee et al.,
1996). Loss ofpl07 or p130 on a Balb/c genetic background, though, causes more
severe phenotypes. p130 - Balb/c embryos do not survive past el3, displaying defects in
neurons, myocytes, and the myocardium (LeCouter et al., 1998a). p107T mice live past
birth, but they develop myeloid hyperproliferation and are growth retarded (LeCouter et
al., 1998b). In addition, these mice have defects in adipocyte development, and 70% die
by three weeks of age (Scime et al., 2005). Interestingly, upon one backcross to C57B1/6
mice, the p]07- animals display a wild-type phenotype (LeCouter et al., 1998b). These
analyses indicate that strain-specific effects and modifier elements affect the phenotypic
consequences upon loss of pocket protein genes.
Although p]07- and p]30/ mice on a C57B1/6 background do not develop any
abnormal phenotypes, the analysis of compound mutant mice has uncovered
compensatory and novel developmental defects and functions for these genes. For
example, Rb+-; p07-/ animals are not born at expected Mendelian frequencies, are
growth retarded, and develop vaginal atresia (Lee et al., 1996). Moreover, the loss of
p107 amplifies the epithelial differentiation defects in mice with Rb conditionally deleted
in the intestine (Haigis et al., 2006). Similarly, deletion ofpl07 exacerbates the
epidermal hyperplasia, hyperkeratosis, and abnormal differentiation of mice with skin-
specific deletions of Rb (Ruiz et al., 2004). p]07T; p130- double mutant mice also
display defects in epidermal differentiation (Ruiz et al., 2003). Another phenotype
observed in the p]07T-; p130- mutant mice is a defect in long bone development. This
defect is due to an inability of chondrocytes to exit the cell cycle, induce Runx2
expression, and terminally differentiate (Cobrinik et al., 1996; Laplantine et al., 2002;
Rossi et al., 2002). MEFs isolated from p10T7-; p130- embryos display an increased
potential to differentiate into adipocytes in culture, a phenomenon that occurs upon
deletion of either pocket protein alone in 3T3 cells (Landsberg et al., 2003; Classon et al.,
2000). However, the knockdown of p107 in the adipocyte cell line, 3T3-L1, inhibits
adipocyte differentiation (May et al., 2001), a phenotype in agreement with the defective
differentiation of fat in the p]07- mice described above (Scime et al., 2005). In the
heart, deletion of pl30 in combination with a cardiomyocyte-specific deletion of Rb
causes an increase in adult heart size and an inability of cardiomyocytes to maintain a
quiescent state (MacLellan et al., 2005). Finally, conditional ablation of all three pocket
proteins in the lung blocks epithelial differentiation of Clara and ciliated cells, increases
neuroendocrine cell number, and ultimately causes lethality by three weeks of age
(Wikenheiser-Brokamp, 2004). Hence, the analyses of mutant mice deleted for multiple
pocket protein genes have uncovered complementary and novel functions in development
and differentiation for these genes.
One important difference among the pocket proteins is that only pRb is a bona
fide tumor suppressor. In humans, there is some evidence ofpl30 alteration in various
tumors (Baldi et al., 1997; Claudio et al., 2000a,b; Helin et al., 1997). However, it is not
known whether RB-1 or other pathway members are functional in those tumors or
whether the mutated p130 facilitates the tumor development. In mice, germline deletion
of either p107 or pl30 does not cause tumorigenesis, suggesting that these genes do not
act as tumor suppressors. However, there is data from conditional and chimeric mouse
models implicating a compensatory role for p107 and p130 in tumor formation. In
conditional Rb mutant mice, where pRb is deleted in the retina in a mosaic fashion, the
additional loss ofpl107 or p130 causes retinoblastoma formation (MacPherson et al.,
2004). Mice chimeric for mutations in Rb and either pl07 or pl30 (Rb-; p07O ' or Rb /-;
p107' or Rb '; p130- ) also develop retinoblastoma (Dannenberg et al., 2004; Robanus-
Maandag et al., 1998). Moreover, the Rb -; p107- and Rb -; p130/ chimeric mice
develop other novel tumor types not observed in Rb ' germline mutants, including
osteosarcoma, ovarian cancer, and lung tumors (Dannenberg et al., 2004). These data
suggest that the pocket proteins act in a compensatory manner to suppress tumorigenesis
in mice, similar to their compensatory function in cell cycle regulation and
differentiation. Further analysis of combinatorial pocket protein mutants in mice will
enable a better understanding of the overlapping and compensatory nature of Rb, p107,
and pl30 in tumorigenesis.
Part II: The E2F Transcription Factor Family
A. Discovery of E2F
The E2F transcription factor was first identified through studies of the oncogenic
adenovirus. Upon adenovirus infection, EIA is initially transcribed. E1A, in turn,
enables the induction of several other viral transcripts, including E2. The transcriptional
activation of E2 is achieved through the recruitment by E1A of a cellular activity termed
the E2 promoter-binding factor, or E2F (Kovesdi et al., 1986). This E2 transcription is
dependent upon a particular E2F DNA recognition sequence, 5'-TTTCGCGC-3', in the
promoter region of E2 (Kovesdi et al., 1987; Yee et al., 1987). Other studies
demonstrated that E1A causes a cellular protein to dissociate from E2F (reviewed in
Trimarchi and Lees, 2002). This led to the finding that E2F is bound to and inhibited by
pRb, a known E1A interacting protein. Therefore, E1A functions by titrating pRb away
from E2F, thereby releasing E2F and enabling it to transcribe E2. E2F promoter binding
sites have since been identified in many endogenous genes related to cell cycle
regulation, nucleotide metabolism, and DNA replication, indicating an important role for
E2F-mediated transcription in cell cycle progression.
Coincident with the characterization of E2F, a protein termed differentiation-
regulated transcription factor 1 (DRTF1) was identified in murine F9 embryonal
carcinoma cells (La Thangue and Rigby, 1987; La Thangue et al., 1990). DRTF1 activity
is downregulated upon stimulation of F9 cells to differentiate. Subsequent work showed
that DRTF 1 interacts with pRb and binds to the same DNA promoter sequence as E2F
(Bandara and La Thangue, 1991; La Thangue and Rigby, 1987), indicating that DRTF1
and E2F are the same factor.
Affinity purification of DRTF 1 led to the discovery of DRTF protein 1, or DP 1
(Girling et al., 1993). A related DP protein, DP2, was identified later (Ormondroyd et al.,
1995; Rogers et al., 1996; Wu et al., 1995; Zhang and Chellappan, 1995). One DP
protein and one E2F/DRTF factor (hereto designated as E2F) heterodimerize, and all
combinations of E2F (with the exception of E2F7 and E2F8) and DP dimer have been
observed in vivo (Bandara et al., 1993; Helin et al., 1993; Krek et al., 1993; Trimarchi et
al., 1998; Wu et al., 1995). Moreover, the amino acids within the E2F and DP proteins
that contact the E2F promoter-binding sequence are perfectly conserved. Nevertheless,
the E2F-DP heterodimer can induce different transcriptional and cellular responses
depending on the specific E2F protein in the complex (discussed below).
To date there are eight E2fgenes (E2fl through E2]8), and a ninth if a distinct
E2J3 gene product, E2J3b, is included. Functional differences have led to the division of
the E2F proteins into three groups. E2F 1 through E2F3 comprise the "activating" E2Fs;
E2F4, E2F5, and possibly E2F3b make up the "repressive" E2Fs; and E2F6 through
E2F8 are grouped as having similarity to the other E2Fs, but acting independently of
pocket protein regulation. The primary focus of the following sections will be on the
activating and repressing E2Fs, E2F1 through E2F5.
B. The activating E2Fs
i. Discovery and structure
The first E2F to be cloned, E2F 1, was isolated by virtue of its ability to bind pRb
(Helin et al., 1992; Kaelin et al., 1992; Shan et al., 1992). E2F1 binds DNA in a DP-
dependent manner, and the resulting heterodimer is a strong transcriptional activator of
E2F-responsive promoters (Bandara et al., 1993; Helin et al., 1993; Krek et al., 1993).
Subsequently, low-stringency library screening with an E2fl probe led to the discovery of
two additional E2F proteins, E2F2 and E2F3 (Ivey-Hoyle et al., 1993; Lees et al., 1993).
These two proteins are structurally similar to E2F 1, display similar DNA binding
characteristics, and are capable of strong transcriptional activation of E2F-responsive
promoters (DeGregori et al., 1997; Ivey-Hoyle et al., 1993; Lees et al., 1993; Lukas et al.,
1996).
The activating E2F proteins are structurally similar and possess distinct domains
for DNA binding, DP dimerization, and transactivation (Figure 1). The pocket protein
binding region is located within the transactivation domain near the C-terminus. These
domains are highly conserved, as the domain regions in E2F2 and E2F3 are between
45%-100% similar to the equivalent regions in E2F 1 (Lees et al., 1993). In addition, all
three activating E2Fs possess a conserved nuclear localization signal near the amino-
terminus (Muller et al., 1997; Verona et al., 1997).
ii. Cell cycle progression and activating E2F regulation
Functionally, the activating E2Fs have well characterized roles in promoting cell
cycle progression. Overexpression of any activating E2F will strongly activate
transcription of E2F-responsive genes, as mentioned previously. In addition,
overexpression is sufficient to induce quiescent cells to re-enter the cell cycle (Johnson et
al., 1993; Lukas et al., 1996; Qin et al., 1994), and in some instances overexpression can
override growth arrest signals (DeGregori et al., 1995; Mann and Jones, 1996; Schwarz et
al., 1995). Conversely, the absence of E2F3 in MEFs causes a delay in proliferation
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Figure 1. Schematic diagram of the activating and repressive E2F proteins
Structural comparison of E2Fs 1 through 5. All of the activating and repressive E2Fs
possess a DNA binding domain, a DP dimerization domain, and a transactivation domain.
The pocket protein binding domain is located within the transactivation domain. E2F 1,
E2F2, and E2F3a and b possess a nuclear localization signal (NLS). E2F4 and E2F5
possess nuclear export signals (NES).
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(Humbert et al., 2000b), and MEFs lacking all three activating E2Fs are blocked in
cellular progression (Wu et al., 2001). These experiments suggest that the activating
E2Fs function in cell cycle proliferation.
Expression and localization experiments have provided further evidence of a
positive role for the activating E2Fs in proliferation. These E2Fs are induced during
G1/S and downregulated during GO. When expressed, the activating E2Fs are localized
almost exclusively in the nucleus, most likely due to the presence of a nuclear
localization signal (Muller et al., 1997; Verona et al., 1997). More specifically, promoter
occupancy experiments have demonstrated that the activating E2Fs are localized and
bound to E2F-responsive genes during G1/S, and these associations correspond with the
transcriptional activation of these genes during Gl/S (Rayman et al., 2002; Takahaski et
al., 2000). Furthermore, transcription of the E2F-responsive genes requires a functional
transactivation domain in E2F and an unaltered E2F DNA consensus sequence within the
gene promoter (Hsiao et al., 1994; Lam and Watson, 1993). Therefore, the localization
and expression patterns of the activating E2Fs further support a role for these proteins in
the promotion of cell cycle progression.
Furthermore, the regulation of the activating E2Fs also corresponds to their
function in Gl/S progression. All E2Fs (except E2F6-8) are regulated predominantly via
interaction with the pocket proteins, although the activating E2Fs interact exclusively
with pRb in normal cells (Lees et al., 1993). The binding of pRb masks the E2F
transactivation domain and is, presumably, the principal method of transcriptional
inhibition of these E2Fs (Flemington et al., 1993; Helin et al., 1993; Hiebert et al., 1992;
Lee et al., 2002). The activating E2Fs are complexed with pRb until G1/S, at which point
mitogenic signals, for example, enable phosphorylation of pRb, triggering the release of
the E2Fs. Importantly, the overexpression of E2F results in similar phenotypic effects in
tissues or in tumors as observed upon loss of pRb. These data indicate that pRb is a
principal regulator of E2F activity and suggest a mechanism whereby the activating E2Fs
promote G1/S progression only upon appropriate mitogenic signaling.
It has been proposed that the activating E2Fs are also regulated by
phosphorylation and acetylation. The activating E2Fs possess a cyclin A binding domain
in the amino terminus (Devoto et al., 1992; Krek et al., 1994; Leone et al., 2000; Mudryj
et al., 1991; Pagano et al., 1992). Through this region, cyclin A/CDK complexes can
phosphorylate E2F1 in vitro (Adams and Kaelin, 1996; Peeper et al., 1995).
Additionally, cyclin A/CDK complexes can phosphorylate DP, resulting in loss of E2F
binding and transcription (Dynlacht et al., 1994; Krek et al., 1995; Xu et al., 1994).
However, the physiological relevance and function of phosphorylation with respect to
cell cycle regulation is unclear and remains to be elucidated.
In a similar fashion to phosphorylation, the activating E2Fs are capable of being
acetylated. P/CAF, likely with p300 and CBP, can acetylate E2F1 on lysines that are
conserved in E2F2 and E2F3 (Martinez-Balbas et al., 2000; Pediconi et al., 2003). The
association of E2F 1, and possibly E2F2 and E2F3, with P/CAF, p300, and CBP
stimulates transcription (Martinez-Balbas et al., 2000; Marzio et al., 2000; Trouche et al.,
1996) and therefore may play a role in E2F-mediated cell cycle regulation. Two recent
studies, though, demonstrate that E2F1 is acetylated and stabilized by these proteins in
response to DNA damage (Galbiati et al., 2005; lanari et al., 2004). Therefore,
acetylation may instead be important for regulating an E2F-mediated response to DNA
damage and apoptosis.
iii. The roles of the activating E2Fs in apoptosis and DNA damage response
The E2Fs, especially E2F 1, have a well-documented role in apoptosis.
Overexpression of E2F1 induces apoptosis along with proliferation (Kowalik et al., 1995;
Qin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994; Vigo et al., 1999).
Conversely, the loss of E2F1 causes defects in apoptosis (Field et al., 1996). In vivo, the
loss of E2F 1 suppresses apoptosis in Rb- animals, including in tissues exhibiting cell
autonomous apoptosis (Tsai et al., 1998). Some in vitro studies have shown that
apoptosis is a specific property of E2F1 (DeGregori et al., 1997; Kowalik et al., 1998;
Lissy et al., 2000). Related to this, microarray analysis of E2F -expressing cells, but not
E2F3-expressing cells, demonstrates an induction of apoptosis-related genes (Black et al.,
2005). Other studies have suggested that all of the activating E2Fs can promote
apoptosis upon overexpression (Moroni et al., 2001; Vigo et al., 1999). Furthermore,
E2F3 loss suppresses apoptosis in Rb - mice, similar to loss of E2F1 (Ziebold et al.,
2001). These data indicate that E2F1, and possibly E2F2 and E2F3, induce apoptosis.
The mechanism of E2F-induced apoptosis is complicated and has not been
completely elucidated. As E2F 1 has a definitive role in apoptosis, most studies have
focused on the role of this protein in programmed cell death. Overexpression of E2F 1 is
capable of inducing p53-dependent apoptosis (Hiebert et al., 1995; Phillips et al., 1997;
Qin et al., 1994; Wu and Levine, 1994). One mechanism of activating p53-dependent
apoptosis is through the induction ofArf an upstream regulator of p53. The activating
E2Fs associate with Arf and induce its transcription in response to oncogenic stress
(Aslanian et al., 2004; laquinta et al., 2005). However, disruption of Arf does not
modulate p53-dependent apoptosis in Rb- embryos (Tsai et al., 2002) or in the presence
of upregulated E2F activity (Tolbert et al., 2002). E2F1 has also been shown to induce
SirTI, which itself is capable of regulating p53, after DNA damage (Wang et al., 2006).
These data indicate that E2F1 may induce p53-dependent apoptosis through several
parallel pathways.
Alternatively, several experiments have suggested mechanisms of E2F 1-mediated
p53-independent apoptosis (Hsieh et al., 1997; Phillips et al., 1997). E2F1 induces
programmed cell death through the transcription ofp 73, a p53-related gene that also
mediates apoptosis (Lissy et al., 2000). In yet another manner, which is p53- and p73-
independent, E2F1 causes cells to undergo apoptosis through induction of the pro-
apoptotic gene Bim (Zhao et al., 2005). E2F1 can also directly upregulate Apaf- 1
(Moroni et al., 2001), whose product can activate the initiator caspase, Caspase-9. E2F1
can even induce the apoptotic caspase effectors, Caspase3 and Caspase7 (Muller et al.,
2001; Nahle et al., 2002). Finally, E2F 1 may mediate apoptosis through transcription-
independent mechanisms. Several studies have demonstrated that the transactivation
domain of E2F1 is dispensable for apoptosis in Saos-2 and WI-38 cells (Hsieh et al.,
1997; Moroni et al., 2001; Phillips et al., 1997). Furthermore, a 75 amino acid segment
within the DNA binding domain of E2F1 is sufficient to induce cell death (Bell et al.,
2006). This segment, which is present in E2F2 and E2F3, does not retain DNA binding
activity and therefore cannot directly transcribe any genes mediating apoptosis.
Interestingly, it has recently been reported that Api5 can suppress E2F 1-mediated
apoptosis without generally affecting E2F-mediated transcription (Morris et al., 2006),
implying that wild-type cells have at least one mechanism to specifically regulate E2F 1-
mediated, transcription-independent apoptosis. Together, these data demonstrate a
definitive, multifaceted function of E2F 1, and possibly E2F2 and E2F3, in mediating
apoptosis.
Related to apoptosis, E2F1 may function in the DNA damage response pathway.
As discussed previously, acetylation of E2F 1 after DNA damage stabilizes the protein
(Galbiati et al., 2005; Ianari et al., 2004). Additionally ATM, a kinase activated by DNA
damage, can phosphorylate and stabilize E2F1 (Lin et al., 2001). E2F1 interacts with
Nbsl at origins of DNA replication, which is thought to recruit the ATM-activated Mrel 1
complex (Maser et al., 2001). Microarray analyses have also identified several E2F
target genes involved in the DNA damage checkpoint and DNA repair (Ren et al., 2002;
Weinmann et al., 2002). However, it is unclear whether any of these gene targets and
interactions is physiologically important for DNA damage response pathways, or if they
are instead normal aspects of E2F-mediated, cell cycle progression.
iv. The roles of the activating E2Fs in differentiation and development
Germline deletions of each of the activating E2Fs have been generated, allowing
for the analysis of the developmental defects present upon loss of each E2F. E2fl " mice
are viable and fertile, but they display tissue-specific abnormalities (Field et al., 1996;
Garcia et al., 2000; Yamasaki et al., 1996; Zhu et al., 1999). These abnormalities include
testicular atrophy by 12 months of age and excessive numbers of T cells, the latter
resulting from a defect in negative selection. Additionally, E2fl- mice are resistant to
obesity induced by high calorie diets (Fajas et al., 2002b). This is likely caused by a
defect in adipocyte differentiation, possibly due to the inability to properly upregulate the
adipocyte transcription factor, PPARy (Fajas et al., 2002b). Surprisingly, these mice also
develop a range of tumors. The potential causes of tumor formation will be discussed in
the next section.
Recent studies suggest that E2F 1 may possess a more extensive role in
development and differentiation. Overexpression of E2fl delays endochondral bone
formation through inhibition of chondrocyte differentiation (Scheijen et al., 2003). The
chondrocyte differentiation defect is most likely due to the inability of the chondrocytes
to stop proliferating. Overexpression of E2F 1 in keratinocytes in vitro also suppresses
differentiation (Wong et al., 2003). Finally, E2F1 induces a group of genes, including
Neogenin, WASF1 and SGEF, that may have roles in differentiation and development
(Iwanaga et al., 2006). Analyses of E2F 1 overexpression and deletion in other cell types
will expand our knowledge concerning the function of E2F 1 in differentiation.
E2J2- mice have been generated (Murga et al., 2001). These mice also survive
and are fertile. The only known developmental defect observed thus far in these mutant
mice is that some of them develop autoimmunity-related defects in adulthood. These
defects include splenomegaly and glomerulonephritis. The cause of the autoimmune
defects is not completely understood. Finally, these mice develop hematopoietic
malignancies, although one lung adenoma and one histiocytic sarcoma were also
observed (Zhu et al., 2001).
Contrary to E2fl and E2J2 null mice, E2f3"- mice are inviable on a pure C57B1/6
or 129/Sv background (Humbert et al., 2000b; Cloud et al., 2002; Saavedra et al., 2002).
These mice die between e13.5 and postnatal day 1 with reduced cardiomyocyte
proliferation (Cloud et al., 2002; Cloud and J.A. Lees, unpublished data). On a mixed
genetic background, a few E2J3- mice survive to adulthood. These mice exhibit
hypoplastic cardiac cells and septal defects leading to heart failure (Cloud and J.A. Lees,
unpublished data). Similar to E2f2/ mice, the surviving E2f3 - mice do not develop
tumors. Based on in vitro studies, the loss of E2F3 may also affect induction of PPARy,
and hence affect adipocyte differentiation (Fajas et al., 2002b). It is worth noting that the
E2f3 - knockout mice and MEFs are missing both E2f3a and E2f3b. Whether the above
phenotypes are due to loss of only one or both of the E2J3 gene products remains to be
determined through the generation of E2J3a-d and E2J3b- single mutant mice.
The generation of compound mutant mice for the activating E2Fs has revealed
that the mild phenotypes observed in the single mutants may be due to functional
compensation by the remaining E2Fs. For example, E2fl"; E2Jf2 double mutant mice
display exacerbated phenotypes of the single mutants, including autoimmunity, T cell
defects, and tumor development (DeRyckere and DeGregori, 2005; Zhu et al., 2001). In
addition, other hematopoietic defects arise in the double mutants, indicating that E2F 1
and E2F2 cooperate in the regulation of hematopoietic proliferation (Li et al., 2003).
Finally, these mice develop diabetes and exocrine pancreatic dysfunction (Iglesias et al.,
2004). E2fl'; E2J3/ and E2Jf2-; E2f3 - double mutant mice similarly demonstrate
exacerbated phenotypes of the respective single mutant mice (Wu et al., 2001; Cloud et
al., 2002). Further analyses of compound E2F mutant mice will elucidate the extent of
the role activating E2Fs possess in differentiation and development. However, such
analyses may be complicated by the lethality of compound E2F mutants due to their role
in proliferation and the compensatory nature of the activating E2Fs.
v. The activating E2Fs in tumorigenesis
Most, if not all, human tumors harbor mutations in RB-1 or some other upstream
member of the pRb pathway. As the activating E2Fs are critical downstream effectors of
pRb, it is reasonable to assume that increased expression or activity of these genes may
also contribute to tumorigenesis. This hypothesis is supported by various data. E2F1, for
example, is overexpressed in metastatic, hormone-resistant prostate cancers (Davis et al.,
2006). Increased E2F1 levels are also observed in lung, breast, and pancreatic cancers
(Eymin et al., 2001; Gorgoulis et al., 2002; Han et al., 2003; Yamazaki et al., 2003) and
in lymph node metastases (Nelson et al., 2006). In addition, alterations in E2F3
expression have been observed in human tumors. E2F3 is amplified in a subset of
retinoblastomas and bladder carcinomas (Feber et al., 2004; Grasemann et al., 2005;
Oeggerli et al., 2006; Orlic et al., 2006; Veltman et al., 2003) and also in prostate,
ovarian, and non-small cell lung carcinomas (Borczuk et al., 2003; Foster et al., 2004; Lu
et al., 2004). Tumors exhibiting amplified E2F3 are often more malignant and correlate
with poor survival.
In vitro experiments and several mouse models support the notion that the
activating E2Fs possess oncogenic properties. In culture, overexpression of any
activating E2F can induce oncogenic transformation of cells (Johnson et al., 1994; Xu et
al., 1995). In mice, conditional, short-term overexpression of E2F1 in the testes results in
histological features reminiscent of carcinoma (Agger et al., 2005). Liver-specific E2F1
transgenic mice develop liver adenomas, with some evidence of progression to carcinoma
by 10 months of age (Conner et al., 2000). Finally, mice overexpressing E2F1 under the
keratin 5 (K5) promoter develop epidermal and other epithelial tumors (Pierce et al.,
1999). Conversely, deletion of E2fl suppresses pituitary and thyroid tumor development
in Rb+- mice (Yamasaki et al., 1998). Similarly, deletion of E2J3 suppresses pituitary
tumors in Rb+- mice (Ziebold et al., 2003).
The most likely explanation for all of the tumorigenic data above is that the
activating E2Fs act as oncogenic factors downstream of pRb to induce cell cycle
progression. However, other hypotheses are formally possible and have not been ruled
out. For example, as explained in section iii, E2F1 and possibly E2F2 and E2F3 function
in promoting apoptosis. This function could cause cells with increased E2F activity to
experience a selective pressure to inactivate p53 and/or other pro-apoptotic machinery.
In a related manner, E2F1 overexpression can induce DNA double strand breaks
(Pickering and Kowalik, 2006), which could cause mutations facilitating tumorigenesis.
Finally, deregulated E2F activity may induce genes that are not normally highly
transcribed by E2Fs in wild-type cells. For example, chromatin immunoprecipitation has
demonstrated that in neuroblastoma cells the activating E2Fs bind to the promoters of
MycN and Bmil, oncogenes known to cooperate in tumorigenesis (Nowak et al., 2006;
Strieder and Lutz, 2003). The E2F-promoter association is likely a cause of the increased
expression of these genes. Regardless of the mechanism, however, it is clear that
increased activating E2F expression is associated with and can possibly promote
tumorigenesis.
The role of the activating E2Fs in tumorigenesis is not as straightforward as laid
out above, however. Several lines of evidence implicate that the activating E2Fs may
also function as tumor suppressors. E2F1, for example, is downregulated in colon
cancer, bladder carcinoma, and diffuse large B-cell lymphoma (Bramis et al., 2004;
Moller et al., 2000; Rabbani et al., 1999; Zacharatos et al., 2004). Additionally, E2F1
overexpression can inhibit transformation in some in vitro situations (Lee and Farnham,
2000). Finally, E2fl - mice develop a wide range of spontaneous tumors (Yamasaki et
al., 1996), and deletion of E2fl enhances tumorigenesis in mice overexpressing Myc in
squamous epithelium (Rounbehler et al., 2002). With respect to the other activating
E2Fs, E2f2Z- mice develop hematopoietic malignancies (Zhu et al., 2001). Although loss
of E2f3 does not induce tumor formation and can suppress pituitary tumors in Rb' - mice,
E2J3 deletion enhances that formation and aggressiveness of thyroid tumors in the Rb+/A
mice (Ziebold et al., 2003). All of these findings are in disagreement with a
straightforward model of the activating E2Fs functioning as oncogenic factors.
Several hypotheses can explain the role of the activating E2Fs as potential tumor
suppressors. For example, E2F 1 and possibly E2F2 and E2F3 promote apoptosis (see
section iii). Through the inactivation of these genes, a tumorigenic cell may elude
programmed cell death. In a related manner, E2F1 has a reported positive role in the
DNA damage response pathway. Aberrations to E2F1 may, therefore, lead to inefficient
DNA repair and tumor-promoting mutations. This latter explanation does not account for
the tumor suppressive properties of E2F2 and E2F3, unless their function after DNA
damage is indirect or otherwise yet unreported. Finally, there are reports that E2F 1 or
E2F3 overexpression induces a senescent-like state (Lazzerini Denchi et al., 2005; Dimri
et al., 2000). By eliminating activating E2F function, tumor cells can avoid senescence.
It is clear from these data that the activating E2Fs may function as both oncogenic
and tumor suppressive factors. The type of tumorigenic function appears to depend on
cell type and probably other oncogenic mutations present. Further study will be required
to elucidate the roles of the activating E2Fs in tumorigenesis.
C. The repressive E2Fs
i. Discovery and structure
E2F4 and E2F5 were isolated and cloned based on their association with p107 and
p130 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995; Sardet et al.,
1995). These two E2Fs are more similar to each other (80% similarity) than to the
activating E2Fs (30-60% similarity). E2F4 and E2F5 do not possess a similar amino
terminus compared to the activating E2Fs, and they are both missing the nuclear
localization signal present in those E2Fs (Figure 1). However, E2F4 and E2F5 do
possess a similar DNA binding domain, DP dimerization domain, and
transactivation/pocket protein domain. Although overexpression of E2F4 activates
transcription in vitro, neither E2F4 nor E2F5 can cause cell cycle re-entry in quiescent or
arrested cells (DeGregori et al., 1997; Lukas et al., 1996). This suggests that the function
of E2F4 and E2F5 is different from that of the activating E2Fs.
The originally cloned E2J3 locus encodes two distinct proteins, as was realized
several years after the initial identification and cloning of this locus (Leone et al., 2000).
E2J3a encodes the originally characterized gene. However, a second gene, E2J3b, is
transcribed from an intronic promoter. The resulting transcript encodes a protein exactly
homologous to E2F3a except for the amino terminal 122 amino acids, which are replaced
in E2F3b by six distinct amino acids. As illustrated in Figure 1, all of the aforementioned
domains identified in the activating E2Fs are present in E2F3b, and E2F3b appears to be
regulated solely by pRb. Although most of section C will be devoted to E2F4 and E2F5,
there is evidence that E2F3b may function as a transcriptional repressor, which will be
discussed briefly later.
ii. Cell cycle progression and repressive E2F regulation
The role of the repressive E2Fs (hereto meaning only E2F4 and E2F5) in cell
cycle regulation is quite different from that of the activating E2Fs. As previously
mentioned, overexpression of E2F4 or E2F5 does not drive progression through the cell
cycle, nor can it cause re-entry into the cell cycle upon cell cycle arrest (DeGregori et al.,
1997; Lukas et al., 1996). Moreover, cell cycle kinetics are normal in E2f4/ and E2f5-
MEFs (Humbert et al., 2000a; Lindeman et al., 1998; Rempel et al., 2000). Instead, the
repressive E2Fs function, at least in part, to regulate and maintain growth arrest. For
example, MEFs lacking E2F4 and E2F5 are unable to arrest upon p 1 6 NK4a
overexpression (Gaubatz et al., 2000). The same result was obtained in cells lacking
p107 and p130, binding partners for the repressive E2Fs, but not the activating E2Fs
(Classon et al., 2000; Hurford et al., 1997). Together with data to be discussed below,
these results suggest that the repressive E2Fs function to inhibit transcription of E2F-
responsive promoters and prevent cells from progressing through the cell cycle.
Expression and localization experiments have suggested a role for E2F4 and E2F5
in gene repression and cell cycle arrest. Unlike the activating E2Fs, which are primarily
expressed in cycling cells, E2F4 and E2F5 are expressed in all phases of the cell cycle,
including GO (Muller et al., 1997; Sardet et al., 1995; Takahashi et al., 2000; Vairo et al.,
1995; Verona et al., 1997; Wells et al., 2000). Also, unlike the activating E2Fs, which
are constitutively nuclear, the repressive E2Fs localize predominantly to the cytoplasm
during the cell cycle. This is not surprising given the lack of a nuclear localization signal
in these proteins (Figure 1). On the contrary, E2F4 possesses two nuclear export signals,
and its cytoplasmic localization is dependent on the CRM1 nuclear export factor
(Gaubatz et al., 2001). However, the repressive E2Fs do demonstrate nuclear
localization. In GO and early G1, upon association with one of the pocket proteins the
repressive E2Fs bind to E2F-responsive promoters (Muller et al., 1997; Sardet et al.,
1995; Takahashi et al., 2000; Vairo et al., 1995; Verona et al., 1997; Wells et al., 2000).
In fact, during GO/Gi, E2F4 and E2F5 account for most of the nuclear, E2F-pocket
protein complexes. Furthermore, chromatin immunoprecipitation experiments show that
repressive E2Fs recruit HDACs to E2F-responsive promoters in GO/G1 (Iavarone and
Massague, 1999; Rayman et al., 2002; Takahashi et al., 2000), suggesting that E2F4 and
E2F5 repress transcription of genes during GO/Gl. Indeed, mutation of E2F binding
sites, such as those within the promoter of B-myb and E2fl, causes increased levels of
these transcripts during GO/G1 (Hsiao et al., 1994; Lam and Watson, 1993). Together,
the expression and subcellular localization patterns of the repressive E2Fs strongly
implicate these proteins in transcriptional repression and maintenance of a GO/G1 growth
arrest.
The regulation of the repressive E2Fs by pocket proteins complements their
expression and localization patterns. E2F4 binds to all three pocket proteins
(Beijersbergen et al., 1994; Ginsberg et al., 1994; Moberg et al., 1996), while E2F5
associates predominantly with p130 (Hijmans et al., 1995; Sardet et al., 1995; Moberg et
al., 1996). Interestingly, E2F4-p130 and E2F5-p130 complexes are present and localized
to the nucleus in GO/G1, precisely when p130 is expressed, and E2F4-p 107 complexes
are present and localized to the nucleus during late G1/S, the time of greatest p 107
expression (Baldi et al., 1995; Beijersbergen et al., 1995; Chen et al., 1989). Upon GU/S
transition, p130 and subsequently p107 are phosphorylated by cyclin/CDK complexes,
thereby causing the release and export of E2F4 and E2F5 into the cytoplasm (Verona et
al., 1997; Zwicker et al., 1996). Functionally, the repressive E2F-pocket protein
association with E2F promoters during GO/G1 coincides with the transcriptional
repression of those genes (Rayman et al., 2002). Taken together, all of the structural,
expression, localization, and pocket protein binding data demonstrate a functional role for
E2F4 and E2F5 in the repression of E2F-responsive genes and the maintenance of cell
cycle arrest.
The regulation and function of the activating and repressive E2Fs provides for a
simple model of cell cycle regulation. During GO/Gl, the repressive E2Fs inhibit the
transcription of E2F-responsive, cell cycle-related genes. Upon transition into G1/S, the
repressive E2Fs are released and replaced by the activating E2Fs, which induce
transcription and progression through S phase. However, there is evidence that such a
straightforward model does not apply in all cases. For example, some genes may be
regulated via repression alone. The B-myb, cdc2, and cyclin A2 promoters are bound by
E2Fs predominantly during GO/G1 (Huet et al., 1996; Tommasi and Pfeifer, 1995;
Zwicker et al., 1996), with release of E2F4 observed upon entry into G1/S (Zwicker et
al., 1996). Activating E2Fs do associate with the B-myb promoter (Takahashi et al.,
2000). However, the levels are very low, and the activation of B-myb transcription may
not require E2F binding (Lam and Watson, 1993). These data suggest that some genes
are regulated via repression alone. Analysis of MEFs missing all of the activating E2Fs,
on the other hand, indicates that several E2F-responsive genes, such as DHFR and
MCM3, are downregulated (Wu et al., 2001). Therefore, it seems likely that
transcriptional regulation is gene-specific, whereby some genes are regulated through
transcriptional repression, other genes are regulated by transcriptional induction, and the
remaining E2F-responsive genes are regulated via both mechanisms.
E2F3b possesses many structural features similar to those of the activating E2Fs
(Figure 1). Additionally, E2F3b appears to be regulated solely by pRb like the activating
E2Fs (Leone et al., 2000). However, E2F3b is expressed throughout the cell cycle,
resembling the expression pattern of the repressive E2Fs. Moreover, an E2F3 epitope
most likely to be E2F3b is associated with the Arfpromoter in normal cells in vitro when
Arftranscription is repressed (Aslanian et al., 2004; Iaquinta et al., 2005). Therefore,
E2F3b may function as a transcriptional repressor similar to E2F4 and E2F5. Further
studies will be required to elucidate the functions of E2F3b.
iii. The roles of the repressive E2Fs in differentiation and development
E2f4- mice exhibit several developmental defects and die prematurely due to
bacterial infections (Humbert et al., 2000a; Danielian et al., 2007). The susceptibility to
bacterial infections stems from a lack of cilia in the airway epithelium (Danielian et al.,
2007). In the nasal epithelium, cilial cells are replaced by columnar cells that produce
mucin. The combination of excess mucin and a lack of cilia prevents clearance and
increases the chances of bacterial infection. The cause of the cilial cell defect is
unknown, although it appears that the defect is independent of cell proliferation. In
addition, E2f4- mice display craniofacial defects that may also contribute to bacterial
infections (Humbert et al., 2000a). Aside from developmental abnormalities leading to
infection, the lack of E2f4 prevents normal crypt formation in the intestinal epithelium
(Rempel et al., 2000). The E2f4- mice are also anemic during development and
demonstrate cell autonomous defects in red blood cell maturation (Humbert et al., 2000a;
Rempel et al., 2000). The likely cause of the erythroid defects stems from impaired cell
cycle progression (Kinross et al., 2006). Consistent with this observation, gene
expression analysis indicates that several cell cycle regulatory genes are downregulated
in the E2f4- red blood cells. Together, these data indicate that loss of E2f4 in mice
results in several developmental defects that are due to proliferation dependent and
independent mechanisms.
The role of E2F4 in the differentiation of other cell types has been studied in
vitro. Overexpression of E2F4, for example, enhances neuronal differentiation and is
important for maintenance of the differentiation state (Persengiev et al., 1999). In
myoblasts, E2F4 complexes with p130 or p107 to repress FGFR1, an important regulator
of skeletal muscle differentiation (Parakati and DiMario, 2005a,b). Finally, E2F4
represses adipocyte terminal differentiation in vitro, in part through repression of PPARy
(Fajas et al., 2002b; Landsberg et al., 2003). Related to this, E2f4- - cells in chimeric
mice contribute to a significantly greater percentage of white adipose tissue compared to
control chimeric cells (Fajas et al., 2002). These data implicate a role for E2F4 in the
development and differentiation of several cell types.
E2f5-' mice have been generated and present developmental defects. These mice
are born at expected frequencies, but die by 6 weeks of age due to hydrocephalus
(Lindeman et al., 1998). The hydrocephalus is due to excessive cerebrospinal fluid in the
choroid plexus, although the role that E2F5 plays in this respect is unknown. It is
possible that other potential developmental defects in the E2f5- mice are masked due to
functional compensation by E2F4. In support of this notion, compound E2f4-'-; E2f5-
embryos die early during development (Gaubatz et al., 2000; J.A. Lees unpublished data).
Thus, developmental studies of the effects upon loss of both repressive E2Fs will be
difficult until the generation of conditional and/or inducible mouse models of these
proteins.
iv. The roles of the repressive E2Fs in tumorigenesis and apoptosis
As repressors of cell cycle genes, one might hypothesize that the loss of E2F4 or
E2F5 would inhibit cell cycle arrest and facilitate unimpeded proliferation. In this
manner, the repressive E2Fs would act as tumor suppressors. In support of this, E2F4 is
mutated in stomach and colon cancer, with loss of heterozygosity sometimes observed
(Schwemmle and Pfeifer, 2000; Souza et al., 1997; Woo et al., 2000; Zhong et al., 2000).
Additionally, low levels of E2F4 correlate with platinum-resistance in ovarian cancer
(Reimer et al., 2007).
However, there are several pieces of data that contradict a tumor suppressor
model for the repressive E2Fs. First, E2f4/ and E2f5- mice do not exhibit tumors
(Humbert et al., 2000a; Lindeman et al., 1998; Rempel et al., 2000) although these mice
may not live long enough to develop them. Moreover, the deletion of E2f4 suppresses
tumorigenesis in Rb +' mice (Lee et al., 2002). Second, despite the finding that ectopic
expression of E2F4 or E2F5 does not efficiently drive cell cycle re-entry in quiescent
cells, their overexpression can in some cell types and conditions contribute to
transformation of cultured cells (Beijersbergen et al., 1994; Ginsberg et al., 1994;
Polanowska et al., 2000). In addition, deletion of the repressive E2Fs does not alter cell
cycle kinetics or transform cultured cells. Finally, the expression levels of the repressive
E2Fs are increased in several human tumors. For example, E2F4 is increased in colon
and breast cancers (Mady et al., 2002; Rakha et al., 2004), while E2F5 in conjunction
with c-myc or c-mos is upregulated in some breast cancers (Polanowska et al., 2000).
The explanation for upregulation of the repressive E2Fs in human tumors is
unclear. One possibility is that upon overexpression, these E2Fs can induce transcription
of cell cycle genes that are normally induced by the activating E2Fs (or that the
repressive E2Fs normally inhibit). This is supported by data indicating that
overexpression of these proteins in vitro can activate transcription of E2F-responsive
genes and transform cells in certain conditions (Beijersberen et al., 1994; Ginsberg et al.,
1994).
A second possibility for oncogenic activity may relate to a potential role for the
E2Fs in apoptosis. E2f4/ MEFs demonstrate increased sensitivity to apoptosis induced
by a number of drugs (Ma et al., 2004). In addition, knockdown of E2F4 in several
human cancer cell lines sensitized the cells to apoptosis (DuPree et al., 2004; Ma et al.,
2004). Physiological significance of this possible effect is demonstrated by the observed
low levels of apoptosis correlating with increased E2F4 expression in colon cancer
(Mady et al., 2002). Although the mechanism through which E2F4 and possibly E2F5
inhibit apoptosis is not known, the suppression may be mediated through an E2F-p 130
complex, as levels of E2F4-p 130 heterodimer increase after ionizing radiation (DuPree et
al., 2004). Further work will be required to determine the exact function of E2F4 and
E2F5 in apoptosis and, ultimately, in tumorigenesis.
Part III: Bone and Osteoblast Differentiation
A. Bone overview
Bones are most appreciated for their role as a protective barrier for the internal
organs. In addition to protection, the skeletal system provides physical support and
facilitates locomotion. Finally, bones act as a storage system for vital inorganic ions such
as calcium and phosphate.
There are two types of bones, identical in chemical composition but structurally
different. Cortical bone (also known as compact bone) makes up 80% of the human
skeletal mass. It is the principal component of flat bones such as those of the skull and
ribs, and it makes up the shaft of long bones such as the femur (Figure 2). Cortical bone
is dense and is the primary bone type functioning in protection of internal organs. The
remaining 20% of skeletal mass is made up of trabecular bone (also known as cancellous
or spongy bone). Trabecular bone is found primarily in the vertebrae and in the
epiphyses, or ends, of long bones (Figure 2). It consists of a lattice of thin threads of
bone called trabeculae and is less dense than compact bone. The orientation of the
trabeculae is affected by the mechanical stress to which the bone is exposed.
Bones derive their physical characteristics from the particular mixture of organic
and inorganic materials that make up the tissue. The organic material makes up 75% of
this mixture and is secreted by the bone forming cells, termed osteoblasts. The principal
component of the organic matter is type 1 collagen. Type 1 collagen is made up of two
Collagenlal protein chains and one Collagenla2 protein chain. The secreted and
deposited collagen matrix is termed osteoid. Along with collagen, osteoblasts secrete
Figure 2. Frontal longitudinal midsection of the femoral head (Gray, 1918)
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several other proteins, including osteopontin (also known as bone sialoprotein) and
osteocalcin, that may incorporate into the collagen matrix.
The collagen matrix does not become bone, however, until the incorporation of
inorganic material into the osteoid. The main inorganic component, hydroxyapatite, is a
crystalline substance containing calcium, phosphate, and hydroxyl ions. Magnesium,
citrate, potassium, and other ions are also found in the matrix. The incorporation of
hydroxyapatite and other ions into the osteoid creates the hard, rigid nature of bone and
completes the formation of the bone matrix.
B. Three cell types and two pathways for bone formation
Bone development occurs through two distinct processes and three cell types. In
the first process, termed intramembranous ossification, mesenchymal progenitor cells
differentiate directly into osteoblasts to produce bone. Several calvarial bones (skull) and
part of the clavicle (collarbone) form via intramembranous ossification. The other
process is endochondral ossification, and it is responsible for the formation of most
bones, including long bones, vertebrae, and ribs. In endochondral ossification, an
intermediate step occurs whereby mesenchymal cells condense and differentiate into
chondrocytes. These chondrocytes proliferate, secrete cartilage matrix, and form the
template for the ossified bone. Upon terminal differentiation, chondrocytes become
hypertrophic and ultimately undergo apoptosis, clearing the way for invading osteoblasts
to take their place and lay down the type 1 collagen osteoid matrix. Finally, bones
formed by both types of ossification are continually remodeled through periods of bone
formation and resorption. Resorption is achieved via a third cell type, the osteoclast.
Therefore, proper bone development occurs through two distinct pathways and requires
the action of three different cell types.
i. Chondrocytes
In endochondral ossification, the first step required is the condensation of
mesenchymal cells that will ultimately differentiate into chondrocytes. Although not all
of the molecular mechanisms that affect this process are understood, it is clear that the
transcription factor Sox9 is involved. Chimeric and conditional knockout animals have
demonstrated that Sox9 is required for proper mesenchymal condensation, chondrocyte
differentiation and proliferation, and prevention of premature hypertrophy (Bi et al.,
1999; Akiyama et al., 2002). Sox9 also regulates the expression of chondrocyte genes
such as the type II collagen gene, Col2al (Lefebvre et al., 1997).
After the production of cartilage matrix, it is essential that chondrocytes exit the
cell cycle and become hypertrophic. The transcription factor Runx2/CBFAl and the
histone deacetylase HDAC4 are required for these latter steps in chondrocyte
differentiation. Mice deficient for Runx2 display defective chondrocyte maturation and a
lack of hypertrophic cells (Inada et al., 1999; Yoshida et al., 2004). Moreover,
overexpression of Runx2 in chondrocytes enhances hypertrophy and converts tracheal
cartilage into hypertrophic chondrocytes and then bone (Takeda et al., 2001; Ueta et al.,
2001). HDAC4, which is expressed in pre-hypertrophic chondrocytes, associates with
and inhibits Runx2 (Vega et al., 2004). In addition, overexpression of HDAC4 inhibits
hypertrophy and mimics the phenotype of Runx2- mice. Thus, HDAC4 and Runx2
function to regulate chondrocyte hypertrophy.
In addition to the genes described above, several other factors have been
implicated in chondrocyte differentiation. For example, the Indian hedgehog (Ihh) and
Wnt signaling factors, including the downstream 3-catenin protein, appear to regulate
chondrocyte differentiation and proliferation, ultimately affecting cartilage and bone
formation (Akiyama et al., 2004; Guo et al., 2004; Hartmann and Tabin, 2000; Kobayashi
et al., 2002; Long et al., 2001; St-Jacques et al., 1999; Yang et al., 2003). Another
example is the transcription factor Dlx5. Dlx5 is expressed in chondrocytes and
promotes hypertrophy in developing chicken limbs (Ferrari and Kosher, 2002). These
proteins, along with Sox9, Runx2, HDAC4 and others, regulate chondrocyte
differentiation, paving the way for endochondral bone formation.
ii. Osteoblasts
Upon differentiation, osteoblasts actively synthesize many proteins, including
those specific to or highly upregulated in bone (Beck et al., 2000; Nakashima and de
Crombrugghe, 2003). For example, insights gained from in vitro studies have
demonstrated that osteoblasts induce type 1 collagen and alkaline phosphatase early
during differentiation. Subsequently, Osteopontin (OSP) and Osteonectin (OSN) are
synthesized as early-mid stage markers. Finally, Osteocalcin (OC) is expressed as a late
stage marker of differentiation, along with the production of calcium-containing bone
nodules. The characterization of the temporal induction of bone markers has
significantly facilitated the study of osteoblast differentiation. However, these insights
do not explain how the osteoblast markers were induced.
A master transcriptional regulator of osteoblast differentiation was discovered
with Runx2. In addition to its function in chondrocytes, Runx2 is highly expressed in
and required for osteoblast differentiation (Ducy et al., 1997; Komori et al., 1997; Otto et
al., 1997). Runx2- mice are devoid of all bone, endochondral and intramembranous,
consisting only of a cartilage skeleton (Komori et al., 1997; Otto et al., 1997).
Furthermore, no osteoblast markers, early or late, are detected in the Runx2-deficient
embryos. Conversely, overexpression of Runx2 in fibroblasts or myoblasts in vitro
results in the induced expression of the aforementioned osteoblast markers (Ducy et al.,
1997). Finally, Runx2 can bind to the DNA element, OSE2, present in the promoter
region of OPN and OC (Ducy et al., 1997). These data indicate that Runx2 is a master
regulator of osteoblast differentiation and is sufficient to induce the differentiation
pathway.
Subsequent to the discovery of Runx2, a second essential regulator of osteoblast
differentiation, Osterix (OSX; Sp7), was isolated (Nakashima et al., 2002). Osterix is a
zinc-finger-containing transcription factor. This protein is highly expressed in and
supposedly specific to osteoblasts, although expression in chondrocytes in vivo and other
tissues in vitro has been characterized (Milona et al., 2003; Nakashima et al., 2002;
Rodda and McMahon, 2006; Yagi et al., 2003). OSX- embryos are devoid of all bone,
exhibiting only a cartilage skeleton, a phenotype reminiscent of the Runx2 - embryos
(Nakashima et al., 2002). The OSX-deficient embryos also do not display any
upregulation of osteoblast markers. However, these mice do demonstrate expression of
Runx2. Combined with the finding that Runx2- embryos do not express OSX, it is
commonly believed that OSX is downstream of Runx2. Finally, in vitro overexpression
of OSX is sufficient to induce osteoblast markers and promote differentiation
(Nakashima et al., 2002; Tai et al., 2004; Wang et al., 2006). Together, Runx2 and OSX
are the two known master regulators of osteoblast differentiation.
Several other proteins function in osteoblast differentiation and the induction of
osteoblast markers. For example, the transcription factor ATF4 can bind to the promoter
of OC and induce its transcription (Yang et al., 2004). Moreover, ATF4 and its kinase
RSK2 can post-transcriptionally regulate the levels of type 1 collagen. Finally, both
Rsk2- and Atf4- embryos display decreased ossification compared to wild-type embryos.
The nuclear protein, SATB2, directly interacts with ATF4 and Runx2 (Dobreva et al.,
2006). Furthermore, SATB2 can associate with the promoters of OPN and OC and
enable an upregulation of their transcription. In addition, deletions to Indian hedgehog
(Ihh) (Long et al., 2004; Rodda and McMahon, 2006), P-catenin (Day et al., 2005; Hill et
al., 2005; Hu et al., 2005, Rodda and McMahon, 2006), Msx2 (Satokata et al., 2000), or
Dlx5 (Acampora et al., 1999) negatively affect bone development in vivo. pRb also
interacts with Runx2, and enhances the transcriptional activity of Runx2, although these
findings have only been demonstrated in vitro (Thomas et al., 2001). Conversely, p53
negatively regulates osteoblast differentiation in vivo and in vitro by indirectly regulating
the levels of either Runx2 or OSX (Lengner et al., 2006; Wang et al., 2006). These data
and other findings demonstrate that osteoblast differentiation and bone formation are
complex processes regulated by multiple factors and pathways.
iii. Osteoclasts
The osteoclast is derived from the monocyte lineage, which also gives rise to
macrophages (Wagner and Karsenty, 2001). Osteoclasts are multinucleated structures
that specialize in the resorption of bone. A lack of osteoclast function leads to
osteopetrosis, characterized by increased bone mass and a filling of the bone marrow
cavity. Conversely, increased osteoclast activity causes osteoporosis, a condition of
decreased bone mass. Interestingly, osteoblasts can regulate the differentiation of
osteoclasts, which will be briefly summarized below.
In the developing bone, osteoblasts secrete three main factors that affect the
differentiation of osteoclasts. Two of those factors, M-CSF and RANKL, promote
progenitor osteoclast proliferation and terminal differentiation. Mice with inactivating
mutations in M-CSF do not produce osteoclasts (Yoshida et al. 1990). Similarly, mice
lacking RANKL, a ligand for the TNF-receptor-related RANK receptor, lack osteoclasts
and become osteopetrotic (Kong et al., 1999; Yasuda et al., 1998b). Finally, osteoblasts
secrete Osteoprotegrin (OPG), a soluble TNFa receptor that acts as a decoy receptor for
RANKL (Simonet et al., 1997; Yasuda et al., 1998a). OPG is a strong inhibitor of
osteoclast differentiation, due to it ability to sequester RANKL, and mice lacking OPG
develop osteoporosis. Through the secretion of these three factors, osteoblasts maintain a
significant role in osteoclast differentiation and the overall remodeling of bone.
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ABSTRACT
Mutation of the Rb tumor suppressor gene is strongly linked to osteosarcoma formation.
This observation, and the documented interaction between the retinoblastoma protein
(pRb) and Runx2, suggests that pRb is important in bone development. To assess this
hypothesis, we used a conditional knockout strategy to generate pRb-deficient embryos
that survive to birth. Analysis of these embryos shows that Rb-inactivation causes the
abnormal development and impaired ossification of several bones. We further show that
Rb-inactivation promotes osteoblast differentiation in vitro and, through conditional
analysis, establish that this occurs in a cell intrinsic manner. Although these in vivo and
in vitro differentiation phenotypes appear paradoxical, we find that Rb-deficient
osteoblasts in each of these settings have an impaired ability to exit the cell cycle that can
account for all of the observed phenotypes. Consistent with this observation, we show
that the cell cycle and the bone defects in Rb-deficient embryos can be suppressed by
deletion of E2fl, a known proliferation inducer that acts downstream of Rb. Thus, we
conclude that pRb acts in a cell autonomous manner to regulate osteoblast differentiation
by mediating inhibition of E2F and consequent induction of cell cycle exit.
INTRODUCTION
The first tumor suppressor to be cloned was the retinoblastoma gene, Rb. Rb is
mutated in approximately one-third of all sporadic human tumors, but there is strong
correlation with certain tumor types. Specifically, Rb mutations are observed in almost
all retinoblastomas (Weinberg, 1992) and also in a large percentage of osteosarcomas and
small cell lung carcinomas. For patients who carry germline Rb mutations, osteosarcoma
is the second most common tumor type after retinoblastoma (Gurney et al., 1995).
Overall, greater than 70% of osteosarcomas demonstrate a molecular change or mutation
at the Rb locus (Belchis et al., 1996; Feugeas et al., 1996).
The gene product, pRb, belongs to a family of proteins, including p107 and p130,
termed the pocket proteins, although only pRb has been demonstrated to possess
significant tumor suppressive properties (Lipinski and Jacks, 1999). The best
characterized role of pRb is its regulation of cell cycle progression. Overexpression of
pRb causes GI cell cycle arrest (Huang et al., 1988), while acute ablation of pRb induces
cell cycle re-entry in quiescent cells (Sage et al., 2003). To execute its cell cycle
inhibitory function, hypophosphorylated pRb binds to and inhibits the E2F family of
transcription factors (Trimarchi and Lees, 2002). During Gl, pRb becomes
hyperphosphorylated by the cyclin D - cdk4/6 complex and subsequently by cyclin E -
cdk2. This phosphorylation releases the E2Fs from pRb to induce the transcription of
cellular genes essential for S phase entry and cell division.
The analyses of in vivo mouse models and in vitro experiments demonstrate that
pRb is required for the differentiation of specific tissues. In erythropoiesis the loss of Rb
results in inefficient enucleation and incomplete terminal differentiation of erythroid cells
(Clark et al., 2004; Spike et al., 2004; J. Zheng and J.A. Lees, unpublished). In skeletal
muscle pRb is required for proper cell cycle exit and differentiation (Huh et al., 2004).
Conditional deletion of Rb in the intestine causes increased proliferation and abnormal
expression of differentiation markers (Haigis et al., 2006; Yang and Hinds, 2007). The
loss of pRb affects the normal expression of differentiation genes, such as P- and y-
crystallins, in the lens (Morgenbesser et al., 1994). These deficiencies in differentiation
appear to be due, at least partially, to a defect in cell cycle exit, a step believed to be
required in most differentiation pathways. However, this does not rule out the possibility
that pRb contributes to differentiation in a more distinct and specific manner. Notably,
pRb binds to NRP/B, a protein upregulated during neuronal differentiation and involved
in neuronal process formation (Kim et al., 1998). Relevant to this, other markers of
neuronal differentiation are decreased in the Rb-deficient embryo (Lee et al., 1994).
With respect to fat cells, pRb physically interacts with C/EBPP, and the loss of this
interaction inhibits adipocyte differentiation (Chen et al., 1996).
Several studies implicate a role for pRb in osteoblast differentiation. Simian virus
40-derived large T-antigen, which targets the pocket proteins, prevents the differentiation
of stromal cell lines into osteoblasts (Feuerbach et al., 1997). The adenoviral E1A 12S
protein also represses osteoblast differentiation, and this is dependent on a functional
E1A pocket protein binding domain (Beck et al., 1998). Most striking is the finding that
in immortalized cell lines pRb physically interacts with Runx2/CBFAl, one of the
transcription factors essential for osteoblast differentiation (Thomas et al., 2001; Luan et
al., 2007). This latter observation suggests that pRb may play a role in osteoblast
differentiation that is independent of cell cycle regulation.
Determining the role of pRb in osteoblast differentiation in vivo may ultimately
provide some important insights concerning the high prevalence of Rb mutations in
osteosarcoma. However, murine embryos deficient for pRb die between embryonic day
(e) 13.5 and 15.5 (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992). This early
lethality has thus far precluded the study of pRb in bone development, which primarily
does not occur until e 15.5 in mice. To circumvent this problem, we generated a
conditional Rb mouse strain that allows pRb-deficient embryos to survive until birth.
This mouse model has enabled us to perform in vitro and in vivo studies to determine the
effects of pRb loss in osteoblast differentiation and bone development.
RESULTS
pRb-deficient embryos exhibit bone defects during development
The retinoblastoma gene, Rb, is mutated in a large proportion of osteosarcomas.
In vitro studies suggest that Rb may play a direct role in bone development (Feuerbach et
al., 1997; Beck et al., 1998; Thomas et al., 2001) but this has not been examined in vivo.
The germline Rb- mice die in mid-gestation (between e 13.5 and el 5.5), prior to the
formation of most bones. However, recent studies show that this mid-gestational lethality
results from a placental defect (Wu et al., 2003; Wenzel et al., 2007). Thus, we
generated a conditional mouse strain that allows Rb mutant embryos to develop in the
presence of a wild-type placenta. Specifically, we crossed a floxable Rb mutant mouse
line (RbC/C; Sage et al., 2003) with a Mox2-Cre transgenic line (Mox2+/cre) that expresses
the Cre recombinase in the embryo proper, but not in the placenta, beginning at
approximately e6.5 (Tallquist and Soriano, 2000). The resulting Mox2+/Cre conditionally
null Rb embryos (Rbc"/ -) survive until birth, allowing us to assess pRb's role in bone
development.
Initially, we examined skeletons of wild-type and Rbc"/ embryos at e17.5 by
alizarin red staining of bone and alcian blue staining of cartilage. Compared to wild-type
littermate controls, the e17.5 Rb-/c- embryos displayed less ossification in a variety of
bones (Figure 1). These include the frontal and parietal calvarial bones of the skull
(Figure lA) that arise through intramembraneous ossification and the hyoid bone (Figure
IB) that develops by endochondral ossification. Moreover, other bones in the Rbc-/"-
embryos, including the pterygoid bone and palatine process in the head and the xiphoid
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Figure 1. Deletion of Rb causes defects in embryonic bone development
(A-D) Alizarin red (bone) and alcian blue (cartilage) staining of embryos. e17.5 Rbc'/c-
mice exhibit less ossification in the cranium (A) and hyoid bone (B). Rbc"/c embryos at
el17.5 and e18.5 display aberrant formation of bones in the head (ventral view of head in
C) and sternum (D). (E) e18 Rbc/c- mice were injected with calcein for 12 hours.
Coronal sections of the frontal bone were analyzed for calcein incorporation. Rbc/c-
embryos incorporate less calcein than their wild-type littermates. 2X magnification
shown. The distance from the front of calcein incorporation (arrow) to the midline of the
suture was measured in several embryos. These data are represented in the histogram.
Error bars signify one standard deviation. * denotes a statistically significant difference,
p< 0.001. Abbreviations: fr, frontal bone; pa, parietal bone; pp, palatine process; pt,
pterygoid bone; xp, xiphoid process.
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process of the sternum, were appropriately ossified but demonstrated an abnormal
structure (Figure 1C,D).
To further explore this defect, we examined the skeletons of mutant embryos at
other developmental stages. At earlier time points, e15.5 and e16.5, the Rbc/c embryos
displayed all of the bone defects described above (data not shown). At the later
timepoints, e 18.5 and e 9.5/birth, the phenotype was altered somewhat: we still observed
aberrantly developed bones, such as the pterygoid, palatine process, and xiphoid process
(Figure 1 C,D; data not shown) but the level of alizarin red staining in the calvaria and
hyoid bone of the Rb -/c- embryos appeared comparable to that of the wild-type littermates
(Figure 1A,B; data not shown). We hypothesized that there were two explanations for
the latter observation. The first possibility is that pRb-loss initially impairs or delays
bone differentiation, but this defect is then corrected by acceleration in the rate of bone
deposition after e17.5. The second possibility is that pRb-loss impairs bone
differentiation at all developmental stages, but this impairment was not apparent at later
time points because the alizarin red detection method is more qualitative than
quantitative. In other words, by e 18.5 there was some ossification in the appropriate
regions of the Rbc~' calvaria and hyoid bone but the level of deposited bone was still
lower than in the wild-type controls. To distinguish between these two possibilities, we
used calcein incorporation to directly determine the rate of new bone formation after
e18.5. Calcein is a fluorescent compound that can be injected into an animal and is then
incorporated into newly forming bones. We analyzed the amount of calcein
incorporation into the frontal bone of e 18.5 embryos 12 hours after the calcein injection
of pregnant females. Notably, the Rbc/- frontal bones incorporated significantly less
calcein compared to wild-type littermates (Figure lE). Similar results were obtained
when calcein was injected approximately 12 hours prior to birth (data not shown). These
data indicate that pRb loss does not cause an acceleration in frontal bone formation in the
late stages of gestation. Instead, the rate of ossification remains considerably lower than
that observed in wild-type embryos. Taken together, our data indicate that the loss of
pRb causes a defect in the rate of ossification and/or proper formation of several bones
throughout embryonic skeletal development.
The loss of pRb affects an early step in the differentiation of osteoblasts in vivo
Notably, pRb-loss impairs the development of bones that arise through two
distinct mechanisms, termed endrochondral (e.g. the hyoid) and intramembraneous (e.g.
the calvaria) ossification. The former is influenced by three cell types: chondrocytes,
which form an essential cartilage template; osteoblasts, which differentiate to secrete the
bone matrix; and osteoclasts, which oppose bone formation by degrading and reabsorbing
bone. In contrast, intramembranous ossification is influenced by osteoblasts and
osteoclasts but occurs in a cartilage-independent manner. This fact, along with the
apparently normal development of the cartilage skeleton within Rbc-/ - embryos (Figure
1B-D; data not shown), suggests that a chondrocyte defect cannot fully account for the
defective bone development. Therefore, we examined both osteoblast and osteoclast
function. To assess osteoclast levels, we screened the frontal bones of e17.5 embryos for
the presence of tartrate-resistant acid phosphatase (TRAP) activity, an osteoclast-specific
marker. There were few to no osteoclasts present in either the wild-type or the Rb~/c-
frontal bones (data not shown). Thus, the decreased ossification in Rbc-/c embryos is
likely not due to either cartilage defects or increased osteoclast activity.
Given these findings, we next screened e17.5 frontal bones for the presence of
osteoblast-specific markers. Two early markers of differentiating osteoblasts are alkaline
phosphatase (ALP) activity and Collagenlal (Coll) mRNA expression. The activity and
expression, respectively, of these two markers were significantly decreased in the Rbc-/c
frontal bone compared to those in wild-type sections (Figure 2). Moreover, the
expression levels of Osteopontin (OPN), an early to mid-differentiation marker, were also
typically downregulated in the Rbc-/c embryos relative to wild-type controls (data not
shown). These data indicate that osteoblast differentiation is perturbed in Rb 'c/ embryos
at the earliest stages of the pathway.
pRb-deficient osteoblasts differentiate to a greater extent than wild-type cells in
vitro
Our in vivo data demonstrate that an early step in osteoblast differentiation is
affected. One possibility is that pRb regulates osteoblast differentiation directly. For
example, it has been reported previously that pRb can interact with and coactivate
Runx2/CBFA1, one of the transcription factors essential for osteoblast differentiation
(Thomas et al., 2001; Luan et al., 2007). To further dissect the role of pRb in osteoblast
differentiation, we utilized a well-defined in vitro osteoblast differentiation system.
Specifically, primary cells were isolated from the calvaria of wild-type and Rbc-/c
embryos, and the progenitor osteoblasts were cultured and then induced to differentiate
upon confluence arrest. In this system, bone-like calcium deposits are secreted by fully
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Figure 2. pRb-deficient frontal bones display decreased levels of osteoblast markers
Coronal sections of frontal bones from el 7.5 embryos were assessed by histochemical
analysis of alkaline phosphatase activity (left column) and in situ analysis of Collagenlal
mRNA (right column). Rb"c- frontal bone sections (bottom row) exhibit decreased levels
of both markers compared to wild-type (top row). 2X magnification shown. The
distance from the front of activity or expression (arrows) to the midline of the suture was
measured in several embryos. These data are represented in the histogram. Error bars
signify one standard deviation. * denotes a statistically significant difference, p< 0.01.
differentiated osteoblasts and can be analyzed by alizarin red staining. Based on our in
vivo data and previous in vitro differentiation studies with fibroblasts (Thomas et al.,
2001), we anticipated that Rbc/- - osteoblasts would differentiate to a lesser extent than
wild-type cells. Contrary to this hypothesis, however, the Rbc-/c osteoblasts secreted a
greater number of calcium deposits than wild-type osteoblasts based on the alizarin red
staining (Figure 3A).
We then used quantitative RT-PCR to analyze the mRNA levels of several
osteoblast markers during the differentiation of these cells. Although the transcriptional
levels of Alp and Coll were unchanged, the Rbc-/ osteoblasts exhibited significantly
greater levels of expression for several other osteoblast genes compared to the wild-type
cells (Figure 3B). Notably, Runx2 and Osterix (OSX), two transcription factors that are
necessary to induce osteoblast differentiation (Ducy et al., 1997; Otto et al., 1997;
Nakashima et al., 2002), were upregulated in the Rbc-I -cells from the earliest stages of
the differentiation process (Figure 3B). Runx2 and OSX have been shown to induce the
transcription of downstream osteoblast differentiation genes (Ducy et al., 1997;
Nakashima et al., 2002; Wang et al., 2006). In accordance with these findings, we
observed the increased expression of the early/mid- and late-differentiation markers,
Osteopontin (OPN) and Osteocalcin (OC) respectively, in the Rbc-/c osteoblasts.
Together, these data suggest that osteoblasts deficient for pRb differentiate to a greater
extent than wild-type cells in vitro, and this correlates with the increased transcriptional
levels of Runx2, OSX, and their downstream targets.
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Figure 3. Rb'c - primary osteoblasts differentiate to a greater extent than wild-type
(A) Terminal differentiation of primary calvarial osteoblasts was determined by alizarin
red staining of secreted calcium deposits from 0 to 35 days. Rbc-/ osteoblasts (bottom
row) secrete a greater number of calcium deposits than wild-type osteoblasts (top row).
(B) Quantitative RT-PCR results of bone marker expression levels from wild-type (red
bars) and Rbc-/c (blue bars) osteoblasts during differentiation. Rbc/C- osteoblasts express
greater mRNA levels of Runx2, Osterix, Osteopontin, and Osteocalcin but not Alkaline
Phosphatase or Collagenlal compared to wild-type osteoblasts. Ubiquitin was used as
an internal control to normalize for RNA levels within the samples. Each time point is an
average of four reactions. Error bars signify one standard deviation. Graphs shown
depict results from a representative littermate pair.
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Acute ablation of pRb promotes the differentiation of osteoblasts in vitro.
The wild-type and Rbc-/c osteoblasts were prepared at e 17.5, when there was a
significant difference in the degree of calvarial differentiation (Figure 1 A). This raised
the possibility that the increased in vitro differentiation of the Rbc/' versus wild-type
cells simply reflected the presence of a larger pool of progenitor osteoblasts in the Rbc-• -
versus wild-type calvaria. To address this hypothesis, we isolated conditional RbC/C
osteoblasts. These cells were brought to confluence and then infected with either a
control adenovirus containing GFP (Adeno-GFP) or one expressing the Cre recombinase
gene (Adeno-Cre) to yield parallel populations of wild-type and Rbc/' osteoblasts that
had identical starting numbers of progenitors. Consistent with previous studies (Sage et
al., 2003), we found that the Adeno-Cre was sufficient to acutely ablate pRb within two
days of infection (data not shown). At this time (denoted Day 0), we placed the confluent
wild-type and Rbc/' - cells in differentiation media. Remarkably, the acutely ablated
Rbc-c- osteoblasts differentiated to a greater extent than the control infected Rbc/ cells, as
we had observed with the germline Rbc/c osteoblasts (compare Figures 4A and 3A).
Moreover, the acutely ablated Rbc/' cells expressed increased levels of Runx2, OSX,
OPN, and OC relative to the Adeno-GFP infected cells in a comparable manner to that
observed in the germline Rbci' osteoblasts (compare Figures 4B and 3B). These data
show that loss of pRb acts in an intrinsic manner to increase the differentiation of primary
osteoblast cultures in vitro.
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Figure 4. Osteoblasts differentiate to a greater extent upon acute ablation of pRb
(A) Rbcc primary calvarial osteoblasts were infected with adenovirus expressing either
the Cre recombinase enzyme or GFP two days prior to differentiation. Terminal
differentiation was assessed by alizarin red staining. Rbc/c osteoblasts acutely ablated for
pRb (bottom row) secrete a greater number of calcium deposits than control infected
osteoblasts (top row). (B) Quantitative RT-PCR analysis, performed as described in
Figure 3. Osteoblasts acutely ablated for pRb (blue bars) express greater mRNA levels of
Runx2, Osterix, Osteopontin, and Osteocalcin but not Alkaline Phosphatase or
Collagenlal compared to control infected osteoblasts (red bars).
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Depletion of pRb in progenitor osteoblasts causes cell cycle exit defects in vitro.
We aimed to understand the molecular changes that accompanied this increased
differentiation. One possibility is that pRb possesses a cell cycle-independent repressive
function in osteoblast differentiation. In this manner, loss of pRb would allow for the
deregulated increase in osteoblast genes such as Runx2 and OSX. However, we have
been unable to detect pRb at the promoter of either Runx2 or OSX using chromatin
immunoprecipitation. Moreover, the promoters of Runx2 and OSX lack conventional
E2F binding sites. Therefore, although we have not definitively ruled out a direct,
repressive role for pRb in osteoblast differentiation in vitro, we believe this to be an
unlikely possibility.
A second potential cause of the observed increase in osteoblast differentiation
upon pRb loss may be related to cell cycle defects. Notably, the increased density of
osteoblast cultures is known to enhance their differentiation (Gerber and ap Gwynn,
2001; Purpura et al., 2004). We hypothesized that loss of pRb may affect the normal
confluence arrest of the calvarial cells, leading to an increase in proliferation and
consequently, an increase in cell density. Thus, we compared the proliferation of wild-
type versus germline Rbc/c cells throughout the differentiation process. At all time
points, we found that a higher proportion of the Rbc/c osteoblast nuclei incorporated
BrdU than the wild-type controls (Figure 5A,B). In agreement with these findings, the
Rb/" - osteoblasts showed elevated levels of cyclin A and cyclin E mRNAs (Figure 5C).
Finally, total cell counts during the first few days of differentiation demonstrated an
increase in the total number of cells present in Rb/c - confluent cultures compared to
wild-types (data not shown). Similar results in all of these assays were observed in the
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Figure 5. Confluent osteoblasts in vitro exhibit excess proliferation upon loss of pRb
(A) Immunofluorescence analysis of BrdU incorporation in differentiating osteoblasts.
Wild-type (top two rows) and Rbc- (bottom two rows) osteoblasts were treated with
BrdU (green) for 24 hours at the indicated time points during differentiation in vitro.
Nuclei are stained with DAPI (blue). 20X magnification shown. (B) Quantitation of the
immunofluorescence analysis in (A). A minimum of 250 cells was counted from each of
three or more separate images for each sample. A greater percentage of Rbc-/c osteoblasts
incorporate BrdU compared to wild-type cells at all time points. (C) Quantitative RT-
PCR analysis was performed as described in Figure 3. Rb-/c~ osteoblasts (blue bars)
express greater mRNA levels of cyclin E and cyclin A relative to wild-type osteoblasts
(red bars) during in vitro differentiation. (D) Nuclei of mock infected (top two rows) and
acutely ablated (bottom two rows) Rbdc osteoblasts were stained for BrdU (green) and
DAPI (blue). 20X magnification shown. (E) Quantitation of the immunofluorescence
analysis in (D). A greater percentage of Rb"c osteoblast nuclei acutely ablated for pRb
(blue bars) stain positively for BrdU incorporation than control nuclei (red bars). (F)
Quantitative RT-PCR demonstrates that acutely ablated Rbc/c osteoblasts (blue bars)
express greater mRNA levels of cyclin E and cyclin A compared to mock infected
osteoblasts (red bars). All error bars signify one standard deviation. * denotes a
statistically significant difference, p<0.05.
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analyses of osteoblasts acutely ablated for pRb (Figure 5D-F; data not shown). Thus, we
conclude that pRb-loss increases the proliferation and, consequently, the density of
confluent osteoblast cultures, thereby leading to an increase in primary calvarial
osteoblast differentiation in vitro.
The loss of Rb prevents osteoblasts from properly exiting the cell cycle in vivo
Having established the likely basis for the increased differentiation of pRb-
deficient osteoblasts in vitro, we wished to determine whether a similar mechanism could
explain the impaired bone development in vivo. Specifically, since appropriate cell cycle
exit is important for the early stages of osteoblast differentiation in vivo, we hypothesized
that pRb loss might impair cell cycle exit in vivo and cause a negative impact on bone
formation. Thus, to assess cell cycle progression in vivo, we analyzed coronal sections of
el 17.5 frontal bones for 5-Bromo-2-deoxyuridine (BrdU), which incorporates into newly
synthesized DNA during S phase. Embryos deficient for pRb exhibited a significantly
greater percentage of osteoblast nuclei that incorporated BrdU compared to the wild-type
embryos (Figure 6A). We also tested frontal bone sections for protein expression of
PCNA, a known proliferation marker. Consistent with our BrdU data, we observed a
greater number of Rbc-/c- osteoblast nuclei that stained positively for PCNA compared to
wild-type nuclei (Figure 6B). Finally, we extracted RNA from the calvaria of Rbc/c and
wild-type embryos to examine the transcript levels of cyclin A and cyclin E. Like PCNA,
these transcripts are specifically induced in proliferating cells. Rbc -/ calvaria typically
expressed greater mRNA levels of cyclin A and cyclin E than wild-type skulls (Figure
6C). Importantly, the unrestricted cell cycle progression in Rbc '/ frontal bones was not
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Figure 6. pRb-deficient osteoblasts do not properly exit the cell cycle in vivo
(A,B) Immunohistochemical analysis of BrdU incorporation (A) or PCNA protein
expression (B) in coronal sections of frontal bones from e17.5 embryos. Pregnant
females were injected with BrdU for two hours. Rbc-/c frontal bones (bottom) exhibit a
greater number of nuclei positively staining for BrdU or PCNA than wild-type littermates
(top). 20X magnification shown. Frontal bones are marked with the bar. Quantified
results from several experiments are represented in the histograms. Error bars signify one
standard deviation. * denotes a statistically significant difference, p<0.05. (C)
Quantitative RT-PCR analysis of cyclin E (top) and cyclin A (bottom) mRNA levels from
Rbc/c and control littermates. mRNA was isolated from the calvaria of el6.5 embryos.
Analysis performed as described in Figure 3. Rbc-/c- calvaria (blue bars) express
increased levels of cyclin A and cyclin E relative to wild-type littermates (red bars). Error
bars signify one standard deviation. Abbreviations: br, brain; de, dermis; fr, frontal bone.
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associated with an apoptotic response, as determined by TUNEL staining (data not
shown). These data suggest that pRb-deficiency impairs osteoblasts from exiting the cell
cycle in vivo at the appropriate developmental stage.
Deletion of E2fl suppresses the cell cycle and ossification defects in Rbc'/c embryos
The cell cycle regulatory activity of pRb is known to be at least partially
dependent on its ability to suppress the E2F transcription factors and prevent the
activation of genes such as PCNA, cyclin A and cyclin E that control cell cycle
progression. E2F1 is an archetypal member of the E2F family. It is bound to and
inhibited by pRb in arrested cells and it contributes to the activation of target genes once
pRb is inactivated by either mitogenic signaling in wild-type cells or genetic lesions in
tumor cells. Previous work has demonstrated that the loss of E2F 1 can suppress the
ectopic cell cycles evident upon the loss of Rb in other tissues (Tsai et al., 1998). Thus,
we crossed a mouse possessing a deletion of E2fl into our conditional Rb model and
examined compound mutant embryos to determine if E2F activity contributes to the
excess proliferation and ossification defects arising in the Rbc-c embryos.
First, we assessed the level of cellular proliferation in the embryonic osteoblasts
through analysis of both BrdU incorporation and PCNA expression in frontal bone
sections from e17.5 embryos (Figure 7A). These two assay methods yielded highly
concordant results. First, there was no significant difference in the levels of either BrdU-
or PCNA-positive nuclei in the wild-type versus the E2fl- osteoblasts. Thus, loss of
E2fl alone appears insufficient to perturb osteoblast proliferation. Second, consistent
with our prior analysis, proliferating osteoblasts were present at significantly higher
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Figure 7. Deletion of E2fl suppresses the bone defects due to the loss of pRb
(A) Immunohistochemical analysis of BrdU incorporation (top) or PCNA protein
expression (bottom) in coronal sections of frontal bones from e17.5 embryos, performed
as described in Figure 6. Deletion of E2fl suppresses the increased BrdU incorporation
and PCNA expression observed in Rbc-/- frontal bone osteoblasts. (B) Skeletal staining
of e17.5 embryos as described in Figure 1. Deletion of E2fl suppresses the decreased
ossification found in the Rbc/- calvaria (first column) and hyoid bone (second column).
Deletion of E2fl also suppresses the aberrant formation of the palatine process and
pterygoid bone (third column) and xiphoid process (fourth column) observed in Rbc"/
skeletons. Error bars sipnify one standard deviation. * denotes a statistically significant
difference between Rb c and wild-type, E2fl-'-, or Rbcc- E2fl-', p < 0.05.
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levels in the Rbc/c frontal bone compared to the wild-type and E2fl - controls. Finally,
the deletion of E2fl was sufficient to almost fully suppress the excess proliferation
arising in the Rbc-/c- embryos. Therefore, we conclude that inappropriate activation of
E2F I makes a major contribution to the ectopic cellular proliferation of pRb-deficient
osteoblasts in vivo.
We then assessed whether E2fl-inactivation modulated the Rbc/c embryonic
skeletal defects observed at e17.5 (Fig 7B). Consistent with the absence of any
proliferation defects, the deletion of E2fl alone did not cause any detectable defects in
skeletal development. As observed previously, Rb deficiency caused decreased
ossification in the skull and hyoid and aberrant formation of the xiphoid process, palatine
process, and pterygoid bone. Notably, in almost all E2fl'-; Rbc/-" double mutant
embryos, the reduced ossification was partially or completely ameliorated (Figure 7B,
first two columns). Moreover, approximately 40% (5 of 13) of the double mutants
exhibited normal formation of the palatine process, pterygoid bone, and the xiphoid
process was completely normal (Figure 7B, latter two columns). Taken together, these
data demonstrate that deletion of Rb causes defects in embryonic skeletal development
that are due, at least in part, to the inappropriate release of E2F1 and a consequent
inability of the osteoblasts to properly exit the cell cycle.
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DISCUSSION
The Rb locus is mutated or altered in greater than 70% of all osteosarcomas
(Belchis et al., 1996; Feugeas et al., 1996). Moreover, several in vitro studies implicate
pRb and the pocket proteins in osteoblast differentiation (Feuerbach et al., 1997; Beck et
al., 1998; Thomas et al., 2001; Luan et al., 2007). Given these observations, we used the
Mox2 +/cre transgene to conditionally inactivate Rb in the Rbc/c embryo proper, but not in
the placenta, and thereby generate pRb-deficient embryos that survive until birth. This
conditional strategy allows us to assess pRb's role in bone development in vivo and
primary osteoblast differentiation in vitro. Our analyses reveal a role for pRb in the
promotion of osteogenesis via the regulation of proper cell cycle exit.
In the developing embryo, the loss of pRb impaired bone formation in a manner
that caused two types of defects. Some bones, such as the pterygoid bone, palatine
process and xiphoid process, developed abnormally and were misshapen, whereas the
skull and hyoid bone exhibited decreased bone formation. The decreased ossification in
the Rbc/c frontal bone was accompanied by reduced alkaline phosphatase activity and
decreased levels of Coll and OPN mRNA. Previous studies have shown that deletion of
the pRb-related proteins, p107 and p130, or overexpression of E2F1 affect chondrocyte
differentiation and development (Cobrinik et al., 1996; Rossi et al., 2002; Scheijen et al.,
2003). Although our data do not rule out a role for pRb in cartilage development, they
clearly show that pRb plays a role in bone development that is independent of
chondrocytes. Specifically, Rbc~ /c skeletons did not show any apparent defects in
cartilage formation and several of the affected bones form via intramembranous
ossification, a process that does not involve chondrocytes. Moreover, the bone defects in
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the Rbc/c frontal bone, and presumably in other affected bones, were not the result of
increased osteoclast activity or apoptosis. Therefore, our data suggest that the loss of Rb
specifically affects osteoblasts and their differentiation in vivo.
There are two limitations to the in vivo studies above. First, they do not prove
that pRb's requirement for osteoblast differentiation is cell autonomous. Second, they do
not provide insight into the underlying cause of the bone defects occurring upon Rb
deletion. To address these issues, we determined how the loss of pRb affects the
differentiation of primary osteoblasts in vitro. Given our in vivo defects and the prior
observation that pRb-deficient MEFs were impaired in their ability to undergo
osteogenesis (Thomas et al., 2001), we anticipated that primary osteoblasts isolated from
Rbc/c embryos would display an impaired differentiation phenotype in vitro. However,
the exact opposite was observed: the Rb'c/ osteoblasts differentiated to a greater extent
than the wild-type controls. Importantly, we found that the acute ablation of Rb in
confluent osteoblasts was sufficient to trigger increased differentiation. These data show
that loss of pRb acts in a cell autonomous manner to promote the differentiation of
osteoblast progenitors in vitro.
Our study also provides insight into the molecular changes that accompany the
improved in vitro differentiation upon loss of pRb. First, we observe a dramatic
upregulation of two osteoblast transcription factors, Runx2 and OSX, in differentiating
pRb-deficient osteoblasts. We attempted to determine if pRb directly represses these
genes. However, we were unable to detect any evidence for pRb binding by chromatin
immunoprecipitation. Moreover, the Runx2 and OSX promoters lack conventional E2F
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binding sites. These negative results do not rule out a direct role for pRb in the regulation
of Runx2 and OSX, but they do argue against this model.
The second molecular change that accompanies the improved in vitro
differentiation of pRb-deficient osteoblasts is an increase in the fraction of cells that are
proliferating and the sustained presence of proliferating cells at later timepoints in the
differentiation process. Since the density of osteoblasts has been reported to correlate
positively with their ability to differentiate in vitro (Gerber and ap Gwynn, 2001; Purpura
et al., 2004), we hypothesize that the increased proliferation of the pRb-deficient
osteoblasts contributes to their improved differentiation simply by increasing the density
of the confluent cells. We attempted two types of experiments to determine whether the
excess cellular proliferation is responsible for the observed increase in differentiation.
First, we attempted to maintain the Rbc/c osteoblasts in the presence of anti-proliferative
drugs prior to the ablation of pRb. However, the experiment requires several days of
drug treatment in which the cells fared poorly. Second, since our in vivo data indicate
that deletion of E2fl suppresses excess proliferation due to the loss of Rb, we analyzed
the consequence of E2fl deficiency in acutely ablated and germline deleted Rbc/-
osteoblasts. Unfortunately, the loss of E2fl did not suppress the cell cycle defects of
osteoblasts in vitro. Hence, neither of these assays allowed us to directly determine
whether the cell cycle defects in the Rb-depleted cells were the cause of the increased
differentiation in vitro. Nevertheless, it is clear that the loss of pRb leads to an increase
in proliferation of confluent differentiating osteoblasts. We believe that this deregulation
of cell cycle exit, and the consequential increase in cell density, is the likely cause of the
altered differentiation of pRb-depleted osteoblasts in vitro.
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Importantly, support for this model comes from further analysis in the in vivo
setting. First, we observed that the progenitor osteoblasts of the Rbc/c frontal bone failed
to exit from the cell cycle at the appropriate stage of development, consistent with the
notion that this is the underlying cause of the ossification defect. Second, we found that
inactivation of E2fl is sufficient to completely suppress the proliferation defects of the
Rbc/- osteoblasts in vivo, which corresponded with a complete suppression of the
decreased ossification of the skull and hyoid bones and, in approximately 40% of cases,
suppression of the abnormal formation of the palatine process, pterygoid bone, and
xiphoid process. This latter finding was particularly unexpected because, prior to that
point, we suspected that the misshapen bones were an indirect consequence of defective
skeletal muscle development in the Rb/c- embryos. However, since the myocyte
differentiation defects of Rb-null embryos are known to be E2f-independent (Tsai et al.,
1998), the misshapen bones must be, at least partially, a myocyte-independent phenotype.
Importantly, it has been previously demonstrated that pRb can positively regulate Runx2
in vitro (Thomas et al., 2001; Luan et al., 2007). Our findings do not discount this
potential function of pRb as one of the causes of the observed bone defects in vivo.
Nevertheless, our data do clearly demonstrate that many if not all of the bone defects in
the Rbc /-c embryos result from defects in osteoblast differentiation that are due, at least in
part, to the inappropriate release of E2F 1 and the consequent inappropriate cellular
proliferation.
Taken together, our data strongly suggest that loss of Rb affects the normal cell
cycle exit of osteoblast progenitor cells. This model is appealing as it can explain the
apparent discrepancy between our in vitro and in vivo data: in both settings pRb loss
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causes a cell cycle defect that can either promote (in vitro) or impede (in vivo) osteoblast
differentiation depending on the context. Given our findings presented here and the fact
that molecular changes to the Rb locus are observed in a disproportionately high
percentage of osteosarcomas, it will be important to develop additional models that will
allow further analyses of the mechanisms by which loss of Rb promotes osteosarcoma
formation.
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EXPERIMENTAL PROCEDURES
Animal maintenance and histological preparations
The generation of Rbc/c and Meox2-Cre mice has been described previously
(Tallquist and Soriano, 2000; Sage et al., 2003). Rbc/l and E2fl - mice were provided by
Tyler Jacks. Meox2-Cre mice were purchased from Jackson Laboratories. Gestation was
dated by detection of a vaginal plug. Pregnant mice were injected with 10 ll/gm body
weight of 5 mg/ml 5-Bromo-2'-deoxyuridine (BrdU) in phosphate buffered solution
(PBS) two hours prior to tissue collection. For calcein incorporation, pregnant mice were
injected with 10 jil/gm body weight of 2.5 mg/ml calcein 12 or 24 hours prior to tissue
collection. Collected embryonic tissue was fixed in 4% paraformaldehyde (PFA) and
embedded in OCT. Frozen sections were cut at 6-8 microns except those for in situ
analysis, cut at 10-12 microns.
Histological analyses
Enzymatic ALP assays were performed on unfixed frozen sections. Briefly, 0.06g
sodium nitrite was dissolved into 1.5 ml of water and added to 600 [tl of 50 mg/ml of new
fuchsin (Sigma) in 2M HC1. This solution was added to 210 ml Tris buffer (pH 9.0).
Finally, 1.8 ml of 83.3 mg/ml Naphthol AS-Bi-Phosphate (Sigma) in DMF (Sigma) was
added. Sections were incubated with this overall solution for 15 minutes, washed in PBS
and counterstained with hematoxylin. Alizarin red staining was performed by incubating
sections for 5 minutes in 20 mg/ml alizarin red (Sigma), pH 4.2. Immunohistochemical
analyses were performed using antibodies against BrdU (1:50 347580, BD Biosciences)
and PCNA (1:2000 sc56, Santa Cruz) as described (Danielian et al., 2007). For
collagenlal in situs, digoxigenin-11-UTP-labeled single-strand ribo-probe was prepared
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(probe was a gift from B. Olsen), and hybridization was carried out overnight in 50%
formamide at 550C. Washing, detection, staining and mounting of slides were carried out
as described previously (Bohme et al., 1995). Statistical significance was determined
using the Student's T Test.
Skeletal staining
Embryos were sacrificed, skinned, and eviscerated. The remaining tissue was
fixed in 95% ethanol for 4 days, transferred to acetone for 3 days, and subsequently
transferred to staining solution (final volume of 0.015% alcian blue 8GX (Sigma),
0.005% alizarin red S (Sigma) and 5% glacial acetic acid in ethanol) at 37*C for two days
and room temperature for a third day. Tissue was cleared in 1% potassium hydroxide for
several days and ultimately stored in glycerol.
Calvarial preparations and culture
Calvaria from e17.5 embryos were removed, treated with several rounds of
collagenase/trypsin digests at 370C, and plated onto 6-well plates. Cells were grown and
expanded in aMEM with 10% fetal bovine serum and Pen/Strep. For differentiation,
upon reaching confluence, calvarial osteoblasts were treated with media supplemented
with 50 [tg/ml of ascorbic acid and 10 mM P-glycerol-phosphate. Adenovirus (U. of
Iowa Gene Transfer Vector Core) was added to the media at 100 plaque-forming units
per cell and washed away 24 hours later. To assay for calcium deposits, plates were
stained with 1% alizarin red S solution (pH 5.0).
Immunofluorescence
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For BrdU incorporation, osteoblasts were plated onto coverslips prior to achieving
confluence. BrdU was added to the media (final concentration of 10 ýtM) and incubated
for 24 hours prior to 4% PFA fixation. Antigen was detected using antibody against
BrdU (1:50 347580, BD Biosciences) with Texas Red-X goat anti-mouse secondary
(1:1000, Invitrogen). Statistical significance was determined using the Student's T Test.
Quantitative real-time PCR
RNA was isolated from differentiation plates using the Qiagen RNEasy kit. First-
strand cDNA was transcribed from 1 tg of RNA using Superscript III Reverse
Transcriptase (Invitrogen) following product instructions. Quantitative RT-PCR with 20-
100 ng cDNA was performed using SYBR Green (Applied Biosystems). Reactions were
run on the ABI Prism 7000 Sequence Detection System and analyzed using the 7000 SDS
software. Primers are listed in Table 1.
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Table 1. Quantitative RT-PCR Primer Pairs
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Gene Primer Sequence
Alkaline Phosphatase For: TCT CCA GAC CCT GCA ACC TC
Rev: CAT CCT GAG CAG ACC TGG TC
Collagenlal For: CGA GTC ACA CCG GAA CTT GG
Rev: GCA GGC AGG GCC AAT GTC TA
Cyclin A For: AGT TTG ATA GAT GCT GAC CC
Rev: TAG GTC TGG TGA AGG TCC
Cyclin E For: TGT TTT TGC AAG ACC CAG ATG A
Rev: GGC TGA CTG CTA TCC TCG CT
Osteocalcin For: CTC TGT CTC TCT GAC CTC ACA G
Rev: CAG GTC CTA AAT AGT GAT ACC G
Osteopontin For: TGC TTT TGC CTG TTT GGC AT
Rev: TTC TGT GGC GCA AGG AGA TT
Osterix For: GCA AGG CTT CGC ATC TGA AA
Rev: AAC TTC TTC TCC CGG GTG TGA
Runx2 For: TGA GAT TTG TGG GCC GGA
Rev: TCT GTG CCT TCT TGG TTC CC
Ubiquitin For: TGG CTA TTA ATT ATT CGG TCT GCA T
Rev: GCA AGT GGC TAG AGT GCA GAG TAA
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Chapter 3
E2F4 is required for proper bone development and normal cell cycle exit of
osteoblast progenitor cells in vivo
Seth Berman, Emily Miller, Tina L. Yuan, Alicia M. Caron, Paul S. Danielian, and
Jacqueline A. Lees
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preliminary observation that E2f4 - embryos have an ossification defect in the skull. All
work was performed in the lab of Jacqueline Lees.
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ABSTRACT
E2F4 is one of the repressive E2Fs, functioning to regulate the cell cycle through
maintenance of a GO/G1 cell cycle state and repression of transcription following S
phase. Its deletion in mice causes defects in development, such as in the airway
epithelium. Here we analyze E2f4' embryos for defects in bone development. We show
that mutation of E2f4 causes a defect in ossification of both intramembranous and
endochondral bones. This defect is observed as early as e13.5, when loss of E2f4 affects
the normal ossification of the clavicle, the first skeletal structure to become ossified. In
addition, the timely deposition of cartilage matrix is delayed during the formation of
some endochondral bones, suggesting that E2F4 may regulate chondrocyte
differentiation. In the frontal bones of E2f4" embryos, decreased ossification is
accompanied by reduced alkaline phosphatase activity, an early marker of osteoblast
differentiation. Furthermore, E2f4/ frontal bones exhibit a significantly greater
percentage of cycling cells compared to wild-type frontal bones. In vitro studies
demonstrate that E2F4 does not possess a specific, cell cycle-independent function in
osteoblast differentiation. Instead, the in vitro experiments indicate that there is a larger
pool of progenitor osteoblasts in the calvaria of E2f4/ embryos compared to the calvaria
of littermate wild-type embryos. Therefore, these data indicate a novel role for E2F4 in
the normal, timely development of cartilage and bone in vivo. Moreover, we suggest that
in intramembranous bone formation, E2F4 functions to promote cell cycle exit in
progenitor osteoblasts and thereby contributes to the commitment of these cells to
differentiate into terminal osteoblasts and form bone.
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INTRODUCTION
The E2F family of transcription factors is best characterized for its role in cell
cycle regulation (reviewed in Trimarchi and Lees, 2002). In general, these proteins can
be categorized based on their ability to either activate or repress transcription of E2F-
responsive genes. E2F4 has been labeled as one of the "repressive" E2Fs and functions
primarily to maintain a GO/G1 cell cycle state. This is opposed to the "activating" E2Fs
that function to promote G 1/S progression. In support of this model, overexpression of
E2F4 or E2F5, the other repressive E2F, in quiescent cells does not drive progression
through the cell cycle as efficiently as observed upon overexpression of the activating
E2Fs (DeGregori et al., 1997; Lindeman et al., 1998; Lukas et al., 1996). Conversely,
murine embryonic fibroblasts (MEFs) lacking E2F4 and E2F5 are unable to arrest upon
p1 6 INK4a overexpression (Gaubatz et al., 2000). In addition, E2F4 and E2F5 are
expressed in all stages of the cell cycle including GO/quiescence, in contrast to the
activating E2Fs that are expressed only in cycling cells (Vairo et al., 1995; Wells et al.,
2000). Finally, E2F4 and E2F5 bind to a different set of pocket proteins than the
activating E2Fs. While the activating E2Fs bind to pRb, E2F5 binds to p130 (Hijmans et
al., 1995; Sardet et al., 1995) and E2F4 binds to pRb, p107, and p130 (Beijersbergen et
al., 1994; Ginsberg et al., 1994; Moberg et al., 1996). Importantly, the E2F4-p130 and
E2F4-p 107 complexes are bound to E2F-responsive promoters during GO/G1, correlating
with the transcriptional repression of those promoters (Rayman et al., 2002). These data
indicate that E2F4 and E2F5 function to repress gene expression and maintain a GO/G1
cell cycle state.
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E2F4 also affects development and differentiation through cell cycle-dependent
and cell cycle-independent mechanisms. E2f4-- mice are anemic during development and
demonstrate cell autonomous defects in red blood cell maturation (Humbert et al., 2000;
Rempel et al., 2000). These erythroid defects stem from impaired cell cycle progression
(Kinross et al., 2006). E2f4/ mice also have a thin intestinal epithelium and a reduction
in crypt formation (Rempel et al., 2000). Finally, E2f4- mice exhibit neonatal lethality
caused by chronic rhinitis and associated opportunistic bacterial infections (Humbert et
al., 2000). The susceptibility to bacterial infections stems from a defect in which the
cilial cells of the airway epithelium are absent and replaced by cells that produce mucin
(Danielian et al., 2007). The combination of excess mucin and a lack of cilia prevents
clearance and increases the chances of bacterial infection. Although the mechanism
underlying the cilial cell defect is unknown, it appears that the defect is independent of
cellular proliferation. E2F4 also functions in a cell cycle-independent manner in vitro to
inhibit adipocyte differentiation, although E2F4 is also likely to be functioning to
maintain growth arrest in differentiating adipocytes (Fajas et al., 2002; Landsberg et al.,
2003).
A potential role for E2F4 in osteoblast and chondrocyte differentiation has not
been investigated. However, its pocket protein binding partners have demonstrated
functions in the differentiation of these cell types. Deletion of pl07 and p130 negatively
affects cell cycle exit in chondrocytes in vivo (Cobrinik et al., 1996), while loss of Rb
inhibits osteoblast differentiation in vitro (Thomas et al., 2001). Therefore, it is plausible
that E2F4 may also function in the differentiation of these cells and, consequently, in
bone development.
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Bone development occurs through two distinct processes (reviewed in Wagner
and Karsenty, 2001). In the first process, termed intramembranous ossification,
mesenchymal progenitor cells differentiate directly into osteoblasts to produce bone.
Several calvarial bones (also known as cranial bones or the skull) and most likely part of
the clavicle (also known as the collarbone) form via intramembranous ossification. The
second process is endochondral ossification, and it is responsible for the formation of the
majority of skeletal bones, including long bones, vertebrae, and ribs. In endochondral
ossification, an intermediate step occurs whereby mesenchymal cells condense and
differentiate into chondrocytes. These chondrocytes proliferate, secrete cartilage matrix,
and form the template for the eventual ossified bone. Upon terminal differentiation,
chondrocytes become hypertrophic and ultimately undergo apoptosis, clearing the way
for invading osteoblasts to take their place and lay down the osteoid matrix.
Here we investigate the role of E2F4 in bone development. We show that E2f4-
embryos exhibit a defect in the normal development of bones forming through either
endochondral or intramembranous ossification. In the skull, this E2f4- ossification
defect is associated with increased proliferation of cells of the osteoblast lineage,
suggesting that osteoblast progenitor cells fail to properly exit the cell cycle.
Furthermore, in vitro experiments suggest that E2F4 does not possess a cell cycle-
independent function in terminal osteoblast differentiation. Instead, the in vitro data
support the hypothesis that osteoblast progenitor cells in vivo are not exiting the cell cycle
and terminally differentiating. Together, our data suggest a novel in vivo function for
E2F4 in promoting the cell cycle exit of osteoblast progenitor cells, thereby contributing
to the commitment of these cells to differentiate into terminal osteoblasts and form bone.
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RESULTS
E2f4"' embryos exhibit defects in murine bone development
We examined the skeletons of wild-type and E2f4' embryos at e18.5 by alizarin
red staining of bone and alcian blue staining of cartilage. At this stage of development,
the E2f4/ embryos displayed less ossification compared to wild-type embryos in several
bones (Figure 1). The frontal and parietal bones of the skull, which form via
intramembranous ossification, were less ossified in the E2f4' embryos based on the
alizarin red staining (Figure 1A). Moreover, endochondral bones such as the presphenoid
bone, xiphoid process, and sternebrae displayed less ossification in the E2f4" embryos
compared to wild-type embryos (Fig. IB,C).
We then examined earlier time points during development for skeletal defects.
We found that at e 15.5, E2f4 - embryos exhibited less alizarin red staining in the head
compared to wild-type embryos (Figure S 1). In addition, we observed incomplete alcian
blue staining of the presphenoid and basisphenoid bones (Figure S ). This latter finding
suggests that the ossification defect in the presphenoid bone at e18.5 may stem from a
defect or delay in the differentiation of the chondrocytes that form the initial template of
this bone. We also looked at e13.5 embryos, at which time the first and only bone to
stain with alizarin red is the clavicle. It is debatable whether the clavicle forms via
intramembranous (Gardner, 1968), intramembranous and endochondral (Andersen,
1963), or a unique form of ossification (Huang et al., 1997). Nevertheless, we observed
that the loss of E2f4 similarly affects the normal ossification of the clavicle (Figure S ).
The data from these embryos indicate that the deletion of E2f4 affects the normal
embryonic development of several bones of the murine skeleton.
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e18.5
Figure 1. Deletion of E2f4 causes defects in embryonic bone development
(A-C) Alizarin red (bone) and alcian blue (cartilage) staining of e18.5 and PO littermate
embryos. el8.5 E2f4"t embryos exhibit less ossification in the cranium (A), presphenoid
bone (B), and sternebrae (arrows) and xiphoid (C). Abbreviations: fr, frontal bone; pa,
parietal bone; pp, palatine process; ps (with arrow), presphenoid; xp, xiphoid process.
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Figure Sl. Deletion of E2f4 causes defects in early embryonic cartilage and bone
development
(A,B) Alizarin red (bone) and alcian blue (cartilage) staining of e13.5 (A) and e15.5 (B)
embryos. (A) e13.5 E2f4/ embryos exhibit less ossification in the clavicles
(arrowheads). (B) e15.5 E2f4/ embryos display less ossification of bone (arrowhead)
and less deposition of cartilage matrix in the presphenoid and basisphenoid elements.
Abbreviations: bs, basisphenoid; ps, presphenoid.
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Finally, we analyzed the skeletons of mice immediately after birth (PO), which
occurred at what would have been the equivalent to e19.5 for these litters of mice. At PO,
most of the E2f4/ mice no longer exhibited less ossification in the skull, sternebrae, and
xiphoid process compared to wild-type littermates (Figure 1A,C). The one exception was
in the presphenoid bone (Figure 1B). Therefore, although the deletion of E2f4 causes a
defect in the normal, timely formation of bones, the deletion does not prevent the
development of the murine skeleton.
E2f4 deletion affects an early marker of osteoblast differentiation in vivo
We were interested in the effect of E2f4 deletion on osteoblast differentiation in
vivo. Thus, we focused our studies on the frontal bone of the skull, as this
intramembranous bone differentiates directly from a mesenchymal progenitor cell into a
terminal osteoblast. We analyzed the enzymatic activity of an early marker of osteoblast
differentiation, alkaline phosphatase (ALP). In e17.5 E2f4/ frontal bones, the ALP
activity was significantly decreased compared to the activity in wild-type frontal bones
(Fig. 2). Testing for a late marker of differentiation, we observed a decrease in alizarin
red staining in the E2f4/ frontal bones compared to wild-type frontal bones (Fig 2).
Notably, the decreased alizarin red staining of the E2f4/ frontal bone sections reaffirmed
our prior skeletal staining analyses (Fig. 1). This data indicates that an early step in the
osteoblast differentiation pathway is affected upon E2f4 deletion in vivo.
E2f4 deletion increases cellular proliferation in the embryonic frontal bone
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Figure 2. E2f4-deficient frontal bones display decreased levels of alkaline phosphatase
Coronal sections of frontal bones from el 7.5 embryos were assessed by histochemical
analysis of alkaline phosphatase activity (left column, ALP) and alizarin red staining of
bone (right column, AR). E2f4" frontal bone sections (bottom row) exhibit decreased
levels of both markers compared to wild-type (top row). 2X magnification shown.
Arrows indicate the front of activity or staining, respectively.
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The deletion of E2f4 in mice causes fetal anemia due to impaired cell cycle
regulation (Humbert et al., 2000; Kinross et al., 2006; Rempel et al., 2000). As cell cycle
regulation and exit are important processes during the initial steps of osteoblast
differentiation, we hypothesized that deletion of E2f4 may affect the ability of progenitor
osteoblasts to exit the cell cycle. Therefore, we assessed cell cycle progression in frontal
bones using two assays, 5-Bromo-2-deoxyuridine (BrdU) incorporation and Ki67
expression. Both of these methods detect entry into S phase and are well-established
assays of cellular proliferation. We found that a greater percentage of osteoblast
progenitor cells were incorporating BrdU in the e17.5 E2f4/ frontal bone compared to
the wild-type frontal bone (Figure 3A). A similar, significant trend was observed in the
e16.5 E2f4/ frontal bone (data not shown). However, at e18.5 there was no longer a
significant difference in the proliferation of osteoblast cells in E2f4/ and wild-type
frontal bones (data not shown). Consistent with our BrdU data, we observed a greater
percentage of e 17.5 E2f4/ osteoblast cells that stained positively for Ki67 compared to
wild-type cells (Fig. 3B). Importantly, the increased cell cycle progression in the e 17.5
E2f4/ frontal bone was not associated with an apoptotic response, as determined by
TUNEL staining (data not shown). These data suggest that E2f4 deletion impairs the
ability of osteoblast cells to exit the cell cycle at the appropriate developmental stage in
vivo.
E2f4" calvarial osteoblast preparations differentiate to a greater extent than wild-
type osteoblasts in vitro
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Figure 3. E2f4-deficient progenitor osteoblasts do not properly exit the cell cycle in vivo
(A,B) Immunohistochemical analysis of BrdU incorporation (A) or Ki67 protein
expression (B) in coronal sections of frontal bones from el 7.5 embryos. Pregnant
females were labeled with BrdU for two hours. E2f4' frontal bones (bottom) exhibit a
greater percentage of nuclei positively staining for BrdU or Ki67 than wild-type frontal
bones (top). 20X magnification shown. Frontal bones are delineated by the bar. Results
of five separate experiments are quantified below the images. Error bars represent one
standard deviation. * represents statistical significance, p<0.05. Abbreviations: de,
dermis; fr, frontal bone; br, brain.
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To further dissect the role of E2F4 in osteoblast differentiation, we used a well-
defined, in vitro osteoblast differentiation system. Specifically, primary cells were
isolated from the calvaria of e 18.5 wild-type and E2f4- embryos. This type of
preparation contains a mixture of dividing fibroblastic cells, some of which are
progenitor cells capable of osteoblastic terminal differentiation. The calvarial
preparations were cultured and then induced to differentiate upon confluence and the
addition of ascorbic acid and f3-glycerol phosphate. Bone-like, calcium-containing
deposits are secreted by terminally differentiated osteoblasts and can be detected by
alizarin red staining. We observed that the E2f4/ - cells secreted a greater amount of
calcium deposits than wild-type cells based on the alizarin red staining (Fig. 4A).
Notably, the rate of "bone formation" was the same for E2f4/ and wild-type cells, as
determined by the number of days after the initiation of differentiation that we first
observed secreted calcium deposits (data not shown).
We then used quantitative RT-PCR to analyze the mRNA levels of several
osteoblast markers during the differentiation of these cells. Runx2 and Osterix (OSX) are
two transcription factors required for osteoblast differentiation (Ducy et al., 1997;
Nakashima et al., 2002; Otto et al., 1997). ALP and Collagenlal (Coll) are early
markers of osteoblast differentiation, while Osteopontin (OPN) and Osteocalcin (OC) are
early/mid- and late-differentiation markers, respectively. Compared to the wild-type
cells, E2f4- -calvarial preparations demonstrated a significant upregulation of OSX, OPN,
and at times, ALP (Figure 4B). These data demonstrate that the E2f4- calvarial
preparations possess increased mRNA levels of several osteoblast differentiation markers
and secrete a greater amount of mineralized deposits compared to wild-type cells.
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Figure 4. E2f4' calvarial cells differentiate to a greater extent than wild-type
(A) Terminal differentiation of primary calvarial cells was determined by alizarin red
staining of secreted calcium deposits after 0 and 35 days. E2f4/" calvarial cells (bottom
row) secrete a greater number of calcium deposits than wild-type osteoblasts (top row).
(B) Quantitative RT-PCR measurements of bone marker mRNA levels from wild-type
(red bars) and E2f4/r (blue bars) calvarial cells during differentiation. E2f4/ calvarial
cells express greater levels of Osterix, Osteopontin, and at times Alkaline Phosphatase
mRNAs compared to wild-type cells. Ubiquitin was used as an internal control to
normalize for RNA levels within each sample. Each time point is an average of four
samples. Error bars represent one standard deviation.
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Given that the loss of E2f4 in vivo resulted in decreased ossification of various
bones, we were initially surprised by the finding that E2f4/ cells in vitro secrete a greater
number of calcium-containing deposits compared to wild-type cells. We reasoned that
the increased ossification potential of E2f4- calvarial preparations was due to one of
three hypotheses. The first hypothesis is that E2f4/ calvarial cells do not confluence
arrest properly. This would lead to continued proliferation at confluence, thereby
increasing the number and density of cells in the monolayer. It has been shown that
increasing the density of calvarial cells increases their ability to form a calcified matrix
(Gerber and ap Gwynn, 2001; Purpura et al., 2004). Therefore, a confluence arrest defect
would lead to increased mineralization due to the greater number of osteoblast progenitor
cells and the increased density of the confluent monolayer. The second hypothesis is that
E2F4 functions in a specific, cell cycle-independent manner to repress osteoblast
differentiation. In this situation, the deletion of E2f4 would allow for de-repression of
and a consequential increase in osteoblast differentiation and mineralization. The final
hypothesis is that the increased mineralization in E2f4/ cells may reflect the presence of
a greater number of osteoblast progenitor cells being isolated during the preparation of
the E2f4/ calvaria. This would lead to a greater percentage of E2f4- cells possessing the
ability to terminally differentiate, induce osteoblast markers, and secrete ossified matrix.
E2f4-depleted calvarial cells display the same cell cycle profile as wild-type cells
We analyzed BrdU incorporation to test the hypothesis that E2f4' calvarial cells
displayed different proliferation rates and cell cycle arrest properties compared to wild-
type cells. In cycling populations, we observed that a similar percentage of E2f4/ and
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wild-type calvarial cells incorporated BrdU during a two-hour pulse (data not shown).
Hence, the E2f4-' calvarial cells were most likely not cycling at a faster rate compared to
wild-type cells.
We then analyzed BrdU incorporation at various time points during differentiation
to determine if the E2f4" calvarial cells were confluence arresting as well as wild-type
cells. For this experiment, a 24-hour pulse of BrdU was performed. We observed that a
similar percentage of wild-type and E2f4/' calvarial cells incorporate BrdU during the
differentiation time-course (Figure 5A). Quantifying the results of several experiments,
we find no statistically significant difference at any time point in the percentage of E2f4-/
cells incorporating BrdU compared to wild-type cells (Figure 5C).
In a similar experiment, we tested confluence arrest in wild-type cells depleted of
E2F4. To accomplish this, we developed hairpins against E2f4 that knock down the
endogenous levels of E2F4 protein in wild-type cells greater than 90% (Figure S2A).
The stable integration of the E2f4 hairpin construct maintained knockdown of the E2F4
protein through the time course of a differentiation experiment (Figure S2A). We found
that wild-type calvarial cells infected with the E2F4 hairpin displayed a similar
percentage of cells incorporating BrdU as did wild-type cells infected with a control
hairpin against luciferase (Figure 5B,D). Taken together, these data indicate that loss of
E2F4 does not alter cell cycle kinetics or the properties of confluence arrest, and thereby
they refute the first hypothesis discussed above.
E2F4 does not possess a cell cycle-independent, repressive function in osteoblast
differentiation
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Figure 5. Depletion of E2f4 does not affect confluence arrest in calvarial cells
(A,B) Indirect immunofluorescence analysis of cell cycle proliferation in confluence
arrested cells. (A) Wild-type (top two rows) and E2f4' (bottom two rows) calvarial cells
were cultured with BrdU for 24 hours at the indicated time points during differentiation
in vitro. Nuclei were stained for BrdU incorporation (green) and DAPI (blue). 20X
magnification shown. (B) Wild-type calvarial cells were stably infected with either a
control hairpin against luciferase (top two rows) or a hairpin against E2f4 (bottom two
rows). Cells were then cultured with BrdU for 24 hours at the indicated time points
during differentiation in vitro. Nuclei were stained for BrdU incorporation (green) and
DAPI (blue). 20X magnification shown. (C,D) Quantitation of the immunofluorescence
in (A) and (B), respectively. A minimum of 250 cells were analyzed per sample from
three separate experiments. Error bars represent one standard deviation. (C) Wild-type
(red bars) and E2f4/ (blue bars) calvarial cells display similar confluence arrest profiles.
(D) Calvarial cells infected with luciferase hairpin (red bars) or E2f4 hairpin (blue bars)
display similar confluence arrest profiles.
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Figure S2. Stable knock down or overexpression of E2F4 over the time course of a
differentiation experiment
(A,B) Western analysis of E2F4 protein levels. (A) Stable infection of the E2f4 hairpin
constitutively knocks down the E2F4 protein through the 35 day duration of a
differentiation time course experiment. GAPDH is shown as a loading control. (B)
Stable infection of the hE2f4 cDNA construct constitutively overexpresses hE2F4 protein
through the 35 day duration of a differentiation time course experiment. GAPDH is
shown as a loading control.
140
Our second hypothesis to explain the increase in ossified matrix in E2f4-
calvarial cells was that E2F4 possessed a specific, cell cycle-independent function to
repress osteoblast differentiation. We reasoned that if this hypothesis were true, then
depletion of E2F4 in wild-type calvarial cells should cause an increase in secreted
calcium-containing deposits. After isolating and culturing wild-type calvarial cells, we
infected the cells with a retrovirus containing a hairpin against E2f4 or against luciferase.
After puromycin selection, the two infected cell populations were each grown to
confluence arrest and induced to differentiate. Based on alizarin red staining, cells with
E2F4 constitutively knocked down secreted a comparable number of calcified deposits as
did cells with the control luciferase hairpin (Figure 6A). Additionally, both infected
populations of cells secreted calcium deposits to a similar extent as wild-type calvarial
cells not infected with retrovirus (data not shown). We then analyzed the expression of
osteoblast genes during the differentiation time-course in the two infected cell
populations. In accordance with the alizarin red staining, we found no major differences
in the expression of osteoblast markers in cells infected with the E2f4 hairpin compared
to those infected with the luciferase hairpin (Figure 6B).
We also performed the converse experiment to test our second hypothesis. We
isolated and cultured E2f41 calvarial cells and then infected them with retrovirus
expressing human E2F4. This retroviral construct efficiently overexpressed E2F4
(Figure S2). As a control, the E2f4/ calvarial cells were infected with the same
retrovirus expressing only the puromycin resistance gene. After puromycin selection, the
cell populations were grown to confluence arrest and induced to differentiate. We
observed no difference in the amount of secreted calcium matrix in the differentiated
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Figure 6. E2F4 does not function to repress osteoblast differentiation in vitro
(A) Alizarin red staining of secreted calcium deposits after 0 and 35 days. Wild-type
calvarial cells were stably infected with either a control hairpin against luciferase or a
hairpin against E2f4. No difference is observed between wild-type cells with E2F4
knockdown or with the lucifase control hairpin (B) Quantitative RT-PCR results of (A)
display no differences in the expression of osteoblast markers between control cells (red
bars) and cells with knock down of E2F4 (blue bars). Quantitative RT-PCR was
performed as described in Figure 4B. (C) Alizarin red staining of secreted calcium
deposits after 0 and 35 days. E2f4-- calvarial cells were stably infected with hE2F4 or an
empty virus. No difference is observed between E2f4/ cells overexpressing hE2F4 or
E2f4-/ control cells (D) Quantitative RT-PCR results of (C) display no differences in the
expression of osteoblast markers between control cells (red bars) and cells
overexpressing E2F4 (blue bars). Quantitative RT-PCR was performed as described in
Figure 4B.
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E2f4 - calvarial cells overexpressing human E2F4 compared to those cells infected with
the empty virus (Figure 6C). Moreover, both infected populations of cells secreted
ossified matrix to a similar extent as E2f4- calvarial cells that were not infected with a
retrovirus (data not shown). In agreement with these findings, we observed no major
differences in the expression of osteoblast markers in E2f4/ cells infected with the
human E2F4 retrovirus or infected with the control retrovirus (Figure 6D). These two
sets of experiments indicate that E2F4 does not possess a specific, cell cycle-independent
function to repress osteoblast differentiation, and therefore these data negate the second
hypothesis discussed previously.
Taken together, we find that the in vitro differentiation experiments support the
third hypothesis proposed, whereby a greater pool of osteoblast progenitor cells are
isolated during the calvarial preparation of E2f4/ embryos compared to the preparations
from wild-type embryos.
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DISCUSSION
E2F4 is primarily considered to be a repressive E2F that functions in GO/G1 cells
to maintain growth arrest. E2F4 binds to all three pocket proteins, pRb, p107, and p130,
in vivo (Moberg et al., 1996). Interestingly, all of these pocket proteins have been
demonstrated to affect bone development. Deletion of p107 and p130 causes an increase
in chondrocyte proliferation in vivo, thereby affecting the development of the long bones
(Cobrinik et al., 1996), whereas pRb can promote osteoblast differentiation in vitro
(Thomas et al., 2001). Therefore, we hypothesized that E2F4 may function in the
development of bone. We demonstrate here that E2f4/ embryos exhibit a defect in the
normal, timely ossification of several skeletal bones. Of the bones forming through
intramembranous ossification, this defect is likely due to an inability of progenitor
osteoblasts to exit the cell cycle. Furthermore, our in vitro studies demonstrate that E2F4
does not function specifically in osteoblast differentiation. Instead, these experiments
support a role for E2F4 in promoting cell cycle exit in osteoblast progenitor cells, thereby
enabling terminal osteoblast differentiation.
We initially observed that the normal development of several bones in el 8.5
E2f4/ embryos was perturbed. Analyzing embryonic skeletons at earlier times during
development, we found that the loss of E2f4 affected bone formation at all stages. This
included e13.5, when loss of E2f4 affected the ossification of the clavicle, the first
skeletal structure to undergo ossification (Huang et al., 1997). However, we observed
that by birth, almost all of the bones in the E2f4- mice were similar to those of wild-type
mice. Therefore, deletion of E2f4 does not prevent ossification. Instead, E2f4 deletion
seems to delay ossification.
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The delay in bone formation was not specific for the process through which the
bones developed. The E2f4' embryos exhibited defects in the timely ossification of
intramembranous bones, including the frontal and parietal bones, and of endochondral
bones, such as the sternebrae and presphenoid. Since endochondral bones form through a
cartilage intermediate, it was important to determine the effect of E2f4 loss on
chondrocyte differentiation. To this end, we observed defective or delayed collagen
matrix deposition of the presphenoid and basisphenoid bones at e 15.5. Therefore, at this
time we cannot rule out that the ossification delay in endochondral bones is due to defects
in chondrocyte differentiation. Ongoing experiments in our lab will address this issue.
Nevertheless, the delayed ossification of intramembranous bones such as the frontal bone
cannot be explained by a defect in chondrocyte differentiation, as these bones do not
form via a cartilage intermediate.
Aside from osteoblasts and chondrocytes, one other cell type, the osteoclast, is
involved in the modeling of bones. Osteoclasts are mutlinucleated cells of monocytic
origin that function to resorb bone. It is possible that the decreased ossification we
observed in the E2f4- embryos was due to increased osteoclast activity. However, in
histological sections of e 17.5 E2f4' frontal bones, we observed the presence of few to no
osteoclasts, similar to our findings for wild-type frontal bones (data not shown).
Therefore, we do not believe that osteoclast activity is contributing to the ossification
defect of the skull in the E2f4/ embryos. By elimination, therefore, our data indicate that
E2F4 is required for the appropriate differentiation of osteoblasts and thereby contributes
to the normal development of bone.
We observed that the decreased ossification in the E2f4-- frontal bone was
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accompanied by reduced alkaline phosphatase activity, an early marker of osteoblast
differentiation. Furthermore, the e17.5 E2f4-' frontal bone exhibited a significantly
greater percentage of cells progressing through the cell cycle compared to the wild-type
frontal bone. We believe that the increase in proliferation represents the failure of
osteoblast progenitor cells to properly exit the cell cycle, a necessary process in the early
steps of osteoblast differentiation. Such a role would not be unprecedented for E2F4.
Studies of adipocyte differentiation in vitro demonstrate that E2F-p 130 complexes are the
predominant E2F-pocket protein species present in GO pre-adipocytes and terminally
differentiated adipocytes (Richon et al., 1997), suggesting that the repressive E2Fs are
important for maintaining GO arrest during adipocyte differentiation.
Another possible explanation for the skeletal defects in the E2f4" embryos is that
the increased proliferation of osteoblasts may activate the apoptotic machinery, thereby
leading to a decreased number of living, functional osteoblasts to produce bone.
However, we found no evidence of increased apoptosis in the frontal bone of either wild-
type or E2f4-'" embryos. Therefore, our in vivo data suggest that the E2f4- ossification
defects are due to an inability of progenitor osteoblasts to properly exit the cell cycle and
proceed with terminal differentiation. It is interesting to note that by e 18.5, progenitor
osteoblasts in the E2f4- frontal bone displayed a similar percentage of cycling cells
compared to that observed in wild-type embryos. This suggests that the E2f4-'- cell cycle
exit defect is not permanent, but is instead a temporary defect. This interpretation is in
accordance with the finding that at birth the alizarin red staining of the E2f4-'- calvaria is
similar to that of wild-type.
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One limitation to these in vivo studies is that they do not rule out the possibility
that E2F4 contributes to the differentiation process in a more direct manner. Thus, to
address these issues, we have determined how the loss of E2F4 affects the differentiation
of primary osteoblasts in vitro. We observed that E2f4- calvarial cells secreted a greater
amount of calcified matrix compared to wild-type cells. This finding was accompanied
by a significant increase in the mRNA levels of the osteoblast markers, OSX, OPN and
possibly ALP, in the E2f4/ calvarial cells.
Given that in vivo the deletion of E2f4 caused a delay in ossification, we were
initially surprised that the E2f4-r calvarial cells deposited a greater amount of ossified
matrix compared to wild-type cells. We proposed three hypotheses to explain the
observed in vitro data. The first is that E2f4/ calvarial cells do not confluence arrest
properly. This would lead to continued proliferation at confluence, thereby increasing the
absolute number and overall density of cells in the monolayer. It has been shown that
increasing the density of calvarial cells increases their ability to form a calcified matrix
(Gerber and ap Gwynn, 2001; Purpura et al., 2004). Therefore, a confluence arrest defect
would lead to an increase in the number of ossified secretions due to the greater number
of osteoblast progenitor cells and the increased density of the confluent monolayer. The
second hypothesis is that E2F4 functions in a specific, cell cycle-independent manner to
repress osteoblast differentiation. The deletion of E2f4, therefore, would cause de-
repression and a consequential increase in osteoblast differentiation and mineralization.
The final hypothesis is that the increased mineralization in E2f4/ cells may reflect the
presence of a greater pool of osteoblast progenitor cells in the E2f4-r calvarial
preparation. As shown in Figure lA, at e18.5 the E2f4/ calvarium is less ossified than
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the wild-type littermate calvarium, and Figure 3 suggests that this may be due to the
inability of E2f4/ progenitor osteoblasts to exit the cell cycle. Therefore, upon isolating
cells from the calvaria of e 18.5 embryos, we may be isolating a larger pool of osteoblast
progenitor cells from the E2f4/ embryos than from the wild-type embryos. All three of
these hypotheses would lead to a greater percentage of E2f4- cells possessing the ability
to terminally differentiate, induce osteoblast markers, and secrete ossified matrix.
We ruled out the first hypothesis by analyzing BrdU incorporation in wild-type
and E2f4-depleted cells. In cycling cells, E2f4/ calvarial cells were not proliferating at a
faster rate than wild-type cells. This observation is in agreement with previous studies
demonstrating the E2f4/ MEFs display cell cycle kinetics similar to wild-type cells
(Humbert et al., 2000; Rempel et al., 2000). Similarly, in confluent populations, we did
not observe any proliferative differences between E2f4/ calvarial cells and wild-type
cells, indicating that E2f4/ calvarial cells confluence arrest properly. Moreover, hairpin-
mediated knockdown of E2F4 in wild-type calvarial cells did not affect confluence arrest.
These observations are in agreement with previous studies demonstrating that E2f4- cells
do not possess defects exiting the cell cycle upon serum starvation or confluence arrest
(Humbert et al., 2000; Landsberg et al., 2003; Rempel et al., 2000). Taken together,
these data demonstrate that loss of E2f4 does not affect cell cycle kinetics or exit in vitro,
and therefore these findings disprove the first hypothesis.
Interestingly, a cell cycle exit defect is physiologically significant in vivo. We
believe that the lack of a cell cycle-related phenotype in vitro is an artifact of the in vitro
assay system. Although in vivo the deletion of E2f4 prevents progenitor osteoblasts from
exiting the cell cycle, thereby delaying differentiation, in vitro the calvarial cells must be
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grown to confluence and exit the cell cycle prior to the induction of differentiation.
Hence, it seems likely that the forced confluence arrest in vitro bypasses the cell cycle-
related effect that E2f4 deletion displays upon osteoblast differentiation.
We next ruled out the second hypothesis that E2F4 possesses a specific, cell
cycle-independent function in repressing osteoblast differentiation. Cells with
constitutive, hairpin-mediated E2F4 knock down secreted a comparable number of
calcified deposits as did cells with a control luciferase hairpin. Moreover, we found no
major differences in the expression of osteoblast genes in cells infected with the E2f4
hairpin compared to control cells. Conversely, E2f4 - calvarial cells overexpressing
human E2F4 secreted a similar amount of calcified matrix as control E2f4- calvarial
cells, and no differences in osteoblast marker expression were observed between the two
cell populations. These data indicate that E2F4 does not possess a specific, cell cycle-
independent function to repress osteoblast differentiation, and therefore these findings
disprove the second hypothesis.
We find, instead, that the in vitro differentiation experiments support the third
hypothesis proposed, whereby a greater pool of osteoblast progenitor cells are isolated
during the calvarial preparation of E2f4/ embryos compared to the preparations from
wild-type embryos. This conclusion lends further support to the notion that deletion of
E2f4 in vivo affects the normal cell cycle exit of progenitor osteoblasts. In conclusion,
we present data demonstrating a novel role for E2F4 in the normal, timely development
of cartilage and bone in vivo. Moreover, we suggest that in intramembranous bone
formation, E2F4 functions to promote cell cycle exit in progenitor osteoblasts and
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thereby contributes to the consequential commitment of these cells to differentiate into
terminal osteoblasts and form bone.
150
EXPERIMENTAL PROCEDURES
Animal maintenance and histological preparations
The generation of E2f4-" mice has been described previously (Humbert et al.,
2000). Gestation was dated by detection of a vaginal plug. Pregnant mice were injected
with 10 1Al/gm body weight of 5 mg/ml 5-Bromo-2'-deoxyuridine (BrdU) in phosphate
buffered solution (PBS) two hours prior to tissue collection. Collected embryonic tissue
was immediately embedded in OCT or fixed in 4% paraformaldehyde (PFA) and
embedded in paraffin. Histological sections were cut at 6 microns.
Histological analyses
Enzymatic alkaline phosphatase assays were performed on unfixed frozen
sections. Briefly, 0.06g sodium nitrite was dissolved into 1.5 ml of water and added to
600 [1 of 50 mg/ml of new fuchsin (Sigma) in 2M HCl. This solution was added to 210
ml Tris buffer (pH 9.0). Finally, 1.8 ml of 83.3 mg/ml Naphthol AS-Bi-Phosphate
(Sigma) in DMF (Sigma) was added. Sections were incubated with this overall solution
for 15 minutes, washed in PBS and counterstained with hematoxylin. Alizarin red
staining was performed by incubating sections for 5 minutes in 20 mg/ml alizarin red
(Sigma), pH 4.2. Immunohistochemical analyses were performed using antibodies
against BrdU (1:50 347580, BD Biosciences) and Ki67 (1:50 550609, BD Biosciences)
as described in Chapter 3 (see Danielian et al., 2007).
Skeletal staining
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Embryos were sacrificed, skinned, and eviscerated. The remaining tissue was
fixed in 95% ethanol for 4 days, transferred to acetone for 3 days, and subsequently
transferred to staining solution (final volume of 0.015% alcian blue 8GX (Sigma),
0.005% alizarin red S (Sigma) and 5% glacial acetic acid in ethanol) at 370 C for two days
and room temperature for a third day. Tissue was cleared in 1% potassium hydroxide for
several days and ultimately stored in glycerol.
Calvarial preparations and culture
Calvaria from e 18.5 embryos were removed, treated with several rounds of
collagenase/trypsin digests at 370C, and plated onto 6-well plates. Cells were grown and
expanded in aMEM with 10% fetal bovine serum and Pen/Strep. For differentiation,
upon reaching confluence calvarial osteoblasts were treated with media supplemented
with 50 [tg/ml of ascorbic acid and 10 mM 3-glycerol-phosphate. To assay for calcium
deposits, plates were stained with 1% alizarin red S solution (pH 5.0).
E2F4 and luciferase hairpins were cloned into the MSCV-LMP retroviral vector
(EAV4679 Open Biosystems). The luciferase hairpin was excised from pPRIME-CMV-
GFP-FF3 (Stegmeier et al., 2005) with EcoRI and XhoI and subcloned into MSCV-LMP.
The E2f4 hairpin, CAGAGATTTAGAAAGATTT, was cloned into MSCV-LMP as
described by product instructions (Open Biosystems). Phoenix cells at 60% confluence
were transfected with 2 [tg/ml MSCV-LMP. The media was replaced 8 hours later and
supernatants were collected at 24 hours and filtered. Supernatants containing 10% FBS
and 8 ýtg/ml polybrene were added to calvarial cells. Infected cells were selected for with
2.5 [tg/ml of puromycin for 2 days. Knockdown of E2F4 protein was confirmed by
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quantitative RT-PCR and by Western, using a monoclonal antibody against human E2F4
(1:10 LLF4.2 Moberg et al., 1996) and GAPDH (1:5000, 4300, Ambion) as an internal
control.
pBabe-E2f4 (Landsberg et al., 2003) was used to overexpress E2f4. Calvarial
cells were infected as described above. Infected cells were selected with 2.5 [tg/ml
puromycin for 2 days. Overexpression of hE2F4 was confirmed via Western analysis
using the same antibodies described for the knockdown experiment.
Immunofluorescence
For in vitro BrdU incorporation, osteoblasts were plated onto coverslips prior to
achieving confluence. BrdU was added to the media (final concentration of 10 [tM) and
incubated for 24 hours prior to 4% PFA fixation. Antigen was detected using antibody
against BrdU (1:50 347580, BD Biosciences) and Texas Red-X goat anti-mouse
secondary (1:1000, Invitrogen).
Quantitative real-time PCR
RNA was isolated from differentiation plates using the Qiagen RNeasy kit. First-
strand cDNA was transcribed from 1 Rg of RNA using Superscript III Reverse
Transcriptase (Invitrogen) following product instructions. Quantitative RT-PCR with 20-
100 ng cDNA was performed using SYBR Green (Applied Biosystems). Reactions were
run on the ABI Prism 7000 Sequence Detection System and analyzed using the 7000 SDS
software. Primers are listed in Table S1 of Chapter 2.
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ABSTRACT
The pocket proteins have a well-defined role in cell cycle regulation. In addition, these
proteins function in the development and differentiation of various tissues. Previous data
indicate that Rb-; pl07' embryos die by e 11.5 with apoptosis in the central nervous
system and liver. However, these may be cell non-autonomous phenotypes caused by
placental defects upon loss of Rb. Therefore, to investigate the cell autonomous
functions of pRb and p107 in murine embryonic development, we have conditionally
deleted Rb in the embryo proper of pl07' animals. We observe that these double mutant
embryos die at approximately e14.5 during development. Analyzing embryos at e13.5,
we find that pRb and p107 act synthetically to regulate proliferation and apoptosis in the
central nervous system and lens, but not in the peripheral nervous system. In addition,
the double mutant embryos exhibit shortened limbs, increased proliferation of blood
vessel endothelial cells, and heart defects including double outlet right ventricle (DORV).
We find that the DORV is caused at least partially by a defect in blood vessel endothelial
cells or mesenchymal cells of the heart. These findings demonstrate novel, synthetic
functions for pRb and p107 in several murine tissues, including the blood vessel
endothelium and heart.
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INTRODUCTION
The human retinoblastoma gene, Rb-1, was the first tumor suppressor to be
cloned. The gene product, pRb, belongs to a family of proteins, including p107 and
p 130, termed the pocket proteins. The pocket proteins have well-defined roles in the
regulation of cell cycle progression. Each of the pocket proteins interacts with the E2F
family of transcription factors to repress transcription and prohibit cellular proliferation
(Trimarchi and Lees, 2002). Upon mitogenic stimulus, the pocket proteins are
phosphorylated by cyclin/CDK complexes, causing release of the E2Fs and subsequent
cell cycle progression. Moreover, ectopic expression of any pocket protein can induce
G1 arrest in certain cell types (Classon and Harlow, 2002), while depletion of all three
proteins fails to arrest cells in response to a variety of growth arrest signals (Dannenberg
et al., 2000; Sage et al., 2000).
The analyses of in vivo mouse models and in vitro assays demonstrate that the
pocket proteins are important for the normal development and differentiation of various
tissues. With respect to Rb, germline deletion results in ectopic proliferation and
apoptosis in the lens, brain, and dorsal root ganglia (Clarke et al, 1992; Jacks et al, 1992;
Lee et al, 1992). However, the apoptosis in the brain is an indirect effect of a disruption
of the Rb- placental architecture, leading to a reduction in nutrient and gas exchange
(Wenzel et al., 2007; Wu et al., 2003). Rb mutant or conditional mice also display defects
in erythroid differentiation (Clark et al., 2004; Spike et al., 2004), skeletal muscle
formation (Zacksenhaus et al., 1996; Huh et al., 2004), and epithelial development
(Haigis et al., 2006; Ruiz et al., 2004; Wikenheiser-Brokamp, 2004; Yang and Hinds,
2007). Moreover, in vitro studies show that pRb functions in adipocyte differentiation
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(Chen et al., 1996; Hansen et al., 2004; Scime et al., 2005) and osteoblast differentiation
(Thomas et al., 2001).
Contrary to the Rb mutant mice, plOT/ and pl30 mice have no overt
phenotypes on a C57B1/6 or 129/Sv background (Cobrinik et al., 1996; Lee et al., 1996).
However, analyses of compound mouse mutants of the pocket proteins have revealed
compensatory functions of these proteins in development. p107T; p130/ double mutant
mice display defects in epidermal differentiation (Ruiz et al., 2003) and long bone
development (Cobrinik et al., 1996). The loss of pl07 amplifies the epithelial defects in
mice conditionally deleted for Rb in the intestine (Haigis et al., 2006) or in the epidermis
(Ruiz et al., 2004). Moreover, p107 deletion accelerates embryonic death in the germline
Rb/ mouse mutant and increases apoptosis in the liver and central nervous system (CNS)
(Lee et al., 1996). However, the phenotypes in the Rb-; plOT 07embryos may be an
indirect consequence of the placental defects due to deletion of Rb.
Several studies have implicated a role for the pocket proteins in cardiac
differentiation and heart development. Rb- embryonic stem cells induced to differentiate
into cardiomyocytes display a delay in the expression of cardiac markers and,
consequently, a delay in differentiation (Papadimou et al., 2005). On the other hand,
conditional ablation of Rb in the murine heart does not result in any observed defects
(MacLellan et al., 2005). However, the additional deletion of p130 causes an enlarged
adult heart, most likely due to an increase in the number of cycling cardiomyocytes.
Similarly, mice overexpressing Cyclin Dl or Cdk2 in cardiomyocytes, thereby
functionally inactivating the pocket proteins, exhibit an increase in cardiomyocyte
number and DNA synthesis (Liao et al., 2001; Soonpaa et al., 1997).
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To study the cell autonomous functions of pRb and p107 during embryonic
development, we have crossed the p107 mutation into a mouse strain that conditionally
deletes Rb in the embryo proper but not in the placenta. We found that these double
mutant embryos die by approximately e14.5. This is associated with an increase in
ectopic cell cycles and apoptosis in the CNS and lens. Furthermore, the double mutant
embryos exhibit a shortening of the limbs, increased endothelial cell proliferation in
blood vessels, and defects in heart development, including double outlet right ventricle
(DORV). Our preliminary findings suggest that the DORV is a consequence of defects in
blood vessel endothelial cells or in mesenchymal cells of the heart. Thus, the combined
disruption of p107 and pRb establishes synthetic and novel functions for these pocket
proteins in several cell lineages of the developing murine embryo.
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RESULTS
Rbc-/c; plOT;0 Mox2+/C' e double mutant embryos die during mid-gestation
The analysis of the synthetic functions of pocket proteins during development is
complicated by the embryonic lethality of the germline Rb- mice (Clarke et al, 1992;
Jacks et al, 1992; Lee et al, 1992). However, recent studies show that this embryonic
lethality is caused by a placental defect (de Bruin et al., 2003; Wenzel et al., 2007; Wu et
al., 2003). Therefore, to study the effects of pocket protein deletion specifically in the
embryo, we crossed a floxable Rb mutant mouse line (Rbc/c; Sage et al., 2003) with a
Mox2-Cre transgenic line (Mox2+/cre). The Mox2-Cre element expresses Cre
recombinase in the embryo proper, but not in the placenta, beginning at approximately
e6.5 (Tallquist and Soriano, 2000). The resulting Mox2+/cre conditionally null Rb
embryos (Rbc/c-) exhibit a normal placenta (Supplementary Fig. 1) and survive until birth.
We then crossed these animals with mice harboring a deletion ofpl07. Neither p107l/
nor Rb-/c; p107T'; Mox2+/Cre placentas displaced any defects (Supplementary Fig. 1).
We therefore analyzed the RbcI/c-; p 107-'; Mox2+/Cre (hereto referred as Rbc-/c; p 107-/ or
double mutant) embryos to study the synthetic functions of these two pocket proteins
during development.
We first determined the general survival of the Rbc-/c-; p107T embryos. We
observed the expected Mendelian ratio of double mutant embryos at embryonic day (e)
13.5 for the genetic cross performed (Table 1). Embryos of all genotypes exhibited
beating hearts at e13.5, indicating that all embryos were alive. However, at e14.5 we
observed a significant decrease in the number of living double mutant embryos versus the
expected number based on the genetic cross performed (Table 2). Furthermore, no
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Supplementary Figure 1. All mutant embryos possess a normal labyrinth architecture
in the placenta.
Sagittal sections through the placenta of e14.5 embryos were stained with H&E. 10X
magnification shown.
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p107'- p107-' pU107'- p107o' p107'
Rb+/c Cre"Rb Cre  Rb C re" Rb Cre +/c CreCe Rb+/Cre"
30 35 19 13 25
23.875 23.875 23.875 23.875 23.875
p107-'- p07T'- p107-'-
Rb+I Cre+ RbCi" Cre " Rb Ic Cre+  Total
26 18 25 191
23.875 23.875 23.875 191
1. Numbers of observed versus expected embryos at e 13.5
Rbc/c; p107T (female) X Rb+/C; p07•"; Mox2+/Cre (male)
p107 " ' p107' " p107'* p107" "  p107"" p107"'"  p107T""  p107"
Genotype Rb+/CCre" Rb+/c Cre + Rbc/c Cre" Rb~/c. Cre+ Rb+/c Cre" Rb+/c Cre + Rb/c- Cre" Rbc-/c Cre +  Total
Observed 12 11 13 12 14 12 10 9 (2) 93
Expected 11.625 11.625 11.625 11.625 11.625 11.625 11.625 11.625 93
Numbers of observed (live) versus expected embryos at e14.5 from the
cross: Rbcc; p107- (female) X Rb+/c-; p107+ ; Mox2+/cre (male)
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double mutant embryos were found at e 15.5 or later stages of development, although all
other genotypes were observed at approximately the expected frequency (data not
shown). Together, these data indicate that the double mutant embryos die by e14.5 of
murine development.
Rbc-/c; plOT" embryos exhibit synthetic defects in the brain and ocular lens, but not
in the peripheral nervous system or erythrocytes
Although we noticed several, novel macroscopic defects in the double mutant
embryos (discussed below), we first wanted to analyze the effects of pl07 deletion in
tissues previously demonstrated to be affected by the loss of Rb. For example, Rb-
embryos exhibit ectopic cellular proliferation and apoptosis in the hindbrain of the CNS
(Clarke et al, 1992; Jacks et al, 1992; Lee et al, 1992). However, the apoptosis in the
brain is likely an indirect effect caused by insufficient gas and nutrient exchange in the
mutated placenta. In support of this, embryos conditionally depleted of pRb using the
Mox2-Cre transgene do not display apoptosis in the brain (de Bruin et al., 2003; Wu et
al., 2003). We examined the hindbrains of our e13.5 mutant embryos to determine the
proliferative and apoptotic effects upon loss of multiple pocket proteins. As expected,
wild-type and p107 Tembryos showed basal levels of cellular proliferation based on
BrdU incorporation (Fig. 1) and Ki67 expression (Supplementary Fig. 2) and a low, basal
level of apoptosis as determined by TUNEL (Fig. 1). The Rbc-/c embryos, on the other
hand, exhibited a significant increase in the percentage of cycling neurons, a phenotype
previously observed in Rbc/c embryos (de Bruin et al., 2003; Wu et al., 2003). This
ectopic proliferation was further enhanced upon the additional loss ofpl07. Surprisingly,
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Figure 1. Deletion ofpl07 exacerbates the proliferative and apoptotic defects observed
in the CNS of Rbc/c" embryos.
Sagittal sections through the hindbrain of e13.5 embryos were assessed by
immunohistochemistry for BrdU incorporation or by TUNEL for apoptosis. Rbc"/c
hindbrains displayed an increase in proliferation and apoptosis, and the additional loss of
p107 exacerbated both phenotypes. Graphs depict the average percentage of nuclei
incorporating BrdU or labeled by TUNEL. Error bars represent one standard deviation.
* denotes statistical significance compared to wild-type and to pOT7" , p < 0.05. **
denotes statistical significance compared to Rbc-/c-, p<0.05. 10X magnification shown.
Genotypes corresponding to WT, p107, Rb, and Rb; p107 are listed in the Experimental
Procedures section.
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Supplementary Figure 2. Deletion ofpl07 exacerbates the proliferative defect in the
hindbrain and lens but not in the dorsal root ganglia of Rbc'/c embryos as determined by
Ki67 expression.
Sagittal sections through the hindbrain (CNS), lens, and dorsal root ganglia (PNS) in
e13.5 embryos were assessed by immunohistochemistry for Ki67 expression. All Rbc-/c-
tissues displayed an increase in proliferation relative to wild-type or plOT07 tissues. The
additional loss of p107 in the Rbc-/ embryos exacerbated the proliferative defect in thehindbrain and lens but not in the DRG. 10X magnification of the hindbrain shown. 20X
magnification of the lens and DRG shown.
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we found that the Rbc-/c embryos displayed a small but significant increase in the number
of apoptotic neurons relative to that observed in control embryos, which was similarly
exacerbated upon deletion ofp107. Altogether, these data indicate a synthetic interaction
between Rb and pl07 in the hindbrain of e13.5 embryos.
We next examined the effects of pocket protein ablation in the ocular lens of
e13.5 embryos. As expected from previous findings (de Bruin et al., 2003; Wu et al.,
2003), the conditional deletion of Rb resulted in ectopic cell cycles and apoptosis (Fig. 2
and Supplementary Fig. 2). The additional loss ofpl07 caused a small, yet significant
increase in both of these phenotypes, .similar to the observed effects in the CNS. These
data indicate that Rb and p107 interact synthetically during the development of the ocular
lens in mice.
We also studied the dorsal root ganglia (DRG) of the peripheral nervous system
(PNS) for defects upon pocket protein loss. Wild-type andpl0T' e13.5 embryos
exhibited a normal range of proliferation and apoptosis at this stage of development (Fig.
3 and Supplementary Fig. 2). Again as expected, the conditional deletion of Rb caused
an increase in proliferation and apoptosis in the DRG. However, the additional loss of
p107 did not enhance either of these phenotypes. Therefore, unlike in the CNS and
ocular lens, pl07 does not synthetically interact with Rb.
Finally, we analyzed the differentiation of erythrocytes, as the deletion of Rb has
previously been demonstrated to cause delayed enucleation and abnormal erythroid
development (Clark et al., 2004; Maandag et al., 1994; Spike et al., 2004). We took
advantage of the fact that fetal erythroid cells are present in the histological sections of
the placenta and analyzed these fetal erythroid cells for defects. We were unable to
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Figure 2. Deletion ofp107 exacerbates the proliferative and apoptotic defects observed
in the lens of Rbc/c embryos.
Sagittal sections through the lens of e13.5 embryos were assessed by
immunohistochemistry for BrdU incorporation or by TUNEL for apoptosis. The Rbc/c-
lens displayed an increase in proliferation and apoptosis, and the additional loss ofpl07
exacerbates both phenotypes. Graphs were performed and statistical significance was
assigned as described in Figure 1. 20X magnification shown.
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Figure 3. Deletion of p107 does not increase the proliferative and apoptotic defects
observed in the PNS of Rbc/c- embryos.
Sagittal sections through the dorsal root ganglia of e13.5 embryos were assessed by
immunohistochemistry for BrdU incorporation or by TUNEL for apoptosis. Rbc-/"c
ganglia displayed an increase in proliferation and apoptosis. The additional loss ofp107
did not significantly affect either of these phenotypes. Graphs were performed and
statistical significance was assigned as described in Figure 1. 20X magnification shown.
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determine whether the loss of Rb and p107 affected proper enucleation, as most wild-type
and mutant erythroid cells in our mouse colony's mixed genetic background remained
nucleated at e13.5, a phenotype that has been observed elsewhere (Maandag et al., 1994).
Nevertheless, we were able to analyze the erythroid cells for abnormal development, such
as irregular shape or multiple or fragmented nuclei. We observed that e13.5 Rbc-/c
embryos exhibited an increase in abnormal fetal erythroid cells (Fig. 4), as previously
published. Similarly, e 13.5 double mutant embryos exhibited abnormal fetal erythroid
development. However, the percentage of abnormal erythroid cells in the double mutant
embryos was not significantly different from that observed in the Rbc-/c embryos.
Therefore, p107 does not synthetically interact with Rb to cause an increase in fetal
erythroid defects.
Rbc-/c-; plOT'0 embryos exhibit several macroscopic defects, including edema
The analysis of e13.5 and e14.5 double mutant embryos revealed macroscopic
phenotypes not present in the other genotypes. Yolk sacs enveloping double mutant
embryos, for example, were bloated and larger than the yolk sacs of other embryos (Fig.
5, data not shown). Although some of the double mutant yolk sacs displayed a pale
appearance with respect to blood vessels, others looked normal (data not shown).
Moreover, the yolk sacs of double mutant embryos were prone to rupture during
dissection.
After removal from the yolk sac, double mutant embryos exhibited several
abnormalities compared to their e13.5 and e14.5 littermate embryos (Fig. 5, data not
shown). In comparison to all other genotypes, the double mutant embryos possessed
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Figure 4. Rbc' /c and double mutant embryos exhibit a similar percentage of abnormal
erythroid cells.
Sagittal sections through the placenta of e13.5 embryos were stained with H&E and
analyzed for the presence of abnormal fetal erythroid cells. Rbc-/c embryos exhibited an
increase in the percentage of abnormal fetal erythroid cells present in the placenta, and
the additional deletion of p107 did not significantly affect that phenotype. Arrows
indicate erythroid cells with multiple nuclei. Graphs were performed and statistical
significance was assigned as described in Figure 1. 40X magnification shown.
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Figure 5. Double mutant embryos display several abnormal, macroscopic phenotypes.
(Left column) e13.5 embryos were dissected out of the uterus of pregnant females,
leaving the yolk sac intact. The yolk sacs of double mutant embryos were enlarged
(arrow) compared to those of the littermate embryos. (Middle column) After removal of
the yolk sac, embryos were analyzed for superficial, macroscopic defects. Double mutant
embryos had several observable defects, including shortened fore- and hind-limbs (see
inset; length of fore-limb is delineated by the bar), a bloated mid-section, a more severely
hunched neck, and occasional hemorrhage (arrow). (Right column) Sagittal sections of
the embryos displayed in the middle column were stained with H&E. Double mutant
embryos exhibited edema (arrow). 4X magnification shown for the H&E sections.
Abbreviations: H = heart; L = liver.
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shortened fore- and hind-limbs. These double mutant embryos also possessed a more
severely hunched appearance by the neck, a bloated midsection, and occasionally
hemorrhage.
The enlarged midsection and hemorrhaging phenotypes led us to investigate the
double mutant embryos in more detail. H&E analysis of sagittal sections from e13.5 and
e14.5 embryos revealed that the double mutant embryos, but not the other genotypes,
were edematous (Fig. 5, data not shown). Edema in the double mutant embryos was most
prevalent along the backbone, although it was also observed in the midsection and around
the skull (data not shown).
Rbc-c-; p107 " embryos possess heart defects
There are several potential causes of edema, including kidney, lung, erythrocyte,
and heart dysfunction. We immediately ruled out kidney and lung dysfunction, as these
organs are not necessary for fetal development. Moreover, H&E analyses indicated that
these organs were developing morphologically normally in the double mutant embryo
(data not shown). Another possibility is that severe erythroid defects in the developing
embryo could lead to edema. Although double mutant embryos exhibited abnormal
erythroid cells, the percentage of these abnormal cells did not differ from that observed in
the non-edematous Rbc' - embryos. Therefore, these data suggest that erythroid defects
are not the underlying cause of edema in the double mutant embryos.
Edema may also occur due to heart dysfunction. We analyzed serial, transverse
sections of the heart from several double mutant and control embryos (Fig. 6). Wild-
type, pl0 7, and Rbc-/c- embryos displayed relatively normal architecture and
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Figure 6. Double mutant embryos display heart defects, including DORV.
(Left column) Transverse section stained with H&E through the pulmonary valve of
el13.5 embryonic hearts. (Middle column) Transverse section stained with H&E through
the aortic valve of e13.5 embryonic hearts. (Right column) Schematic diagram of a
normal heart or one with DORV as seen in a transverse histological section through the
aortic valve. Double mutant hearts displayed several defects: dilated atria (arrowhead), a
thin myocardial wall (arrow), and double outlet right ventricle (DORV). Abbreviations:
Ao = aorta and aortic valve; LA = left atrium; LV = left ventricle; RA = right atrium; RV
= right ventricle; PA = pulmonary artery and pulmonary valve. 4X magnification shown.
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development of the heart, great arteries (pulmonary artery and aorta), and valves. The
only observed defect was a thin myocardial wall/compact zone in the Rbc-/cembryo.
Contrarily, the heart of double mutant embryos exhibited several defects, including
dilated atria, a thin myocardial wall/compact zone, and double outlet right ventricle
(DORV), in which both the pulmonary artery and the aorta exit from the right ventricle
(normally, the aorta exits from the left ventricle). In addition, the double mutant embryos
may also possess ventricular septal defects. However, the septum is only beginning to
complete formation at e13.5, and therefore the individual variation among control
embryos makes it difficult to conclusively state if the double mutant embryos possess a
true septal defect. Taken together, these data demonstrate that Rb and p107 synthetically
interact during the development of the embryonic heart.
No evidence of cardiac marker downregulation or pocket protein compensation in
mutant embryonic hearts
Previously, Papadimou et al. (2005) showed that Rb-' embryonic stem cells are
impaired in their capacity to induce cardiomyocyte genes and differentiate in vitro. We
hypothesized that the heart defects in the double mutant embryos could be due to a
similar defect. We isolated RNA from the hearts of e 13.5 mutant embryos and analyzed
the mRNA expression levels of several cardiac transcription factors and differentiation
markers using quantitative RT-PCR (Fig. 7). In contrast to the in vitro data, we did not
observe downregulation of cardiomyocyte markers in any mutant hearts in vivo. In fact,
we observed a slight increase in the expression level of several cardiomyocyte markers of
the Mespl/2 transcriptional pathway (i.e., Mesp2, Nkx2.5, GATA4, and ANF) in the
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Figure 7. Mutant embryonic hearts do not exhibit a decrease in the expression of several
cardiac markers.
RNA was isolated from the hearts of e13.5 embryos, reverse transcribed, and subjected to
quantitative RT-PCR analysis. No mutant hearts showed any decrease in the expression
level of the cardiac markers tested. Ubiquitin was used as an internal control to
normalize for RNA levels within each sample. Error bars represent one standard
deviation.
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double mutant embryos compared to other embryos. Based on these findings, it is
unlikely that the observed heart phenotypes in double mutant embryos are due to a defect
or delay in cardiomyocyte differentiation. However, we cannot rule out that the observed
incremental increase in expression of several cardiac markers may contribute to the
double mutant heart phenotypes.
We also tested for pocket protein compensation, hypothesizing that compensation
could be a reason that heart defects were not observed in the single mutant embryos (i.e.,
pl07' or Rbc-/c-). Using quantitative RT-PCR, we did not observe an increase in p]07
mRNA levels in the Rbc-/c heart (Supplementary Fig. 3). The reverse experiment did not
indicate a significant increase in Rb transcripts upon loss of p107 either. Therefore, the
lack of cardiac defects in the single mutant embryos is not due to pocket protein
compensation at the transcriptional level.
DORV in the double mutant embryo is likely due to endothelial or mesenchymal cell
defects
Based on the relatively normal expression of cardiomyocyte markers in the heart
of double mutant embryos, we hypothesized that the DORV may be caused by a defect in
the development of the great arteries and/or other blood vessels. We therefore performed
immunohistochemical analyses of several blood vessel markers. All embryos expressed
smooth muscle actin normally (Fig. 8A), suggesting that there is no defect in the smooth
muscle vasculature in the double mutant embryos. Similarly, all embryos expressed
laminin and fibronectin normally (Fig. 8A and Supplementary Fig. 4), signifying normal
matrix formation in all mutant blood vessels.
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Supplementary Figure 3. No compensation at the transcriptional level by Rb or p107 is
observed in single mutant embryos.
RNA was isolated from the hearts of el 3.5 embryos, reverse transcribed, and subjected to
quantitative RT-PCR analysis. There was no compensation by pRb inpl07"/ hearts.
Similarly, in Rbc-/ c- hearts there was no compensation by p107. It is of interest to note
that in the conditionally deleted Rb mutant hearts, the mutant Rb mRNA is transcribed at
approximately wild-type levels. Ubiquitin was used as an internal control to normalize
for RNA levels within each sample. Error bars represent one standard deviation.
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Figure 8. Double mutant embryos exhibit a significant increase in the percentage of
proliferating endothelial cells lining the blood vessels.
A. Sagittal sections of el 3.5 embryos were assessed by immunohistochemistry for
smooth muscle actin and laminin expression in the blood vessels of the head. All
embryos displayed normal expression of these blood vessel markers. 20X magnification
shown. B. Blood vessels in sagittal sections of e13.5 embryo heads were assessed by
immunohistochemistry for BrdU incorporation (arrows indicate positively stained cells)
or by TUNEL for apoptosis. Double mutant embryos exhibited an increased percentage
of proliferating endothelial cells lining the blood vessels. No embryos displayed signs of
apoptosis in the blood vessels. Graphs were performed and statistical significance was
assigned as described in Figure 1. 40X magnification shown.
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Supplementary Figure 4. Double mutant embryos exhibit an increase in proliferating
endothelial cells lining the blood vessels as determined by Ki67 expression.
Sagittal sections of e13.5 embryos were assessed by immunohistochemistry for
fibronectin and Ki67 expression in the blood vessels of the head. All embryos displayed
normal expression of fibronectin. Double mutant embryos exhibited an increase in
proliferating endothelial cells lining the blood vessels based on Ki67 expression. 20X
and 40X magnifications shown.
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We next performed experiments to determine the levels of cellular proliferation
and apoptosis in the blood vessels. No embryos displayed apoptosis in any blood vessel
cells (Fig. 8B). However, the double mutant embryos exhibited a significant increase in
the number of proliferating endothelial cells lining the blood vessels (Fig. 8B and
Supplementary Fig. 4). Hence, it is possible that ectopic proliferation in endothelial cells
may result in the abnormal formation or development of blood vessels including the
aorta, possibly leading to DORV.
To genetically test this possibility, we crossed the Tie2-Cre mouse strain
(Kisanuki et al., 2001; Koni et al., 2001) into our conditional Rbc/C; p107/ mice. This
transgene expresses the Cre recombinase in all endothelial cells during embryonic
development. It is noteworthy, however, that Cre recombinase activity is also observed
in the mesenchymal cells of the developing pulmonary and aortic valves and the
atrioventricular canal (Kisanuki et al., 2001). We observed that five of six Rbc/c'; plOT107
Tie2-Cre double mutant embryos possessed either a full DORV phenotype (Fig. 9) or a
partial DORV phenotype (two full DORV, three partial DORV). Importantly, no Rbc/C,;
Tie2-Cre or other littermate embryos presented any cardiac defects (data not shown).
Furthermore, we did not detect any germline transmission or "leaky" Cre recombinase
activity in any mutant embryos (data not shown). These findings indicate that the DORV
phenotype of the double mutant embryos is at least partially due to defects in endothelial
cells or cardiac mesenchymal cells, thereby implicating Rb and p107 in a novel, synthetic
role in murine heart development.
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Figure 9. Rbc-/c; p107"; Tie2-Cre hearts display DORV phenotypes
(Left column) Transverse section stained with H&E through the pulmonary valve of an
e13.5 Rbc/-; p07T; Tie2-Cre embryo. (Right column) Transverse section stained with
H&E through the aortic valve of the Rbc /c pl07T; Tie2-Cre embryo. Tie2-Cre double
mutant embryos developed hearts displaying DORV phenotypes. 4X magnification
shown. Abbreviations are listed in Figure 6.
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DISCUSSION
Embryos deleted for both Rb and pl07 die by el 1.5, prior to the formation of
most organs, and exhibit increased levels of apoptosis in the CNS and liver (Lee et al.,
1996). However, the early embryonic lethality and apoptotic defects could be an indirect
consequence of placental defects, as the germline deletion of Rb affects the labyrinth
architecture of the placenta and perturbs efficient gas and nutrient exchange (Wenzel et
al., 2007; Wu et al., 2003). Hence, the placental defect complicates the analysis of the
functions of pRb and p107 during development. Therefore, we crossed a floxable Rb
mutant mouse line (Rbc/c; Sage et al., 2003) with the Mox2-Cre transgenic line to
inactivate Rb in the embryo proper, but not in the placenta. We then crossed these
animals with mice harboring a deletion ofpl07 to study the functions of these two pocket
proteins during development. Our analyses reveal a synthetic role for pRb and p107 in
the brain and ocular lens. In addition, we identify novel, synthetic functions for these
proteins in embryonic limb, blood vessel, and heart development.
Placentally rescued Rb-/c-; Mox2+/cre embryos live until birth, displaying defects
in several cell types, including those of the CNS, lens, PNS, and erythroid lineage (de
Bruin et al., 2003; Wu et al., 2003). We found that the additional deletion ofpl07
resulted in embryonic lethality at approximately e14.5. To determine how p107 loss
modifies the known conditional Rb phenotypes, we first focused on the effects in the
aforementioned cell types at e13.5 of development. In the hindbrain of the CNS,
conditional deletion of Rb resulted in ectopic proliferation and apoptosis compared to
wild-type and p07T/ embryos. The additive loss ofpl07 exacerbated both of these
defects. Similarly, the ectopic proliferation and apoptosis in the lens of conditional Rb'c/c
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embryos was enhanced upon the deletion ofpl07. Contrarily, the deletion ofpl07 in the
DRG of the PNS did not alter the proliferative and apoptotic defects observed in Rbc/c-
embryos, nor did depletion ofpl07 affect the percentage of abnormal fetal erythroid cells
present in Rbc./c embryos. Together, these data indicate that pRb and p107 function
synthetically during development in the hindbrain of the CNS and in the lens, but not in
the DRG of the PNS or in erythroid cells.
We were surprised to observe apoptosis in the CNS of our Rb-/- embryos.
Several groups have demonstrated that the apoptosis in the CNS is a cell non-autonomous
defect caused indirectly by the Rb- placental defect (de Bruin et al., 2003; Lipinski et al.,
2001; Maandag et al., 1994; MacPherson et al., 2003; Wenzel et al., 2007; Williams et
al., 1994; Wu et al., 2003). These studies were performed using various methods, such as
Rb' chimeric experiments, conditional Rb deletions, and tetraploid aggregation.
Nevertheless, we are not the first to observe apoptosis in the CNS of rescued Rb mutant
embryos. Lipinski et al. (2001) detected a small but significant increase in the number of
apoptotic cells in the CNS of e 13.5 Rb - chimeric animals compared to the CNS neurons
of control mice. One possibility is that minor genetic variation among the mice used in
the various studies may account for the observed differences in CNS apoptosis. Another
possibility is that the Mox2-Cre transgene in our mouse colony is slightly "leaky,"
thereby deleting Rb in some of the placental trophoblast precursors and causing the cell
non-autonomous apoptosis. We do not believe this second explanation to be the case, as
we did not observe other cell non-autonomous apoptosis in our embryos. For example,
we did not detect apoptosis in the liver of our Rbc-/c; p107T embryos as was
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characterized in the original Rb/; p107T germline double mutant embryos (Lee et al.,
1996).
Gross inspection of the double mutant embryos revealed several phenotypes.
First, the yolk sac enveloping double mutant embryos was bloated and larger than the
yolk sacs of the other embryos. Moreover, the yolk sac of double mutant embryos was
prone to rupture. At this time we do not know if the latter phenotype is due to a
weakened yolk sac, excessive pressure from an increase in fluid, or some other, unknown
reason.
The second phenotype we observed was a noticeable shortening of the fore- and
hind-limbs of the double mutant embryos compared to those of littermate embryos.
Defects in limb development were observed inpl07-T; p130- embryos, and subtle limb
phenotypes were observed in pl07T' single mutant embryos (Cobrinik et al., 1996).
These limb abnormalities were due to an inability of pl07-'; p]30/ chondrocytes to exit
the cell cycle. It is a likely possibility that the shortened limbs in the Rbc'/c-, p107T/
embryos are caused by a similar deregulation of proliferation in chondrocytes, and we are
currently testing this hypothesis in the lab. Regardless of the mechanism, however, this
observation demonstrates a synthetic role for pRb and p107 in limb development.
Third, double mutant embryos possessed an enlarged or bloated midsection. A
percentage of these embryos also displayed hemorrhaging. These phenotypes were most
likely secondary effects of the edema observed in the double mutant embryos. Edema
has not been described previously in mouse models of pocket protein mutations, and it
represents a novel function of pRb and p107 in development.
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Edema can occur through several mechanisms. For example, lung and kidney
dysfunction may lead to edema. However, these organs are not functional during fetal
development and, therefore, are not reason for the edema observed in the double mutant
embryos. Another possible cause of edema is erythroid defects. We did observe a
significant increase in the percentage of abnormal erythroid cells in double mutant
embryos compared to controls. However, Rbc/c embryos exhibited a similar percentage
of abnormal erythroid cells but did not develop edema. Therefore, it appears unlikely
that the abnormal erythroid cells of the double mutant embryos are the underlying cause
of the edema.
Given the above information, we immediately analyzed the double mutant
embryos for heart defects, a common cause of edema in humans. We found that the
single mutant embryos had normally developed hearts, except for a thin myocardial wall
in the Rbc-c- heart. The double mutant embryos, in contrast, possessed several heart
defects. The atria were severely dilated, the myocardial wall was thin, and the ventricular
septum was incomplete. However, at e 13.5 this latter defect is difficult to determine
conclusively because even some wild-type embryos have not completed ventricular
septation. Finally and most strikingly, the double mutant embryos displayed double
outlet right ventricle (DORV), in which both great arteries, the pulmonary artery and the
aorta, originate from the right ventricle.
The presence of heart defects in the double mutant embryos but not in the single
mutant embryos may be due to the ability of Rb and p107 to compensate for each other in
the heart. To test this possibility, we checked the levels of Rb and p107 mRNA
expression in the heart in wild-type and single mutant embryos. Through this analysis,
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we did not observe any upregulation in either Rb or p107 mRNA levels. Therefore, it is
unlikely that the lack of heart defects observed in the single mutant embryos is due to
pocket protein compensation. Taken together, our data from the double mutant embryos
indicate that both pRb and p107 are important for and synthetically interact during
embryonic heart development.
It is interesting to note that the organs in which Rb and p107 demonstrate
synthetic interactions corresponds to the organs that demonstrate expression of both of
these pocket proteins during development. In the CNS, where the additional deletion of
p107 exacerbated the defects due to Rb depletion, both Rb and pl07 mRNA transcripts
are expressed at relatively high levels (Jiang et al., 1997). Similarly in the heart, where
the loss of both pocket proteins caused DORV and other cardiac defects, expression of
p107 (Jiang et al., 1997; Kim et al., 1994) and Rb (Kim et al., 1994; Zacksenhaus et al.,
1996; our quantitative RT-PCR data) is observed. On the other hand, significantly high
levels of Rb mRNA, but not pl07 mRNA, are observed in the PNS (Jiang et al., 1997),
corresponding to our finding that the additional deletion ofpl 07 does not exacerbate the
defects due to Rb loss in the DRG. The exception is the lens, where our data indicate that
Rb and p107 interact synthetically to regulate proliferation and apoptosis. In situ
analyses indicate that only Rb transcripts are present in the lens (Jiang et al., 1997).
However, pocket protein complex analyses suggest that both pRb and p107 are present
and functional in the developing rat lens (Rampalli et al., 1998), which is in accordance
with our genetic findings in mice. Taken together, the correlation between the embryonic
organs expressing both pRb and p107 and those exhibiting synthetic interactions between
Rb and p107 suggests that the observed phenotypes are cell autonomous.
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Given the suggestion that the synthetic interaction phenotypes are cell
autonomous, we were interested in determining the cell type responsible for the observed
heart defects. One potential cause of the DORV and other defects in the double mutant
embryos is improper cardiomyocyte differentiation. In fact, it has been previously
demonstrated that Rb /- embryonic stem cells have a defect in cardiomyocyte
differentiation in vitro and exhibit a significant downregulation of cardiac muscle
markers (Papadimou et al., 2005). We, therefore, analyzed mRNA levels in the e13.5
mutant hearts for a similar phenotype. However, we did not observe a downregulation of
cardiomyocyte markers in any mutant embryos in vivo. This is in accordance with the
finding that conditional deletion of Rb specifically in cardiomyocytes in vivo (using the
aMHC-Cre transgene) does not cause any heart defects (MacLellan et al., 2005).
Surprisingly in fact, we observed a slight increase in the expression levels of several
cardiomyocyte markers of the Mespl/2 pathway in the double mutant heart. We do not
yet know the cause of this small yet seemingly specific increase in the expression of
genes of the Mespl/2 pathway upon loss of both Rb and p107. This is an area of further
experimentation and interest in our lab. Nevertheless, these data indicate that the DORV
and cardiac defects in the double mutant embryos are not due to a downregulation of
cardiomyocyte markers and likely not due to a defect in their differentiation.
As the heart defects did not appear to be due to a cardiomyocyte defect, we
hypothesized that the DORV may be caused by a defect in the development of the great
arteries and/or other blood vessels. Blood vessels in all embryos expressed smooth
muscle actin, laminin, and fibronectin normally, suggesting that there is no defect in the
smooth muscle vasculature or blood vessel matrix in the double mutant embryos.
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However, the double mutant embryos did exhibit an increase in the percentage of cycling
endothelial cells lining the blood vessels. As the blood vessels exhibited apparently
normal smooth muscle and matrix, we do not believe that the increased proliferation
affected the integrity or function of the blood vessels. Nevertheless, it remains a formal
possibility that the vasculature may be compromised. Another related possibility is that
the increased proliferation in blood vessel endothelial cells may affect the normal
patterning of blood vessels. This abnormal patterning could affect the heart and the great
arteries, thereby leading to cardiac defects such as DORV.
To test this possibility, we crossed the Tie2-Cre transgenic mouse strain (Kisanuki
et al., 2001; Koni et al., 2001) into our conditional Rbc/C; plOT107 mice. The Tie2-Cre
transgene expresses the Cre recombinase in all endothelial cells during embryonic
development. It is important to note, though, that Cre recombinase activity in Tie2-Cre
embryos is also observed in mesenchymal cells of the pulmonary and aortic valves and
the atrioventricular canal (Kisanuki et al., 2001). It is quite plausible that defects to these
mesenchymal cells could lead to DORV and other cardiac defects. Our data demonstrate
that a majority (five of six) of Rbc-/c", pOT;07 Tie2-Cre embryos exhibited a partial or full
DORV phenotype. These findings indicate that the DORV phenotype in the double
mutant embryos is due, at least partially, to a synthetic interaction between Rb and p107
in the endothelial cells of blood vessels or the mesenchymal cells of the heart, implicating
these two pocket proteins in a novel, synthetic role in murine heart development.
In conclusion, through the use of double mutant mice deleted for p107 and
conditionally deleted for Rb, we have identified a synthetic role for pRb and p107 in the
hindbrain and lens of the developing embryo. Furthermore, we have identified novel,
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synthetic functions for pRb and p107 in the development of the limbs, blood vessel
endothelium, and heart. These findings significantly enhance our understanding of the
roles of the pocket proteins during the development of various tissues and cell types.
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EXPERIMENTAL PROCEDURES
Animal maintenance and histological preparations
The generation of Rb c/c, plOT , Mox2-Cre, and Tie2-Cre mice has been described
previously (Lee et al., 1996; Koni et al., 2001; Tallquist and Soriano, 2000; Sage et al.,
2003). Rbc/c and p107T mice were provided by Tyler Jacks. Mox2-Cre (also known as
Meox2-Cre) and Tie2-Cre mice were purchased from Jackson Laboratories. All mice
were of a C57B1/6 and 129/Sv mixed background or were crossed into this mixed
background and bred for at least two generations. Transmission of the Cre transgenes
was always through the male parent to avoid germline deletions (Koni et al., 2001).
Gestation was dated by detection of a vaginal plug. Pregnant mice were injected with 10
tl/gm body weight of 5 mg/ml 5-Bromo-2'-deoxyuridine (BrdU) in phosphate buffered
solution (PBS) two hours prior to tissue collection. Collected embryonic tissue was fixed
in 4% paraformaldehyde (PFA) and paraffin embedded. For all histological analyses
except those of the heart, embryos were cut and sectioned sagittally. Serial transverse
sections through the body of embryos were cut to analyze defects in the embryonic heart.
All histological sections were cut 6 microns thick. Hematoxylin and eosin (H&E)
staining was done using standard procedures. The following genotypic animals were
analyzed by histology and immunohistochemistry: Rb+/C; p107+'; Mox2+/+ (listed as WT
in figures), Rb+/c; plOT7 , Mox2+/+ (listed as p1 07), Rbc/c-; p107'/+; Mox2+/cre (listed as
Rb), and Rbc-/c-; p107/; Mox2+/Cre (listed as Rb; p107). Importantly, no differences were
observed between Rbc-/C-; p107+/+; Mox2+/cre embryos and Rbc-/c-; p1 0 7+/-; Mox2+/cre
embryos or between Rb+/c; pl07T/; Mox2+/ + embryos and Rb+/C, pl0T/; Mox2+/cre
embryos in any experiments presented here.
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Immunohistochemistry
Immunohistochemical analyses were performed using antibodies against BrdU (1:50
347580, BD Biosciences), Ki67 (1:50 550609, BD Biosciences), smooth muscle actin (no
dilution, U7033, DakoCytomation), laminin (1:100 rabbit Ab, a gift from the R. Hynes
lab), and fibronectin (1:100 rabbit Ab, a gift from the R. Hynes lab). For all procedures,
slides were re-hydrated through an ethanol series following de-waxing in xylene and
rinsed in water or PBS as required. Slides were then washed in PBS with 0.15% Triton
X-100 followed by inactivation of endogenous peroxidases by incubation with 3% H20 2
in PBS or 0.5% H202 in methanol (Ki67). Antigen retrieval was performed by heating in
an 800 W microwave for 6.5 min at full power followed by three rounds of 5 min at 60%
power using a solution 8.2 mM sodium citrate, 1.8 mM citric acid, pH 6.0. Slides were
blocked with PBS containing 5% of the appropriate serum and incubated overnight with
the primary antibody diluted in PBS 0.15% Triton X-100 or this buffer alone or a non-
specific antiserum as controls. Secondary antibodies (Vectastain ABC kits, Vector
laboratories) were diluted 1:200 in PBS containing 0.4% of the appropriate blocking
serum and detected using a DAB substrate (brown in color) following the manufacturer's
instructions (Vector Laboratories). Following the detection reaction, slides were
counterstained with Harris hematoxylin and mounted using standard protocols. TUNEL
analysis was performed as described by the manufacturer's instructions (Roche). To
assess the levels of proliferation (BrdU only) and apoptosis (TUNEL), between 250 and
1000 total nuclei were counted per sample (except for blood vessels), with three or more
samples per genotype assessed. Then, the number of positively stained nuclei was
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assessed, and the percentage of positively stained nuclei was calculated. For blood
vessels, only large blood vessels (>8 endothelial cells) were analyzed. Usually more than
one large blood vessel were present in each figure. The percentage of positively stained
nuclei was determined per blood vessel and averaged thereafter. Means and standard
deviations were calculated for the samples. Statistical significance was determined using
the two-sample t-test. Error bars in graphs represent standard deviations except for blood
vessels, where standard error of the mean is displayed (as this analysis was performed by
averaging results in figures).
Quantitative real-time PCR
Hearts were isolated via dissection from e 13.5 embryos. Hearts were
homogenized using a Polytron in Trizol solution (Invitrogen). RNA was extracted
following the Trizol instructions. First-strand cDNA was transcribed from 1 microgram
of RNA using Superscript III Reverse Transcriptase (Invitrogen) following product
instructions. Quantitative RT-PCR with 20 ng cDNA was performed using SYBR Green
(Applied Biosystems). Reactions were run on the ABI Prism 7000 Sequence Detection
System and analyzed using the 7000 SDS software. Primer sequences are available upon
request.
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Chapter 5
Discussion
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The pocket proteins, through their interaction with the E2F transcription factors,
ensure the proper regulation of cell proliferation. By doing so, these protein complexes
affect other fundamental processes such as differentiation. Here we analyzed the in vivo
roles of three proteins, pRb, E2F4, and p 107, in murine embryonic development and
differentiation in vitro. In chapters 2 and 3, we analyzed the role of pRb and E2F4 in
murine bone development. We found that both of these proteins function in vivo to
promote or maintain cell cycle exit and thereby enable the normal, timely development of
bone. Interestingly, our in vitro studies demonstrated that pRb may also possess a direct,
repressive function in osteoblast differentiation. In chapter 4, we studied the cooperative
roles of pRb and p107 during embryonic development. We found that these two pocket
proteins possess complementary functions in the CNS. Moreover, our studies uncovered
novel, cooperative roles for pRb and p107 in limb, blood vessel endothelium, and heart
development. These studies, therefore, provide evidence of much broader and novel
roles for pRb, p107, and E2F4 in the development and differentiation of murine tissues.
pRb in skeletal development, differentiation, and tumor formation
The in vivo analysis of the function of pRb in bone development was not possible
in the original Rb- mice, as they died between e13.5 and e15.5 (Clarke et al., 1992; Jacks
et al., 1992; Lee et al., 1992). However, placental defects were responsible for the
embryonic lethality of the Rb / mice (de Bruin et al., 2003; Wenzel et al., 2007; Wu et al.,
2003). Rb mutant embryos with a wild-type placenta, though, survive until birth, at
which time they die due to skeletal muscle defects. Therefore, we conditionally deleted
Rb in the embryo proper, and not in the placenta, using the Mox2-Cre transgene
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(Tallquist and Soriano, 2000). We found that these conditionally mutant embryos (Rbc/c-
) displayed defects in the formation of several bones during development. Furthermore,
we determined that at least some of the skeletal defects were due to an inability of the
progenitor osteoblasts to properly exit the cell cycle, thereby temporarily preventing
terminal differentiation. Interestingly, we found that the depletion of pRb in vitro had the
opposite effect. Osteoblasts in vitro secreted a greater amount of calcified matrix upon
acute ablation of pRb. We propose that this in vitro phenotype is due to a cell cycle-
independent, repressive function of pRb in osteoblast differentiation.
Although our studies suggest that the increase in secreted calcium deposits in
vitro upon pRb depletion represents a novel, repressive function for pRb in osteoblasts,
we have not ruled out that this may be related to cell cycle effects. The deletion of Rb in
the calvarial osteoblast cultures causes a defect in confluence arrest, enabling the
monolayers to become denser than control cultures. It has been shown that increasing the
density of calvarial cultures increases their differentiation potential (Gerber and ap
Gwynn, 2001; Purpura et al., 2004). Therefore, we may be observing an indirect effect of
the confluence arrest defect.
To determine definitively if pRb functions specifically to repress osteoblast
differentiation, it is important to remove the cell cycle exit component from these
analyses. We attempted this genetically by introducing an E2fl deletion into the Rb
mutant strains. However, deletion of E2fl does not suppress the confluence arrest defect
in Rb depleted cells in vitro. A second possibility is to introduce the E2J2 deletion into
the E2fl/ Rbc/- calvarial cells in an attempt to suppress the confluence arrest defect. If
the combined loss of E2fl and E2J2 suppressed the cell cycle exit defect, one could assay
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for matrix deposition in the Rb mutant cells. An increase in secreted calcified deposits in
the E2fl' E2J2- Rbc/c calvarial cells would argue in favor of a cell cycle-independent,
repressive role for pRb in osteoblast differentiation.
A third strategy for determining whether Rb possesses a cell cycle-independent
function in osteoblast differentiation would be to use mesenchymal stem cells (MSCs).
MSCs can be induced to differentiate into osteoblasts without the requirement of
confluence arrest. One could isolate Rbc/c MSCs, infect them with Adeno-Cre or Adeno-
GFP, and then induce them to differentiate prior to confluence. If the pRb-depleted cells
differentiated to a greater extent than controls, it would support the hypothesis that pRb
functions to repress osteoblast differentiation. However, it would be important to assay
for cellular proliferation to ensure that the pRb-depleted cells do not divide faster or for
an extended period of time compared to control cells, as this would complicate the
analysis.
We observed that the depletion of pRb induced the expression of osteoblast
markers, in accordance with the increase in secreted calcium deposits. Therefore, it is
possible that pRb represses osteoblast differentiation by directly binding to and inhibiting
the transcription of osteoblast genes. Our initial attempts to test this hypothesis using
chromatin immunoprecipitation (ChIP) did not work. However, we did not perform an
adequate positive control. To test this hypothesis more thoroughly, one could evaluate a
range of pRb antibodies for ChIP signal at the OPN promoter, where pRb has been shown
to associate (Thomas et al., 2001). Once the appropriate antibody and ChIP conditions
have been worked out, one could test for pRb association at the promoters of the various
genes shown to be upregulated in Rbc/' calvarial cells, such as Bmp2, Msx2, Runx2, and
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OSX. The hypothesis would predict a pRb association at the promoter prior to
differentiation, when the gene(s) is repressed, and a lack of association during osteoblast
differentiation, when the gene(s) is induced. If such an association pattern were to be
observed, these findings would lend considerable supporting evidence for a cell cycle-
independent, repressive function for pRb in osteoblast differentiation. However, it is
important to note that it is also possible that pRb may repress the pro-osteoblastic genes
in an indirect manner.
In vivo mouse models could also be used to determine if pRb functions to repress
osteoblast differentiation. If our hypothesis is true, then once Rbcc- progenitor
osteoblasts exit the cell cycle, these cells should overexpress Runx2 and OSX, thereby
increasing differentiation and the secretion of bone. However, the Mox2-Cre Rb' -/ - mice
die shortly after birth. Instead, one could cross the Rbc/c mice with another transgenic
animal, such as the OSX-Cre mouse (Rodda and McMahon, 2006). This transgene
expresses Cre recombinase only in cells normally expressing the osteoblast transcription
factor, OSX. Mice conditionally deleted for Rb in this manner are alive (our unpublished
data) and can be analyzed as adults for an increase in bone density or bone formation.
For example, double label calcein assays could be used to determine the rate of bone
formation in adult Rb mutant bones compared to controls. ýtCT analyses could also be
utilized to compare the thickness of cortical bone and the amount of trabecular bone in
the mutant and wild-type mice. Finally, one could histologically section bones to
determine, via in situ experiments, if the conditional Rb mutant mice express greater
levels of osteoblast markers compared to wild-type mice. If these assays demonstrated
that the loss of pRb in the bone caused an increase in bone formation or in osteoblast
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marker expression, these data would support the hypothesis that pRb possesses a
repressive, cell cycle-independent function in osteoblast differentiation.
In our original in vivo skeletal analyses, we observed defects in both
intramembranous and endochondral bones upon deletion of Rb. Although we
demonstrated that Rb loss specifically affects osteoblasts in the intramembranous bones,
it is formally possible that the loss of Rb disrupts bone development in the endochondral
bones by perturbing chondrocyte differentiation. To test the possibility that pRb
functions in chondrocyte differentiation, one could employ several techniques.
To test for a role in chondrogenesis, one could first take advantage of the Mox2-
Cre and Rbc/c mice already in the lab. For example, one could study cartilage formation
in the presphenoid and basisphenoid elements of the Rbc•- - head at e 15.5 using Alcian
blue staining. The cartilage development of other bones could be analyzed at even earlier
time points during gestation. Immunohistochemical (IHC) analyses of cartilage elements
could also be used to determine if the deletion of Rb affects chondrocyte development.
For example, BrdU, Ki67, or PCNA IHC analyses may demonstrate that the deletion of
Rb prevents cell cycle exit in chondrocytes similar to its the osteoblasts. Additionally,
one could analyze markers of chondrocyte differentiation, such as Sox9 and Collagen
type 2, to determine if a particular point in chondrocyte differentiation is affected in Rbc-
/c- embryos.
One could also test for a defect in cartilage development upon loss of Rb using a
cartilage-specific Cre recombinase transgene (see Table 1 at the end of this chapter for a
list of Cre recombinase described in this Discussion). For example, one could use the
Sox9-Cre transgene (Akiyama et al., 2005) to deplete pRb in progenitor chondrocytes.
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This would allow one to determine if pRb is required for chondrocyte proliferation and
the initiation of differentiation. In addition, one could conditionally delete Rb in
chondrocytes after the initiation of differentiation through the use of the Col2al-Cre
transgene (Ovchinnikov et al., 2000). These mice would allow one to determine if pRb is
necessary for later steps in cartilage formation and the maintenance of terminal
chondrocyte differentiation. Once the Rbc allele has been crossed into these transgenic
mice, homozygous, conditional Rbc-/c embryos could be analyzed for cartilage and bone
defects using all of the assays discussed above or described in Chapter 2.
Finally, three related protocols have been published to examine chondrocyte
differentiation in vitro. For example, one could isolate murine embryonic chondrocytes
and progenitors to study the potential differences in differentiation between wild-type and
RbC-/c cells (Pfander et al., 2003; Shakibaei, 1995). One could also induce embryonic
stem (ES) cells to differentiate into chondrocytes and analyze the potential effects of Rb
deletion in this system (Tanaka et al., 2004). Finally, one could isolate embryonic limb
bud mesenchymal progenitor cells and culture them in micromass to induce chondrocyte
differentiation (Zhang et al., 2004). Again, by comparing the effects of Rb loss on
chondrocyte differentiation in this system, one could determine whether pRb functions in
the normal differentiation of chondrocytes in vitro.
Aside from determining the role of pRb in the differentiation of chondrocytes and
osteoblasts during development, one could also use the conditional Rb mice to study the
effects of Rb loss in tumorigenesis. Human osteosarcomas often exhibit aberrations to
the Rb-1 locus (Belchis et al., 1996; Feugeas et al., 1996). However, mice heterozygous
for Rb do not develop osteosarcoma, possibly because they die prematurely of pituitary or
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thyroid tumors (Hu et al., 1994; Jacks et al., 1992). Therefore, one could conditionally
delete Rb in the bones using a transgene such as OSX-Cre to determine if Rb deletion
alone is sufficient to induce osteosarcoma formation. Moreover, one could introduce
mutations in other genes, such as p53 or pl07, in addition to the conditional deletion of
Rb, to facilitate osteosarcoma formation and to better understand the mechanism of
osteosarcoma development upon mutation to these genes. Studies such as these are
currently ongoing in the lab.
E2F4 in skeletal development and differentiation
The repressive E2F, E2F4, can bind to all three pocket proteins (Moberg et al.,
1996). Interestingly, all three of these proteins have been implicated in murine bone
development. p107 and p130 cooperate in limb development (Cobrinik et al. 1996),
while pRb affects osteoblast differentiation (Thomas et al., 2001; Chapter 2). Therefore,
we hypothesized that E2F4 may also function in the development of bone. We studied
E2f4- embryos and found that they exhibited defects in ossification at all stages in
development. These bone defects were accompanied by decreased alkaline phosphatase
activity, an early marker of osteoblast differentiation. Furthermore, progenitor
osteoblasts continued to proliferate in E2f4/ embryos compared to osteoblasts in wild-
type embryos. Therefore, we believe that the deletion of E2f4 temporarily prevents
progenitor osteoblasts from properly arresting, a necessary initial step in terminal
osteoblast differentiation. Additionally, our in vitro studies indicated that E2F4 does not
possess a specific, cell cycle-independent function in osteoblast differentiation. Instead,
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the in vitro experiments supported the suggestion that E2f4/ " progenitor osteoblasts are
failing to appropriately exit the cell cycle.
Although our data indicate that the deletion of E2F4 prevents the pool of
osteoblast progenitor cells in skeletal elements from terminally differentiating, we have
not definitively proven that hypothesis. However, there are additional experiments one
could perform to further test that hypothesis. For example, one could perform a
progenitor assay in vitro. In this assay, E2f4/ and wild-type calvarial cells are isolated as
usual. After one day in culture the cells are plated sparsely onto new culture dishes.
Presumed progenitor osteoblasts will form individual colonies on the plate and, with the
appropriate media, induce markers of differentiation in the center of those colonies where
the cells are the most confluent. Cells that are not progenitors presumably will not form
colonies and will not initiate osteoblast differentiation. Therefore, if we are isolating
more progenitor cells from the E2f4- calvaria, as hypothesized, then this assay should
demonstrate a greater number of E2f4/ colonies expressing early osteoblast
differentiation markers, such as alkaline phosphatase, compared to the wild-type cells.
MSC preparations could also be used to test the progenitor hypothesis. Unlike the
calvarial cells, MSCs can differentiate into bone in vitro without the requirement of
reaching confluence arrest. Therefore, one could test whether E2f4- MSCs display
defects in osteoblast differentiation. Assuming that MSCs must exit the cell cycle to
initiate osteoblast differentiation, our hypothesis would predict that E2f4/ MSCs would
exhibit a defect in cell cycle exit and hence, a delay in the secretion of calcium deposits.
One could perform a similar experiment to test if constitutive knock down of E2F4, via
stable integration of a short hairpin RNA against E2F4 in wild-type MSCs, delayed the
209
secretion of calcified matrix compared to control MSCs. One drawback to these
experiments, however, is that we do not yet know if MSCs in vitro continue to proliferate
as they differentiate. Therefore, it would be important to determine the cell cycle profile
of wild-type and E2f4- MSCs over the time course of the experiment. If it is found that
wild-type MSCs proliferate as they differentiate, then it may be difficult to determine if
the E2f4/ MSCs possess a defect in cell cycle exit and, consequently, a defect in
differentiation.
It is important to note that although we have demonstrated in our studies that
circumstances affecting osteoblasts contribute to the E2f4-' defect in intramembranous
ossification, we have not proven that the defects are cell autonomous. For example, E2f4
' mice are anemic during fetal development. It is possible that the anemic state of the
embryo could prevent adequate nutrients and gases from reaching cells of all types,
including the osteoblasts. In this circumstance, many cellular processes could be
adversely affected, thereby causing a delay in the development of various embryonic
tissues. To test this hypothesis, one could generate a new colony of mice possessing a
conditional allele of E2f4. These could then be mated to mice harboring the OSX-Cre
transgene, thereby enabling one to study the effects of E2f4 deletion specifically in the
bones without the accompanying anemia. One could also use Prx-Cre, which expresses
the Cre recombinase in mesenchymal progenitor cells (Logan et al., 2002). If our
hypothesis is true, then the conditional deletion of E2f4 in the mesenchymal progenitor
cells, and likely in the OSX-expressing cells, would cause a similar defect in bone
formation as we observed in the germline E2f4/ embryos.
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In our initial studies we also observed that E2f4-' embryos displayed a defect or
delay in the deposition of collagen matrix, suggesting that the loss of E2F4 affects
chondrocyte development. It would be interesting to determine if this latter suggestion is
true. In the previous section, we laid out a series of experiments to test for effects in
chondrocyte differentiation and cartilage development upon deletion of Rb. This same
set of experiments could be performed with the E2f4-ý- and the proposed E2f4c/c embryos
to evaluate the function of E2F4 in chondrocyte differentiation.
Finally, it is possible that pRb and E2F4 possess similar roles in promoting or
maintaining cell cycle exit in osteoblasts and chondrocytes. If confirmed, it could be
interesting to create compound mutants of Rb and E2f4. One could analyze the effects on
cartilage and bone development in these double mutant embryos to determine if the two
genes function in concert or in parallel pathways during the differentiation of osteoblasts
and chondrocytes.
pRb and p107 function cooperatively in embryonic development
Cooperative roles for the pocket proteins have been demonstrated in several
tissues. p107 and p130 function together in chondrocyte (Cobrinik et al., 1996) and
epidermal differentiation (Ruiz et al., 2003). Similarly, pRb and p107 act in a
complementary manner in adult epithelial differentiation (Haigis et al., 2006; Ruiz et al.,
2004). A previous attempt to study the cooperative roles of pRb and p107 during
embryogenesis demonstrated that Rb-'-; plOT0 embryos died by e 11.5, prior to the
formation of most organs (Lee et al., 1996). However, the early lethality was likely
caused by enhanced defects of the placenta (de Bruin et al., 2003; Wu et al., 2003).
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Therefore, we generated pl07" embryos that were conditionally deleted for Rb only in
the embryo proper. We found that these double mutant embryos died by approximately
e14.5, even though no placental defects were apparent. We showed that pRb and p107
exhibited complementary roles in cellular proliferation and apoptosis in the central
nervous system (CNS), but not in the peripheral nervous system (PNS) or in the lens.
Furthermore, the double mutant embryos displayed defects in limb development and
excessive proliferation in the endothelial cells of blood vessels. Finally, the double
mutant embryos possessed heart defects, including double outlet right ventricle (DORV).
Using the Tie2-Cre transgene instead of the Mox2-Cre, we have preliminary data
indicating that the DORV is caused by defects in endothelial cells or in the mesenchymal
cells of the heart. Together, our data demonstrate novel, cooperative functions for pRb
and p107 in murine embryonic limb, blood vessel endothelium, and heart development.
There are many aspects of this project that are open to discussion and future
experiments. Initially, there are obvious assays to perform to solidify some of the
findings presented. For example, one could perform BrdU and Ki67 IHC and TUNEL
staining of the lens for more embryos of all genotypes. This would provide a quantitative
analysis of the cell cycle and apoptotic defects in the lens, and thereby provide a more
definitive demonstration (if true) that the deletion ofpl 07 does not exacerbate the defects
observed in the Rbc/c lens. One could also perform similar experiments to analyze cell
cycle and apoptotic defects in the skeletal muscle, as Rbc-/c embryos have been shown to
demonstrate defects in muscle (de Bruin et al., 2003; Wu et al., 2003; Zacksenhaus et al.,
1996). Finally, one could determine, based on H&E stainings of placental sections, if
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there is an increase in the percentage of abnormal erythroid cells in the double mutant
embryos compared to the Rbc-/c embryos.
Our data suggest that the heart defects in the double mutant embryos are not
caused by a decrease or delay in the differentiation of cardiomyocytes at e 13.5.
However, it is possible that the combined loss of pRb and p107 does cause a defect or
delay in cardiomyocyte differentiation at earlier time points during development and that
by e13.5, this phenotype is no longer apparent. Therefore, one could analyze by
quantitative RT-PCR the expression of cardiomyocyte markers in the hearts of embryos
at earlier stages of development. Furthermore, one could use a transgene that expresses
the Cre recombinase specifically in cardiomyocytes. The most commonly used transgene
of this sort is the Myh6-Cre construct, whereby Cre recombinase is driven by the
cardiomyocyte-specific myosin heavy chain (Myh6) promoter. We have received a
tamoxifen-inducible version of this transgene (Sohal et al., 2001) in order to genetically
test if the cardiomyocyte-specific deletion of Rb inpl07T' embryos causes defects in
heart development. Together, such experiments would test more definitively whether
defects in cardiomyocyte differentiation are the cause of the heart defects observed in the
double mutant embryos.
Although we did not observe a decrease in the expression of cardiomyocyte
markers in the e 13.5 hearts of any mutant embryos, surprisingly we noticed that the
expression of several markers in the double mutant hearts was slightly induced. The
affected markers (Nkx2.5, GATA4, and ANF for example) all fell into the Mespl/2
transcriptional pathway (Satou et al., 2004). Interestingly, a constitutively active form of
Mesp in Ciona intestinalis did not affect the differentiation of the heart but did affect the
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proper migration of the heart (Davidson et al., 2005). Notably, the cardiac differentiation
pathway and aspects of migration in Ciona are similar to those observed in vertebrates.
Therefore, it is possible that in the double mutant embryos, the slight overexpression of
Mesp2 may affect the proper migration of cells, thereby resulting in DORV.
Another avenue of interest concerning the role of Rb and p107 in cardiac
development involves the protein Jumonji (Jmj). Jmj associates with the cardiomyocyte
transcription factors Nkx2.5 and GATA4 and represses Nkx2.5- or GATA4-mediated
transcription of downstream targets, such as ANF (reviewed in Jung et al., 2005).
Accordingly, jmj mutant embryos demonstrate increased expression of ANF. Moreover,
the hearts ofjmj mutant embryos exhibit defects similar to those observed in the Rb'/c-;
p107 " embryos, including DORV. Finally, Jmj binds to pRb. Therefore, it is possible
that pRb and p107 could cooperate with Jmj to repress the transcription of cardiomyocyte
markers. Furthermore, it is possible that this potential function could be the underlying
cause of the heart defects observed in the double mutant embryos. To test this
hypothesis, one could isolate protein from wild-type embryonic hearts and perform co-
immunoprecipitations to determine if pRb or p107 associate with Jumonji in vivo. In
addition, one could perform similar experiments to demonstrate an association between
pRb or p107 and one of the cardiomyocyte transcription factors, such as Nkx2.5 or
GATA4. If such associations were observed, one could design in vitro experiments to
test whether these associations repressed the transcriptional activity of Nkx2.5 or
GATA4. Additionally, one could test for genetic interactions between Rb, p107, and Jmj.
By determining if the effects on ANF expression levels, for example, remain the same or
are exacerbated, one could test whether these genes function in the same pathway or in
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parallel pathways, respectively. Although our preliminary data (discussed below)
indicates that the DORV is caused by endothelial or mesenchymal defects, that data does
not exclude the possibility that pRb and p107 function to repress cardiomyocyte
transcription, possibly through cooperation with Jumonji.
We crossed the Tie2-Cre transgene (Kisanuki et al., 2001; Koni et al., 2001) into
our Rbc/c, pl07/ mice to genetically test the possibility that endothelial cell defects were
the underlying cause of the DORV. At this time, only two Tie2-Cre Rb-/c-; p1 0 7/
embryos have been analyzed. At e13.5, one of these double mutants exhibited partial
DORV, in which the aorta was exiting from in between the right and left ventricle. The
second double mutant possessed a true DORV phenotype. Assuming these preliminary
findings are observed in other double mutant embryos, one could argue that defects in
endothelial cells are responsible for the heart defects, or at least the DORV.
However, the analysis of these two double mutant mice is complicated by the
expression patterns observed in the Tie2-Cre mice. First, the Tie2-Cre transgene
expresses Cre recombinase in the mesenchymal cells of the pulmonary and aortic valves
and of the atrioventricular canal. Thus, the DORV may likely be due to defects in these
mesenchymal cells upon loss of pRb and p107. Second, a percentage of circulating cells
(i.e., erythroid cells) also express Cre recombinase. Therefore, it is formally possible that
defects in erythroid cells leading to anemia or decreased nutrient and gas uptake may be
responsible for the heart defects.
As evident from the above caveats and lack of definitive data, there are many
experiments that one could perform in the Tie2-Cre RbcI/c~ p]07/ embryos to clear up
several issues. For example, as a control, one could perform BrdU and Ki67 IHC to test
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whether the double mutant blood vessel endothelial cells display an increase in
proliferation compared to other embryos. In a related experiment, one could test for
increased proliferation in transverse sections of the great arteries and valves in the double
mutant mice compared to controls. Since the Tie2-Cre expresses Cre recombinase in
some circulating cells, it would be important to determine if the Tie2-Cre Rbc-/c or double
mutant embryos exhibit abnormal erythrocytes as observed in the Mox2-Cre embryos. If
not, or if the percentage of abnormal cells is lower than that observed in the Mox2-Cre
Rbc-c- embryos, this would argue against the hypothesis that defects in erythroid
development are the cause of the heart defects in the double mutant embryos. Finally,
assuming the DORV in Tie2-Cre RbcYC; p]07" embryos is confirmed, it would be of
interest to determine if the DORV is the cause of the edema and of the e 14.5 lethality.
Therefore, one could analyze H&E histological sections of these double mutant embryos
for edema. One could also determine if the Tie2-Cre double mutant embryos die at
e14.5. Depending on the outcome of these experiments, one could determine if defects in
endothelial cells and/or mesenchymal cells of the heart are the underlying cause of the
DORV, edema, and mid-gestational lethality in the Mox2-Cre double mutant embryos.
Although the above experiments are important to gain a better understanding of
the defects in the Mox2-Cre double mutant embryos, it is already clear at this point that
pRb and p107 cooperate in the development of the CNS, limbs, blood vessel
endothelium, and heart. These studies, therefore, significantly enhance our understanding
of the cooperative roles of pRb and p107 during the development and differentiation of
various tissues.
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Cre Transgenes Cre Recombinase Expression Pattern
Mox2-Cre Embryo proper (not the placenta)
OSX-Cre Differentiating osteoblasts and progenitor osteoblasts
Sox9-Cre Proliferating, progenitor chondrocytes
Col2al-Cre Differentiating chondrocytes
Prx-Cre Progenitor mesenchymal cells
Tie2-Cre Blood vessel endothelial cells, mesenchymal cells of the heart, and
some circulating cells
Myh6-Cre/Esrl Differetiating cardiomyocytes. Induced by tamoxifen.
Table 1. List of Cre recombinase transgenes discussed in Chapter 5.
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Appendix A
Osteosarcoma and neuroendocine tumor development in mice conditionally deleted
for Rb and p53 with the OSX-Cre transgene
Seth Berman, Paul S. Danielian, Alicia Caron, Siddhartha Mukherjee, Mary Bouxsein,
Esther Cory, Emily Miller, and Jacqueline A. Lees
The author contributed all text, graphs, and most figures. Paul Danielian contributed to
the data collection necessary for the Kaplan-Meier curve and has continued the work on
this project. Siddhartha Mukherjee assisted with the initial dissections and provided
valuable advice. Alicia Caron performed all of the histological sectioning. Emily Miller
performed some of the alizarin red and alkaline phosphatase stainings in Figure 3C and
Figure 5. Mary Bouxsein and Esther Cory performed the [CT analyses at the Beth Israel
Deaconess Medical Center/Harvard Medical School Orthopedic Biomechanics Lab. All
other work was performed in the lab of Jacqueline Lees.
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INTRODUCTION
Osteosarcoma accounts for 3-4% of all childhood malignancies and is the most
common malignant tumor of bone, comprising 31% of all bone tumors (Souhami and
Tobias, 1998). Treatment for this cancer has significantly improved with the
combination of chemotherapy and surgical procedures, as the current estimated five-year
survival for patients is greater than 70% (Rosen, 1985; Smeland et al., 2003; Winkler et
al., 1984). However, osteosarcoma is prone to metastasize, often to the lung or to other
bones, decreasing the three-year survival rate to 20-30% and the five-year survival rate to
12% (Fagioli et al., 2002; Inoue et al., 1998). Moreover, 15% of patients will present
metastatic disease at the time of diagnosis (Kaste et al., 1999) and nearly 60% will
ultimately develop lung metastases (Toguchida et al., 1992).
It is apparent that the tumor suppressor genes, Rb and p53, play a significant role
in the development of osteosarcoma. Among patients who carry germline Rb mutations,
osteosarcoma is the second most common tumor type after retinoblastoma and is
observed at a 500-fold higher incidence compared to the general population (Gurney et
al., 1995). Overall, some studies suggest that up to 78% of osteosarcomas exhibit
mutations or genetic alterations to Rb (Belchis et al., 1996; Feugeas et al., 1996;
Toguchida et al., 1988). Similarly, Li-Fraumeni patients, whom most often carry
mutations in p53, are predisposed to various sarcomas, including osteosarcoma (Malkin,
1993; Nichols et al., 2001). In the general population, some studies suggest that
alterations to p5 3 or the chromosomal location 17p, where p53 resides, occur in up to
70% of osteosarcomas (Toguchida et al., 1988; Toguchida et al., 1989). Finally, it is
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likely that in many of the osteosarcomas analyzed, both Rb and p53 are affected
(Toguchida et al., 1988).
To gain insight into the development and metastatic disease progression of
osteosarcoma, we have engineered a mouse model for this tumor type by crossing mice
harboring conditional alleles of Rb and p53 with a strain carrying the OSX-Cre transgene
(Rodda and McMahon, 2006). Osterix (OSX, Sp7) is a transcription factor expressed
predominantly in osteoblast cells that is essential for bone formation in vivo (Nakashima
et al., 2002). Therefore, we have used the OSX-Cre transgene to conditionally delete Rb
and p53 specifically in osteoblast cells, thereby creating the first mouse model for
osteosarcoma possessing mutations in these two tumor suppressors.
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RESULTS AND DISCUSSION
We crossed the OSX-Cre transgene into mice carrying floxed alleles of Rb and
p53 to conditionally delete these tumor suppressors in osteoblasts, leaving other tissues
functionally wild-type. In doing so, we hoped to generate a mouse model specific for
osteosarcoma harboring mutations in Rb and p53. As a control, we confirmed that the
conditional alleles of Rb and p53 are indeed recombined in the bones (data not shown).
Notably, we observed a low presence of recombined PCR products in other samples, such
as ear clips and the thyroid (data not shown), suggesting that low levels of Cre expression
may exist in other cell types besides the osteoblasts.
Conditionally mutant mice of all genotypes were alive, although all OSX-Cre
positive mice were smaller than OSX-Cre negative mice (data not shown). Nevertheless,
the smaller size did not appear to affect their survival, and by two to three months of age
all Cre-positive and Cre-negative animals were of equal size (data not shown). We are
allowing this cohort of mice to age, and the preliminary data obtained from this study is
presented below.
The average survival time for the conditional Rb and p53 mutant mice (hereby
designated Rb'c/;p53/c,; OSX-Cre and termed double mutant) is approximately 4.5 months,
based on our preliminary data (Figure 1). However, as this cohort has not finished aging,
it is not yet possible to determine the average survival time for any of the other
genotypes. Nevertheless, it is clear at this point that the double mutant mice are dying
earlier than mice of any other genotype in the cohort.
Histological examination of the sacrificed double mutant mice demonstrated that
these mice died as a result of tumor formation. These tumors were primarily
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Figure 1. Conditional double mutant mice survive approximately 4.5 months
Kaplan-Meier survival curve through 4.5 months, thereby including all mice in the
cohort. The preliminary data suggest that the average survival of the conditional, double
mutant mice is approximately 4.5 months. The average survival time for mice of all
other genotypes cannot yet be determined.
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osteosarcomas and neuroendocrine tumors, with half of the tumors being osteosarcomas.
Some mice presented both tumor types. In addition to these tumors, we have also
observed one pinealblastoma and one hibernoma (brown fat tumor) in the double mutant
mice.
At this point, only a few mice of other genotypes have died (Figure 1). Four
Rbc/c;p53+/c,'OSX- Cre mice have been histologically analyzed, and all died as a
consequence of tumor development. Three of these animals exhibited osteosarcoma,
while one possessed a neuroendocrine tumor. In addition, one Rb+/c;p53c/c;OSX -Cre
mouse has been studied histologically, indicating that this mouse died of an
osteosarcoma. No Rb+/c,'p53+/1 ;OSX-Cre or Rbc/c;OSX-Cre orp53c1c;OSX-Cre mice have
died at this point in the study. As this cohort of mice ages, the tumor spectrum and
average survival time of all the control genotypes will be determined and compared to the
data obtained from the double mutant mice.
In humans, osteosarcoma occurs most often in the long bones, such as above or
below the knee or in the upper arm near the shoulder. Similarly, mice carrying a p53RI
72H
mutation often develop osteosarcomas in the long bones and the vertebrae (Olive et al.,
2004). Surprisingly, the double mutants in this study developed osteosarcomas primarily
in the head (discussed below), although we observed one osteosarcoma in a femur of a
double mutant mouse. This femoral osteosarcoma had completely invaded the marrow
cavity and eroded some of the cortical bone (Figure 2A), as demonstrated by H&E
analysis. Moreover, micro computed tomography (ýtCT) X-ray analyses showed that the
tumor exhibited a periosteal mass containing radioluscent, ossified specules (Figure 2B).
These phenotypes are reminiscent of human femoral osteosarcoma.
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Figure 2. Femoral osteosarcoma in conditional double mutant mice
(A) Hematoxylin and eosin staining of a control femoral head (top) and a double mutant
femoral head (bottom) with osteosarcoma. Arrow indicates osteosarcoma cells invading
the marrow cavity of the femur. Arrowhead illustrates degraded cortical bone. Pictures
created by merging two 4X magnification captures. (B) ptCT analysis of the double
mutant femur. X-rays demonstrate a periosteal mass (*) containing radioluscent, ossified
specules.
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As mentioned above, the double mutant mice of this study developed
osteosarcomas predominantly on the face, usually above or below the jaw or around the
incisors (Figure 3A). Hematoxylin and eosin (H&E) staining indicated that these tumors
were composed of osteoblasts or mesenchymal progenitor cells, a collagen matrix, and
bone nodules, all of which are characteristics indicative of osteosarcoma. Sirius red
staining confirmed that the tumors contained a collagen matrix (Figure 3B), and alizarin
red staining of un-decalcified tumor sections verified that the tumors produced calcified
bone deposits (Figure 3C).
We then isolated mRNA from these tumors and tested for the expression of
known osteoblast differentiation markers by quantitative RT-PCR. The osteosarcoma
samples all expressed markers of osteoblasts, such as the transcription factors Runx2 and
OSX, the early differentiation markers Alkaline Phosphatase (ALP) and Collagenlal
(Coll), and the late differentiation protein Osteocalcin (OC) (Figure 4). Notably, the
expression level of these transcripts was equal to or greater than that observed in wild-
type long bones. The one exception was the early/mid-differentiation marker,
Osteopontin (OPN), which was not induced in one of the tumors analyzed. As a control,
we tested for expression of these markers in adipocytic tumors depleted for Rb and p53
and found that the osteoblast genes were not induced. Together with the previous data,
our findings indicate that the tumors in the head of the double mutant mice are
osteosarcomas.
We isolated cells from two double mutant osteosarcomas and grew them in
culture. These two tumor preparations appear to be immortalized cell lines, as they have
not senesced or died after greater than 14 passages (data not shown). We assayed for
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Figure 3. Conditional double mutant mice develop osteosarcoma in the head
(A) Hematoxylin and eosin staining of a sagittal section through the head of a
conditional double mutant mouse that developed osteosarcoma in the snout (arrowhead).
Picture created by merging four separate 2X magnification captures. (B) Sirius red
staining for collagen, performed as described in (A). The tumor (arrowhead) contains a
collagen matrix as determined by Sirius red staining. (C) Alizarin red staining
demonstrates the presence of bone in a histological section of a tumor that was not
decalcified. 10X magnification shown.
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Figure 4. Osteosarcomas in conditional double mutant mice express osteoblast markers
Tumors from conditional double mutant mice were analyzed for the expression of
osteoblast genes. Three separate osteosarcomas (OS), as determined by H&E analyses,
demonstrate expression of osteoblast markers. The neuroendocrine tumor (NE), as
determined by H&E, shows induction of Osterix, but not of the osteoblast genes Coll,
OPN, and OC. WT indicates an RNA sample obtained from a wild-type long bone.
DKO indicates an RNA sample from a conditional double mutant long bone that did not
exhibit an osteosarcoma. HIB signifies adipocytic tumors depleted for Rb and p53.
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OSX promoter activity based on GFP fluorescence, as the Cre recombinase in the OSX-
Cre transgene is actually a fusion protein of Cre recombinase and GFP. Neither tumor
cell line expressed GFP during asynchronous, non-confluent growth. Not surprisingly,
these cells also did not produce bone during asynchronous, non-confluent growth (data
not shown). These data indicate that the tumor cells are not terminally differentiated.
Interestingly, the previous in vivo quantitative RT-PCR data (Figure 4) demonstrated that
OSX is upregulated in the osteosarcomas. Therefore, as OSX is presumably not induced
in vitro based on a lack of GFP fluorescence, the data suggest that the tumor cells
suppress transcription of OSX upon the transition into an in vitro setting.
We grew the tumor cells to confluence and tested their ability to differentiate into
bone producing cells. After seven days in differentiation media, the tumor cells
expressed GFP (Figure 5). Moreover, these cells demonstrated alkaline phosphatase
activity and secreted calcified matrix (Figure 5). As a comparison, it takes 21-35 days for
wild-type, primary calvarial osteoblasts to differentiate after confluence arrest and
exposure to differentiation media (data not shown). We then tested for spontaneous
osteoblast differentiation. Seven days post confluence, these cells demonstrated very low
levels of GFP expression, alkaline phosphatase activity, and secreted ossified deposits
(Figure 5). However, fourteen days post confluence, a significant number of tumor cells
expressed GFP, demonstrated high alkaline phosphatase activity, and secreted calcium-
containing deposits (Figure 5, data not shown). Therefore, these osteosarcoma cells are
capable of spontaneous osteoblast differentiation in vitro upon confluence. We are
currently performing experiments to determine if these tumor cells can form new tumors
upon injection into nude mice.
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Figure 5. Cells isolated from osteosarcomas differentiate and secrete bone in vitro
Cells were isolated from osteosarcomas of conditional double mutant mice. The cells
were grown to confluence and then switched to differentiation media (+) or kept in alpha
MEM (-). At the indicated time points the cells were analyzed for GFP expression
(GFP), alkaline phosphatase activity (ALP), or alizarin red staining (AR). Osteosarcoma
cells grown in differentiation media demonstrated GFP expression, alkaline phosphatase
activity, and alizarin red staining on day 7. These cells also spontaneously differentiated
after 14 days when grown in alpha MEM, as evidenced by the GFP expression, alkaline
phosphatase activity, and alizarin red staining. GFP pictures are 20X magnification.
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Despite the low prevalence of osteosarcoma in the long bones, we have observed
other phenotypes in the long bones, hips, and vertebrae of the double mutant mice. H&E
analyses have demonstrated that these mice exhibit excessive bone growth, osteoma, and
osteopetrosis (data not shown). [tCT analysis confirmed that the femur of a double
mutant mouse developed excessive bone growth, if not osteoma (Figure 6). H&E and
[CT analyses demonstrated that ap53c-c; OSX-Cre mouse also demonstrated excessive
bone growth (Figure 6, data not shown). An Rb-/c-; OSX-Cre mouse, on the other hand,
showed less cortical and trabecular bone in the femur, based on tCT (Figure 6). These
data are very preliminary, however. More analyses are required before a definitive
conclusion can be made concerning the effects in bone development of deleting one or
more of these genes.
Finally, we analyzed the expression level of osteoblast markers in a
neuroendocrine tumor from a double mutant mouse. These tumors were found in the
brain, outside of the skull, and in the neck region of the double mutant mice. They did
not contain bone, nor did they secrete a type 1 collagen matrix (data not shown).
Interestingly, this tumor type demonstrated a significant level of OSX transcript (Figure
4). This would suggest that OSX is not exclusively expressed in bones and that some
neuroendocrine cells can also induce transcription of this gene. Furthermore, this may
explain the prevalence of neuroendocrine tumors in the double mutant mice, as Rb and
p53 would be deleted in these cells upon expression of the OSX-Cre transgene. Notably,
the osteoblast-specific genes, Coll, OPN, and OC were not upregulated in the
neuroendocrine tumor, providing further evidence that this tumor was not of osteoblast
origin.
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Figure 6. [tCT analyses of femurs
Femurs from mice of the indicated genotypes were analyzed by pLCT. The conditional,
double mutant femur demonstrates excessive bone growth (arrowhead). The p 5 3C/C-.;
OSX-Cre femur may also exhibit excessive bone growth (arrow). The Rbc-/-; OSX-Cre
femur, however, exhibits less ossification in both the cortical and trabecular bone of the
femur compared to all other femurs shown.
234
I ý t
Rbcc; 
53 
g
I
I I
Together, these data indicate that the conditional deletion of Rb andp53 in mice
possessing the OSX-Cre transgene causes primarily osteosarcoma and neuroendocrine
tumor formation. Osteosarcomas from these mice exhibit similarities to human tumors
and represent the first mouse model of osteosarcoma possessing mutations in these two
tumor suppressors. Future experiments to further characterize these tumors and their
potential metastatic development are ongoing and will provide valuable insight into the
formation and malignant development of this particular tumor type.
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Appendix B
Mesenchymal cell tumor development in mice conditionally deleted for Rb and p53
with the Prx-Cre transgene
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The author contributed all text, graphs, and figures. Paul Danielian contributed to the
data collection necessary for the Kaplan-Meier curve and has continued the work on this
project. Alicia Caron performed all of the histological sectioning. All work was
performed in the lab of Jacqueline Lees.
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RESULTS AND DISCUSSION
The retinoblastoma gene product, pRb, has a well known and defined role in
regulating cell cycle progression and exit (Classon and Harlow, 2002). This role is likely
the primary basis for its tumor suppressive properties. In addition, pRb functions in the
differentiation and development of several tissues, including those of mesenchymal
origin. For example, pRb functions to regulate the differentiation of brown fat versus
white fat (Hansen et al., 2004; Scime et al., 2005). In myocytes, pRb plays an important
role in the switch from proliferation to differentiation (Huh et al., 2004). Finally, in vitro
experiments and our own data (Chapter 2) demonstrate that pRb functions to regulate
osteoblast differentiation (Thomas et al., 2001).
The role of pRb in vivo in these adult tissues has not been studied due to the
embryonic lethality of mice depleted of pRb (Clarke et al., 1992; de Bruin et al., 2003;
Jacks et al., 1992; Lee et al., 1992; Wu et al., 2003). Therefore, we mated conditional Rb
mutant mice (Rbcc) to mice carrying the Prx-Cre transgene, which expresses Cre
recombinase in mesenchymal progenitor cells (Logan et al., 2002). These conditionally
deleted mice (Rbc/c;Prx-Cre) survive into adulthood. We are currently beginning an in
depth study of the effect of Rb deletion in these adult tissues.
We are also interested in the role of pRb in tumorigenesis in these mesenchymal
cell types. To facilitate tumorigenesis, we crossed the conditional p53 allele (p53c/c) into
the Rbc/ ;Prx- Cre mice. Mice of all genotypes were born at the expected Mendelian
frequencies and displayed no abnormal phenotypes. Interestingly, only Rb/c,;p53c/c;Prx-
Cre mice (double mutant mice) have developed tumors at this point in the study (Figure
1). These mice have an average survival time of approximately 5.5 months. Histological
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Figure 1. Conditional double mutant mice exhibit an average survival of 5.5 months
Kaplan-Meier survival curve through 7.5 months. The preliminary data indicate that the
average survival of the conditional double mutant mice is approximately 5.5 months.
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analyses indicate that these mice develop sarcomas of various mesenchymal tissues,
including the fat, muscle, and bone. PCR analyses indicate that both Rb and p53 are
recombined in fat and muscle tumors and in bone tissue (Figure 2). As the cohort of mice
ages, it will be interesting to determine if any of the other genotypes in the study develop
tumors.
We focused our attention on the fat tumors, as these were the most common
tumor type observed in the double mutant mice. Hematoxylin and eosin (H&E) analysis
indicated that the tumors were comprised of brown adipocytes (Figure 3A,B). In
addition, we tested several fat tumors for the expression of various adipocyte markers.
We found that the fat tumors expressed general adipocyte genes, such as PPARy,
C/EBPa, and SREBP-1 c (Figure 4). In addition, these tumors demonstrated expression
of brown-fat specific genes, such as UCP-1, PPARa, and PGC-1. Therefore, these
analyses clearly indicate that the tumors are hibernomas.
Interestingly, we observed the progression of benign hibernoma cells into more
malignant ones within the same tumor (Figure 3A,B). Moreover, we observed metastatic
hibernomas, which we have termed hibernosarcomas, within blood vessels of the lung
(Figure 3C) and within the cardiac muscle (Figure 3D). Therefore, hibernomas, which
are rare and believed to be benign in humans, clearly have the potential to become more
malignant and metastatic in this mouse model system.
These data indicate that the conditional deletion of Rb and p53 in progenitor
mesenchymal cells using the Prx-Cre transgene is sufficient to induce tumors in
adipocytes, myocytes, and osteoblasts. The future analyses of single and double mutant
mice in this cohort will provide insight into the function of these genes in the
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Figure 2. DNA recombination of bone cells, hibemoma tissue, and rhabdomyosarcoma
tissue
PCR to detect the recombination of Rbc or p 5 3C alleles in various tissues of Prx-Cre
double mutant mice. The expression of Cre recombinase using the Prx promoter enables
the recombination of these alleles in cells of the bone, hibernoma (brown fat) tumor, and
rhabdomyosarcoma (muscle) tumor, all cells of a mesenchymal lineage.
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Figure 3. Conditional double mutant mice develop hibernoma
(A-D) Hematoxylin and eosin staining of hibernomas from conditional double mutant
mice. (A) Benign (pink staining) and malignant (arrowheads, purple staining) regions
within the same hibernoma. 10X magnification. (B) A 40X representation of the
indicated area in (A). (C) Metastatic hibernoma (arrow) in a blood vessel of the lung.
10X magnification. (D) Metastatic hibernoma (arrow) in the cardiac muscle. 10X
magnification.
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Figure 4. Hibernomas in conditional double mutant mice express brown fat markers
Tumors from conditional double mutant mice were analyzed for the expression of
adipocyte genes. Four separate hibernomas (as determined by H&E) demonstrated
expression of the adipocyte transcription factors PPARy, C/EBPa, and SREBP-1c. These
tumors also demonstrated induction of genes expressed in brown adipocytes but not white
adipocytes, including UCP- 1, PPARa, PGC- 1, and NRBF- 1. White adipose tissue
(WAT) and brown adipose tissue (BAT) from wild-type mice were used as controls. A
rhabdomyosarcoma (Rhab) from a conditional double mutant mouse is also shown, as are
a neuroendocrine tumor and two osteosarcomas from mice depleted of Rb and p53.
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development and maintenance of fat, muscle, and bone. Moreover, these studies will
expand our knowledge concerning the roles of Rb and p53 in sarcoma formation and
metastasis.
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Appendix C
The Rps4 proteins may function to monitor and regulate tubulin levels
Seth Berman and Frank Solomon
The author contributed all text, tables, and figures. All work was performed in the lab of
Frank Solomon.
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ABSTRACT
In the yeast Saccharomyces cerevisiae, the regulation of tubulin protein levels is
important not only to maintain a threshold level of heterodimer, but also to prevent an
excess of undimerized f3-tubulin, which is toxic to the cell. Excess 3-tubulin can arise as
a consequence of a number of genetic mutations. One example is the ca-tubulin mutant,
tubl-724, that destabilizes the tubulin heterodimer, thereby giving rise to free, toxic P3-
tubulin. Below 250 the destabilization is exacerbated, increasing the amount of free P3-
tubulin and causing lethality. I used cells containing tubl-724 as the sole ca-tubulin gene
to screen for genes that are important for the regulation of tubulin levels. I found that
deletion of the gene encoding the 40S ribosomal subunit protein, Rps4Ap, suppresses the
cold sensitivity conferred by the tubl-724 mutation. Moreover, deletion of RPS4A delays
the kinetics of death stemming from overexpression of P-tubulin. Our data demonstrate
that rps4aA causes an upregulation of tubulin mRNA, and consequently, of tubulin
protein. This upregulation is suppressed by deletion of the prefoldin subunit, PACIO,
providing genetic evidence for a signaling pathway responsible for changes in tubulin
transcription. Furthermore, the transcription factor, CIN5/YAP4, is important for the
increase in tubulin mRNA. We discuss the possibility that RPS4A may be involved in a
pathway to monitor and regulate tubulin levels.
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INTRODUCTION
Microtubules are important for many cellular functions. For example,
intracellular localization of various proteins relies on or is facilitated by microtubules
(Campbell and Hope, 2003); transport of some organelles, such as melanosomes, also
requires microtubules (Maniak, 2003); cell motility and sensory signaling mediated by
cilia or flagella are microtubule-based (Scholey, 2003); and the faithful segregation of
sister chromatids during mitosis requires functional microtubules (Zhou et al., 2002).
In order to perform such a diverse set of cellular activities, microtubule dynamics
must be properly regulated. Some proteins are involved in the stabilization of
microtubules. Tau and other microtubule-associated proteins (MAPs) drive microtubule
assembly through stabilization of microtubules and an increase in rescue frequency
(Panda et al, 1995). Several other proteins act to perform the opposite task of
destabilizing microtubules. XKCM1 promotes catastrophe (Walczak et al, 1996), while
katanin severs microtubules in order to promote depolymerization (McNally and Thomas,
1998). This repertoire of proteins allows the cell to properly regulate microtubule
assembly and dynamics, thereby supporting several biological processes.
Various proteins and complexes possess activities that affect the formation of the
a-1-tubulin heterodimer, the subunit comprising the microtubule polymer, indicating that
these activities are important for microtubule assembly and function. The cytosolic
chaperonin (CCT/TriC) is an essential protein complex involved in the folding of many
polypeptides including tubulin (Dunn et al, 2001; Llorca et al., 2000). The
GimC/prefoldin complex binds to and stabilizes nonnative polypeptides, including actin
and tubulin, to prevent aggregation and assist the CCT in the proper folding of these
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substrates (Geissler et al., 1998; Vainberg et al., 1998). In S. cerevisiae, the gene PLPI
encodes a protein that is involved in the early steps of P-tubulin folding, specifically
(Lacefield and Solomon, 2003). Finally, several cofactors have been shown to act in
heterodimer exchange in vitro (Tian et al., 1997), suggesting a possible pathway for
heterodimer formation in vivo. However, in S. cerevisiae these cofactors are not essential
(Archer et al.., 1995; Fleming et al., 2000; Hoyt et al., 1997; Stearns et al., 1990),
indicating that another mechanism for facilitating heterodimer formation exists in S.
cerevisiae.
Although dedicating all of these proteins to the proper folding of heterodimer may
seem excessive, the efficient formation of tubulin heterodimer is essential for the cell.
First, the cell requires a certain level of heterodimer in order to maintain the proper
number and length of microtubules to function. Remarkably, S. cerevisiae diploid cells
grow as well as wild-type cells do with only 50% of the normal levels of tubulin (Katz et
al., 1990). Nevertheless, a threshold level of tubulin heterodimer must exist in order for
the cell to be viable. This is supported by the finding that a yeast strain possessing very
low levels of tubulin displays mitotic defects (Lacefield et al., 2006). Second, properly
folded but undimerized P-tubulin is toxic to yeast cells (Burke et al., 1989; Weinstein and
Solomon, 1990). At sufficiently high levels, the 3-tubulin excess results in an
irreversible G2/M cell-cycle arrest and cell lethality. A large excess of cC-tubulin, on the
other hand, has few if any negative consequences to the cell (Katz et al., 1990; Weinstein
and Solomon, 1990). Why P-tubulin is lethal is not understood. Regardless, it is clear
that the cell must efficiently form heterodimer and regulate the levels of tubulin.
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Studies concerning the regulation of tubulin levels in cells have suggested that an
autoregulatory pathway exists in response to changes in tubulin levels. Addition of
microtubule depolymerizing drugs or injection of free tubulin polypeptide causes a
decrease in both a- and P-tubulin mRNA levels (Ben-Ze'ev et al., 1979; Cleveland,
1983; Cleveland et al., 1981; Magendantz and Solomon, unpublished results).
Conversely, addition of vinblastine, a drug that aggregates tubulin, causes an increase in
tubulin synthesis (Ben-Ze'ev et al., 1979). In order to determine the mechanism of this
autoregulation, the downregulation of tubulin was studied in more detail.
In animal cells with increased levels of tubulin heterodimer, one mechanism
responsible for the downregulation of f3-tubulin message occurs cotranslationally
(Pachter et al., 1987). The data suggest that a ribonuclease recognizes and degrades 3-
tubulin mRNA that is being translated by polysomes (Pachter et al., 1987). For a-
tubulin, a significant amount of the decrease in mRNA observed in whole cells was not
observed in enucleated cells (Pittenger and Cleveland, 1985). Therefore, other regulatory
mechanisms must exist to affect the levels of tubulin within the cell.
Upregulation of mRNA levels is another method of tubulin regulation that has
been implicated in S. cerevisiae (Lacefield et al., 2006). Deletion of the genes PACIO, a
member of the prefoldin complex, and PLP1 causes a significant percentage of 3-tubulin
to improperly fold and aggregate. The decrease in functional P-tubulin causes the cells to
possess a limited amount of tubulin heterodimer. To maintain levels of heterodimer
above the threshold necessary to prevent mitotic phenotypes, the cells upregulate the
levels of P-tubulin mRNA. Initial experiments suggest that the half-life of P-tubulin
mRNA does not increase in these cells (Lacefield et al., 2006). Although other
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experiments are necessary to more definitively rule out a change in mRNA stability as the
underlying mechanism, the current data implicate a transcriptional upregulation as the
cause of the increased P1-tubulin mRNA levels.
We are using S. cerevisiae to study the regulation of tubulin levels. In the yeast S.
cerevisiae, the regulation of tubulin levels is important not only to maintain a threshold of
heterodimer, but also to prevent an excess of undimerized 3-tubulin, which is toxic to the
cell. The a-tubulin mutation, tubl-724, weakens the heterodimer association, thereby
giving rise to free, toxic P-tubulin (Schatz et al., 1988; Vega et al., 1998). In
temperatures below 250 the amount of free P-tubulin is increased, causing lethality. We
used yeast carrying the tubl-724 mutation as their only source of a-tubulin to screen for
genes that are important for the regulation of tubulin levels. We found that deletion of
the gene RPS4A suppresses the cold sensitivity conferred by the tubl-724 mutation.
RPS4A is a member of the 40S ribosomal small subunit (26-Warner and Gorenstein,
1978). We demonstrate that deletion of RPS4A causes an increase in a- and 3-tubulin
mRNA levels and consequently, in protein levels. The following data suggest that this
rps4a-mediated upregulation in tubulin mRNA levels occurs through the purported
transcription factor, CIN5.
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RESULTS
Deletion of RPS4A rescues cells with tubl-724 from cold sensitivity.
To find genes involved in the regulation of tubulin levels, I screened for
insertional mutations that would rescue cells from the cold-sensitivity conferred by the
tubl-724 mutation (Schatz et al., 1988; Vega et al., 1998). tubl-724 is an a-tubulin
mutation that destabilizes the heterodimer, thereby increasing the amount of free, toxic 3-
tubulin in the cell. Below 250 the destabilization is exacerbated, further increasing the
amount of free P-tubulin and ultimately causing lethality. Using a yeast strain possessing
tubl-724 as its only source of a-tubulin, I screened for genes that, when disrupted, would
allow the yeast to grow even at 180.
Genetic disruption of genes was accomplished by using the mTn-lacZ/LEU2
insertion library (Burns et al., 1994). I recovered one independent insertion in the RPS4A
locus that allowed for cell survival at 180, but interestingly, not at 150 (Figure 1B & C).
It is noteworthy to mention that I do not believe this screen was saturated, as I screened
with only -2X coverage and know that at least one other gene disruption would satisfy
the screen (see below) but was not recovered.
An independent knockout of the RPS4A locus confirmed that deletion of the gene
rescued cells from tubl-724 cold-sensitivity at 180 (Figure 1B). RPS4A is a member of
the 40S ribosomal small subunity (Warner and Gorenstein, 1978). It is eukaryotic-
specific, and its localization and function within the ribosome are not known. S.
cerevisiae possess a gene, RPS4B, that is nearly identical to RPS4A, possibly due to the
hypothesized duplication of the yeast genome (Wolfe and Shields, 1997). I tested for
rescue of tub1l-724 cold sensitivity by deletion of RPS4B (Figure IB) and found that the
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Figure 1. rps4aA and rps4bA rescue cells from cold-sensitivity conferred by tubl-724
(A) Yeast strains were streaked onto standard YPD plates and grown for two days at 300.
(B) After 6 days at 180, cells possessing tubl-724 as their only source of a-tubulin are
dead. Deletion of either RPS4A or RPS4B, but not RPSOA, suppresses the tubl-724 cold-
sensitivity. (C) rps4aA and rps4bA cannot suppress the tubl-724 lethality at 150. Wild-
type and rps4aA control strains are viable. Cells were allowed to grow for 14 days.
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degree of rescue was similar to that by rps4ad. All other experiments performed using a
deletion of RPS4B were comparable to those using rps4ad. Therefore, I focused on
deletion of RPS4A and will discuss results pertaining to rps4ad for the remainder of this
work.
In order to test the specificity of the tubl-724 cold sensitivity rescue, I deleted
another ribosomal subunit, RPSOA. This gene is a member of the 40S ribosomal small
subunit like RPS4A. Deletion of RPSOA produces similar growth and size phenotypes in
the cells as is observed by deletion of RPS4A (see below). Finally, there is a nearly
identical gene, RPSOB, to RPSOA in the yeast genome. I tested whether deletion of
RPSOA could rescue cells containing tub1-724 at 180. As shown in Figure IB, deletion of
RPSOA does not provide any observable increase in viability compared to tub]-724 cells
alone. Therefore, the suppression of tubl-724 cold sensitivity may be specific to deletion
of RPS4A/B, and not to the deletion of any ribosomal gene.
rps4aA cells exhibit phenotypes similar to those caused by mutations affecting
translational efficiency and ribosome function.
It was not obvious why the deletion of a particular ribosomal gene would suppress
the cold sensitivity conferred by tubl-724. Perhaps deletion of RPS4A affected mitosis,
the phase in the S. cerevisiae cell cycle when microtubule function is essential, in a
manner that could allow tubl-724 cells to grow at 180. Performing some initial
characterization of rps4aA in an otherwise wild-type background with wild-type a-
tubulin, I tried to gain insight into the mechanism of the tubl-724 suppression. As shown
in Figure 2A, cells deleted for RPS4A were slow growing compared to wild-type cells.
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Figure 2. rps4aA cells are slow-growing, small in diameter, and experience delays in GI
compared to wild-type cells
(A) Wild-type and rps4aA cells were grown in YPD media over a time-course to obtain a
growth curve. Cell counts (yeast/ml) were obtained every hour during mid-log phase
growth. Numbers adjacent to each curve on the graph represent the calculated doubling
time (in minutes) for each cell type. (B) Wild-type and rps4aA cells were grown in YPD
and samples were taken during mid-log phase growth. Samples were fixed and
visualized under DIC. OpenLab software was used to calculate the diameter of
unbudded, G1 cells. Approximately 100 unbudded cells were measured for each cell
type. A representative image of cells for each strain is shown. Error bars represent one
standard deviation. (C) Wild-type and rps4aA strains were grown asynchronously to log
phase, stained with DAPI, and visualized to determine cell cycle distribution. Error bars
represent one standard deviation. Asterisks represent p-values < 0.05 using a pooled t
test.
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rps4ad cells were also smaller in diameter than wild-type cells (Figure 2B), a result that
is contrary to a report indicating that rps4ad cells are larger than wild-type cells
(Jorgensen et al., 2002). Finally, cells deleted for RPS4A experience a delay in the G
phase (when yeast display no bud) of the cell cycle compared to wild-type cells (Figure
2C). The increase in the number of cells in GI corresponds to a roughly equivalent
decrease of cells in the G2/M phase of the cell cycle. These data do not suggest that
mitosis is affected in rps4ad cells. Instead, these phenotypes are more typical of those
observed in yeast when translational efficiency is perturbed. By deleting RPS4A, it is
possible that the amount of the RPS4A/B subunit is reduced, leading to fewer ribosomes,
less protein synthesis, and hence slower growth and a delay in GI as cells take longer to
grow. This is supported by the fact that rpsOad cells exhibited similar phenotypes (data
not shown).
Deletion of RPS4A delays the kinetics of death in cells overexpressing P-tubulin.
I next tested whether deletion of RPS4A could rescue cells from excess P-tubulin,
an experiment to determine more directly the mechanism underlying the suppression of
tubl-724 cold sensitivity by rps4aA. For this experiment, an extra copy of the P-tubulin
gene, TUB2, was recombined into a wild-type yeast strain adjacent to the endogenous
TUB2 locus. This extra copy of TUB2 is behind the GAL] promoter. Therefore, when
grown on glucose the cells have wild-type levels of 3-tubulin. When the cells are grown
on galactose, (3-tubulin is highly overexpressed causing an irreversible G2/M arrest after
4 hours (Figure 3). When RPS4A is deleted in this genetic background, the cells arrest
and become inviable similar to the control cells. However, the deletion of RPS4A causes
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Figure 3. Deletion of RPS4A delays the kinetics of death from P-tubulin overexpression
Wild-type and rps4aA strains containing an integrated galactose-inducible P-tubulin gene
were grown in raffminose to early log phase. Galactose was added at time zero to induce
P-tubulin expression. At the given time points, cells were plated to glucose to repress the
galactose promoter. After two days of growth, cell colonies were counted and plating
efficiency was calculated.
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a delay in the kinetics of the toxic, P-tubulin-induced death by approximately two hours
(Figure 3). This result is not due to the slow-growth of rps4aA, as the deletion of the
gene NEW] exhibits a similarly slow growth rate but does not affect the kinetics of death
in this assay (data not shown). Although this data demonstrates that rps4aA does not
render cells immune from toxic P3-tubulin, it does indicate that deletion of RPS4A may
rescue cells from slight excesses of P3-tubulin.
rps4aA causes an upregulation of tubulin protein and mRNA.
Previous work in our lab has shown that changes to the levels of tubulin can affect
the cell's sensitivity to 3-tubulin. I performed Western analysis to quantitate the levels of
ca- and P3-tubulin protein in rps4aA cells relative to wild-type cells. To achieve this, I
normalized the intensity of the tubulin bands against that of the internal control,
carboxypeptidase (CPY). As shown in Figure 4A, both ca- and P-tubulin protein levels
are increased relative to those in wild-type cells. Notably, the increase in protein was
slightly greater for a-tubulin than for P-tubulin. To ensure that the protein increase was
due to rps4ad, I transformed a plasmid containing the wild-type copy of RPS4A into the
rps4aA strain. Adding RPS4A back into the rps4aA yeast abrogated the increase in
tubulin protein (data not shown).
Since deletion of RPS4A presumably affects the ribosome, one plausible
explanation for the increase in tubulin protein is that tubulin is being more efficiently
translated. However, other possibilities exist, such as a change in tubulin mRNA levels.
To test this latter hypothesis, I performed RNAse Protection Assays (RPAs) to quantitate
the levels of tubulin mRNA in rps4aA cells relative to wild-type cells. CPY was used as
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Figure 4. Deletion of RPS4A upregulates a- and P-tubulin mRNA and protein levels.
(A) Extracts from wild-type and rps4aA cells were taken during log phase growth and
analyzed for levels of a-tubulin, 0-tubulin, and carboxypeptidase (CPY) protein by
immunoblotting. As an internal control, tubulin levels were normalized to the levels of
CPY. Normalized wild-type tubulin levels were defined as 100 percent. Values were
obtained from three separate experiments. Error bars represent one standard deviation.
Representative immunoblots are shown. (B) mRNA levels for a-tubulin, P-tubulin, and
CPY were obtained using a ribonuclease protection assay (RPA). RNA extracts from
wild-type and rps4aA cells were obtained during log phase growth. Levels of tubulin
message were normalized to CPY levels, and wild-type tubulin levels were defined as
100 percent. Values were obtained from four separate experiments. Error bars represent
one standard deviation. Representative one-hour radioactive exposures are shown.
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an internal loading control for the RPAs in the same manner as was done for the
Westerns. As illustrated in Figure 4B, the mRNA levels of both a- and P-tubulin are
increased in rps4aA cells compared to wild-type cells. This mRNA increase is roughly
comparable to the increase in tubulin protein. Together, these data demonstrate that
deletion of RPS4A causes an upregulation of a- and P-tubulin mRNA, which
consequently results in an increase in tubulin protein.
Deletion of the prefoldin component, PACO1, suppresses the rps4aA-mediated
upregulation of tubulin mRNA.
The deletion of various genes can alter the levels of tubulin mRNA and protein
(Alvarez et al., 1998; Lacefield and Solomon, 2003). It is possible that deletion of
RPS4A may affect one or more of these genes or their substrates, thereby leading to the
increased tubulin levels. To see whether deletion of RPS4A interacts genetically with
these genes, I created several combinations of mutants and performed RPAs.
The two genes of interest that I tested with rps4aA were PACIO and PLP1.
PACIO 0 is a member of the prefoldin complex that facilitates in the folding of a- and P-
tubulin. As shown in Figure 5, deletion of PACIO causes a decrease in both a- and 3-
tubulin mRNA relative to wild-type cells. The cause of this decrease is not understood.
If PACIO is deleted in combination with RPS4A, the rps4aA-mediated upregulation of
tubulin is suppressed.
PLP1 is involved in the folding of P-tubulin polypeptide specifically. Deletion of
PLP1 alone does not significantly alter the levels of tubulin compared to wild-type
(Figure 5). When deleted in combination with rps4aA, unlike deletion of PACIO, the
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Figure 5. pacl0A, but not plplA, suppresses the rps4aA-mediated upregulation of
tubulin mRNA.
RNA extracts of yeast strains were obtained during log phase growth and analyzed for
levels of a- and 3-tubulin by RPA, as described in Figure 4B. Values of tubulin levels
for each strain were obtained from up to four separate experiments. Error bars represent
one standard deviation.
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rps4aA-mediated upregulation of a- and P3-tubulin is not suppressed. These data indicate
that PA C10 or one of its substrates affects the pathway leading to tubulin upregulation in
rps4aA cells.
Folding defects are not the signal to upregulate tubulin levels in rps4aA cells.
If PAC10 or PLP1 is deleted in yeast, some of the tubulin polypeptides do not
fold properly and form a non-functional aggregate (Abruzzi et al., 2002; Lacefield and
Solomon, 2003). When these genes are deleted in combination, P-tubulin folding is
severely hindered. This causes significant aggregation of P-tubulin polypeptide and
consequently, very low levels of functional tubulin heterodimer. It is hypothesized that
the levels of heterodimer in pacl OA plpl A fall below a certain threshold, and this results
in a signal to upregulate the levels of P-tubulin mRNA (Figure 5; Lacefield et al., 2006).
During translation, nascent polypeptides can be bound by a chaperone present at
the polypeptide exit site of the ribosome (Hartl and Hayer-Hartl, 2002). It is possible that
deletion of the ribosomal gene, RPS4A, may affect the association of the chaperone with
the ribosome, and thereby affect the proper folding of tubulin polypeptides. This, in turn,
could result in a signal for the upregulation of tubulin mRNA in the rps4aA cells. To test
for this possibility, I ran cellular extracts from wild-type and rps4aA cells on a gel-
filtration column. In wild-type cells, almost 100% of the tubulin runs in a single
heterodimer peak (Figure 6A). Cells deleted for RPS4A, on the other hand, exhibited
tubulin running in two peaks. Most of the a- and P-tubulin ran as heterodimer, but the
remaining 15% of the tubulin ran as a second peak in the void volume of the column,
indicative of aggregated tubulin (Figure 6B). Thus, rps4aA cells do possess aggregated
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Figure 6. rps4aA cells contain a small percentage of aggregated tubulin.
(A) Wild-type cell extracts were resolved on a Sephacryl 300S column. Fractions were
analyzed for a- and P3-tubulin by immunoblot. The graph represents the percentage of
total tubulin present in each individual fraction. Aggregated tubulin ran in the void
volume of the column, separate from the heterodimer peak. (B) Extracts from rps4aA
cells were analyzed for aggregated tubulin as described in (A).
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tubulin. However, even if the hypothesized folding defects are causing 15% of the
tubulin to aggregate in rps4aA cells, such a decrease in heterodimer is not enough, based
on previous data, to cause a signal for upregulation of tubulin mRNA.
CIN5 is required for at least part of the tubulin upregulation in rps4aA cells.
Figure 5 shows that when PACIO 0 and PLPI are deleted in combination, P-tubulin
mRNA levels are upregulated. Deletion of RPS4A did not further increase 3-tubulin
levels or affect a-tubulin expression in these cells, which was expected since deletion of
PACIO abrogates any upregulatory effects caused by rps4ad. We were interested in
determining the mechanism of this mRNA upregulation in pacl0A plplA cells. Time
course experiments to measure changes in the stability of TUB2 message indicated that
the half-life of P-tubulin mRNA in paclO pplplA cells is similar to that in wild-type cells
(Lacefield et al., 2006). Thus, it seems likely that the increase in 3-tubulin mRNA is due
to a transcriptional upregulation. Further work demonstrated that deletion of the
purported transcription factor, CIN5/YAP4, suppresses the 3-tubulin upregulation.
CIN5/YAP4 is a member of a family of yeast genes that are homologous to the
AP- 1 family of transcription factors. CIN5 contains a bZIP DNA binding domain at its
C-terminus, and Cin5p binds to the YAP DNA site in vitro (Fernandes et al., 1997).
Cin5p is localized to the nucleus and to the cytoplasm (Furuchi et al., 2001; Huh et al.,
2003; Kumar et al., 2002). Intriguingly, both a- and P-tubulin possess YAP-like sites
within 100 basepairs of their start codon. Therefore, it is plausible that Cin5p may be the
transcription factor responsible for tubulin upregulation in the pacl OA pplA double
mutant cells.
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I tested to determine whether CIN5 is also required for the a- and P-tubulin
upregulation in rps4aA cells. Using RPAs, I compared the levels of tubulin mRNA in
cells deleted for both RPS4A and CIN5 relative to wild-type or rps4aA cells. As observed
previously, deletion of RPS4A alone caused an increase in both a- and P3-tubulin message
compared to wild-type cells. When CIN5 was deleted in the rps4aA cells, the mRNA
increase was significantly suppressed to levels closer to that observed in wild-type cells
(Figure 7A).
To determine if the changes in mRNA levels corresponded to alterations in
tubulin proteins levels, I performed Western analysis on these cells. Similar to the
observed effect on mRNA levels, deletion of CIN5 in the rps4aA cells significantly
suppressed the rps4aA-mediated increase in tubulin protein (Figure 7B). These data
demonstrate that CIN5 is required, at least in part, for the upregulation of ca- and [P-
tubulin mRNA, and consequently protein, in rps4aA cells.
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Figure 7. CIN5 is necessary for at least part of the mRNA, and consequently the protein,
upregulation in rps4aA cells.
(A) Total RNA extracts from wild-type, rps4aA, and rps4aA cin5A cells were obtained
during log phase growth and analyzed for a-tubulin, 13-tubulin, and CPY mRNA levels
by RPA, as described in Figure 4B. Values were obtained from four separate
experiments. Error bars represent one standard deviation. (B) Extracts from wild-type,
rps4aA, and rps4aA cin5A yeast strains were obtained during log phase growth. Protein
levels of a-tubulin, 13-tubulin, and CPY were determined by immunoblot, and normalized
values were calculated as described in Figure 4A. Values were obtained from up to five
separate experiments. Error bars represent one standard deviation.
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DISCUSSION
The data presented here support the hypothesis that perturbations to the ribosome
can affect the mRNA levels of tubulin in S. cerevisiae. Deletion of the RPS4A or RPS4B
gene results in an upregulation of TUB1 and TUB2, which encode a- and P-tubulin,
respectively. The upregulation in tubulin mRNA accounts for the observed increase in
tubulin protein in rps4aA cells. We have further shown that this upregulation occurs, at
least in part, through the transcription factor, CIN5.
We identified RPS4A in a screen for genes that, when disrupted, rescue cells
containing the a-tubulin mutation tubl-724 (Schatz et al., 1988; Vega et al., 1998). The
tubl-724 allele contains a point mutation in codon 106, changing the amino acid from
threonine to arginine. This amino acid may contact the non-exchangeable GTP at the a/P
interface, and thereby weaken the association of the a- and P-tubulin monomers within
the heterodimer (Vega et al., 1998). When yeast cells are placed in temperatures below
250, the microtubules depolymerize more readily than at the permissive temperature of
300. If the yeast cells contain the tubl-724 allele, then the microtubule depolymerization
at these colder temperatures releases more of the weakened heterodimer, which can then
dissociate into free ct- and P-tubulin monomers. The free, toxic P-tubulin causes the cells
to be inviable at temperatures below 25'. It is also possible that dissociation of the
heterodimer at cold temperatures decreases the amount of tubulin heterodimer below a
critical threshold level. However, in cells containing tubl-724, loss of viability as a
consequence of low heterodimer levels has not been conclusively demonstrated . We
found that deletion of RPS4A suppressed the cold-sensitivity conferred by the tubl-724
allele at temperatures as low as 180 (Figure 1).
268
When RPS4A is deleted in tubl-724 cells, the tubulin protein is upregulated,
thereby increasing the amount of heterodimer. Deletion of RPS4A also causes a slightly
greater upregulation of a-tubulin compared to P-tubulin (Figure 4). The extra a-tubulin
can bind to and sequester toxic P-tubulin. Therefore, by increasing tubulin heterodimer
levels or by P-tubulin sequestration, or by both mechanisms, the deletion of RPS4A
rescues cells containing tubl-724 at 180.
Interestingly, the rescue of tubl-724 cold sensitivity by rps4aA occurs at 18' but
not 150 (Figure 1). At 15' the dissociation of heterodimer may be greater than at 180. At
this lower temperature, the upregulation of tubulin by rps4ad may no longer be great
enough to overcome the increase in toxic P3-tubulin and the potential loss of heterodimer
caused by tubl-724. A similar idea can explain how deletion of RPS4A affects cells
overexpressing P-tubulin (Figure 3). When yeast cells containing a GAL 1-promoted
TUB2 gene are placed in galactose, P-tubulin is overexpressed, creating high levels of
toxic P-tubulin. Deletion of RPS4A causes a slight increase of a-tubulin, which can
sequester away the toxic P3-tubulin. However, the increase in a-tubulin is slight, and
therefore the deletion of RPS4A can only delay the kinetics of death from toxic P-tubulin
for approximately two hours (Figure 3). The delay is not due to the slow growth of
rps4aA (Figure 2) because deletion of another gene, NEW1, that causes a similar rate of
slow growth in our yeast strains does not delay the kinetics of death from TUB2
overexpression. This experiment and those utilizing the tubl-724 allele demonstrate that
rps4ad rescues cells from tubulin-related defects through upregulation of a- and P-
tubulin.
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Given that deletion of RPS4A causes an upregulation of tubulin levels, we sought
out the signal for the upregulation. One possibility is low levels of tubulin heterodimer.
There is precedent for heterodimer levels being correlated to changes in tubulin monomer
levels. Vinblastine is a drug that causes tubulin to aggregate, thereby decreasing
heterodimer levels. When vinblastine is added to animal cells, synthesis of tubulin
increases (Ben-Ze'ev et al., 1979), although this increase is via protein synthesis, a
mechanism different than what we observe in yeast cells. In S. cerevisiae, deletion of
RPS4A causes an increase in tubulin protein via a corresponding increase in mRNA
levels. This mRNA increase is likely to be transcriptional, as the tubulin mRNA half-life
does not appear to change upon mRNA upregulation (data not shown). Regardless of the
difference in mechanism, the initial signal for tubulin upregulation in both animal cells
and yeast may be low levels of tubulin heterodimer.
We tested the possibility that rps4aA cells have low levels of tubulin heterodimer
by measuring the amount of tubulin aggregate in the cells. Excess or misfolded tubulin
monomers often aggregate into a form that elutes in the void volume of a size-exclusion
column (Abruzzi et al., 2002; Lacefield and Solomon, 2003). The more tubulin that is
present in the aggregate, the less tubulin that exists as heterodimer. We found that cells
deleted for RPS4A possessed some a- and P-tubulin in an aggregated form (Figure 6).
However, the aggregate comprised only -15% of the total tubulin in the cell. Given the
fact that diploid yeast with 50% of the wild-type levels of tubulin heterodimer can
survive without any upregulation of tubulin mRNA (Katz et al., 1990), it is unlikely that
rps4aA cells signal for an upregulation of tubulin due to the -15% tubulin aggregate.
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It is possible, instead, that perturbations to the ribosome in rps4aA cells could be
the signal to trigger an upregulation of tubulin. Each cell contains 200,000 ribosomes
and synthesizes 2000 new ribosomes per minute due to their high turnover (Warner,
1999). Any perturbation to the function of ribosomes, such as deletion of one of its
subunits, results in a significant decrease in the number of ribosomes. Fewer ribosomes
cause lower overall protein synthesis, slower growth, and a smaller average cell size,
phenotypes observed in cells deleted for RPS4A (Figure 2). By deleting RPS4A, the
number of ribosomes may be decreased, consequently affecting the efficient translation
of proteins. This may be detrimental to rps4aA cells, and therefore the cells may signal
for various biological changes in order to respond to the new translational stress. In fact,
it is not unprecedented that ribosomal subunits monitor ribosomal biosynthesis and signal
for certain cellular changes if necessary. Deletion of RPS6 blocks cell proliferation in
mice (Volarevic et al, 2000). In human cells RPL11 interacts with and regulates HDM2
activity, thereby leading to activation of p53 (Lohrum et al., 2003). Indeed, individual
ribosomal proteins have been implicated in a wide range of biological functions,
including cell-cycle progression, apoptosis, DNA damage response, and tumorigenesis
(Amsterdam et al., 2004; Lohrum et al., 2003; Sonenberg, 1993; Volarevic et al., 2000).
For several of these cellular processes, microtubule function is essential. Therefore, it is
reasonable to postulate that a ribosomal protein may be directly responsible for the signal
to upregulate tubulin in order to maintain the necessary amount of heterodimer for proper
microtubule function. In the yeast S. cerevisiae, RPS4A could possess this function.
However, more experiments are necessary to validate such a hypothesis.
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The data presented here indicate that the upregulation of tubulin protein is due to
an increase in mRNA levels. However, once the signal to upregulate tubulin levels is
triggered, what genes are involved in the signal cascade to effectuate that upregulation?
Our data indicate that PAC1O, a member of the prefoldin complex that facilitates in
folding tubulin polypeptides, may play a role in the signal cascade. Deletion of PACIO
suppresses the upregulation of a- and P-tubulin mRNA in rps4aA cells (Figure 5).
However, deletion of PLPI, a gene that functions in the folding of P3-tubulin specifically,
does not affect the rps4a-mediated tubulin upregulation. It is possible that PaclOp is
involved directly in the signaling pathway. It is also plausible that one of the prefoldin
substrates is involved, such as a kinase, phosphatase, or nuclear import factor. It will be
interesting to determine the components of the signal cascade leading toward the
upregulation of tubulin mRNA in rps4aA cells.
Finally, once the signal cascade is activated, what is the final downstream
effector? At this time the data do not support the hypothesis that the downstream effector
causes an increase in the half-life of the tubulin mRNAs (data not shown). Although this
is still a potential mechanism, we support the hypothesis that the downstream effector
causes an increase in tubulin mRNA through an upregulation in transcription. In this
case, the most likely candidate is a transcription factor. We found that the putative
transcription factor, CIN5, was responsible for at least part of the observed transcriptional
upregulation, as deletion of CIN5 abrogated the rps4a-mediated increase in tubulin
mRNA levels (Figure 7). CIN5 is a member of the AP-1 transcription factor family; it is
also known as YAP4 in S. cerevisiae. The protein contains a bZIP DNA binding domain
in its C-terminus, similar to other AP-1 transcription factor family members, and it has
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been shown to bind the YAP DNA binding site in vitro (Fernandes et al., 1997). Both the
a-tubulin (TUB]) and P-tubulin (TUB2) promoters contain YAP-like sites within 100
basepairs of the start codon. It is possible that CIN5 binds the tubulin promoters and
directly activates transcription when RPS4A is deleted. Attempts to determine whether
Cin5p binds to the tubulin promoters using chromatin immunoprecipitation techniques
have proven inconclusive thus far. One reason for this could be that in the original ChIP
experiment we used a CIN5 fusion protein whereby Cin5p was fused to three HA tags at
the C-terminus. This tag does not provide a strong signal in immunoprecipitation assays
or Western blots (data not shown). Other tags are currently being tested for these
experiments. However, it is also possible that CIN5 acts indirectly to initiate the
upregulation of tubulin mRNA. Further experiments are required to determine with more
certainty whether CIN5 is the ultimate downstream transcription factor responsible for
the tubulin upregulation in rps4aA cells.
We have demonstrated that deletion of RPS4A increases the levels of a- and P-
tubulin protein via a transcriptional upregulation of tubulin mRNA. At least part of this
transcriptional upregulation is mediated by the transcription factor, CIN5. Determining
the signal and downstream factors will be important aspects to pursue in order to gain
more insight into the mechanisms of tubulin regulation.
273
EXPERIMENTAL PROCEDURES
Yeast Strains and Media.
The strains used in this study are listed in Table 1. All strains are derived from FSY 183
(wild-type), FSY 625, or FSY 937. FSY 625 is a haploid segregant from a wild-type
diploid strain transformed with the LEU2-pGAL1-TUB2 DNA construct, similar to that in
FSY 875 (Alvarez et al., 1998). FSY 937 was generated via a plasmid swap to change
selective markers for the original tubl-724 plasmid in FSY 157 (Schatz et al., 1988).
Yeast were grown in standard media and manipulated using standard techniques (Guthrie
and Fink, 1991; Solomon et al., 1992). RPS4A, RPS4B, RPSOA, and PLP1 were deleted
using a PCR-based method (Longtine et al., 1998).
Plasmids.
Plasmids used in this study are listed in Table 1. pLV27 was created by restriction digest
of pRB624 (Schatz et al., 1988) with SphI and AatII. This fragment was then inserted
into the SphI and AatII restriction sites of YCpS50 (Rose et al., 1987). pSB53 was
designed using a PCR-amplified 1.9-kb fragment of the wild-type RPS4A ORF, promoter,
and 3' UTR. The sequences of the upstream and downstream primers, respectively, are
CCTTgtcgacGGGTACTGCATTTTTTCGATGTT and
AATgcggccgcGTCAATATGCGAACCATATAAGC. The amplified RPS4A fragment
was restriction digested with SalI and NotI (sites are listed as lower-case italics in the
primer sequences), and cloned into the plasmid, pRS316 (Sikorski and Hieter, 1989).
Mutagenesis.
FSY 937 cells (tubl:.:HIS3 tub3::TRP1 + tubl-724/URA3/CEN) were mutagenized with
the mTn-lacZ/LEU2 insertion library (Bums et al., 1994) according to the Yale Genome
274
~1 6*
aa
,
.~Ii .m
rfr~
P
ru·
aaY"3~~1J" ~t 9$a
15i~bd V1I~E3vl 4jI
.M.~ at,~y ~_
f-j
c-J
·9E
. E r-
,a -*
Ss, e
.... LLA
er ri -4 N. rj
ele
ejd~
NNN
ri r 4 r1 rjFr r,
r r4 r I
L. fLL L L,
w-, k 2i22-222t2r
e;r l r i$ -y -I -
rE-, ~~ C 4 m -
275
~ .CI rri ~~ c~; ~en*l~ rr C~1 "i3 =ss
s
Analysis Center protocol (http:i//ygac.med.yale.edli/). Library transformants were plated
to synthetic complete (SC) media lacking leucine (leu) at 300. Colonies were allowed to
grow for three days and were then replica plated to a new SC-leu plate at 180. To
determine the gene that was mutagenized by insertion, DNA preps were made from
transformed yeast that displayed growth after 5 to 7 days at 180. DNA preps were
digested with the HindIII restriction enzyme, which cuts between the LEU2 and AMPR in
the mTn insertion and also cuts randomly in the yeast genome. The digested DNA was
then ligated to form circularized fragments. Two primers were used to PCR amplify
around the circularized DNA beginning at the AMPR gene. Since the AMPR gene is not
present in the yeast genome, the primers only amplify around circularized DNA
fragments containing the mTn insertion. The sequences for the primers used were
CACGACGGGGAGTCAGGCAACTATGGATG (forward primer) and
GTAACCCACTCGTGCACCCAACTGATCTTC (reverse primer). The PCR amplified
DNA was run on a 0.8% agarose (UltraPure Agarose, Invitrogen) gel and purified with a
Qiaex II Gel Extraction Kit (Qiagen).
DNA sequencing.
Sequencing of the PCR purified transposon-inserted candidate alleles was performed by
the MIT Biopolymers facility.
Growth rates, cell size measurements, and cell cycle distributions.
Wild-type (FSY 183) and rps4aA (SBY 564) cells were grown overnight in YPD media
(1% yeast extract, 2% peptone, and 2% glucose) to saturation. Cells were counted the
next day and pulled back to early log phase density (3*106 yeast per ml). After one hour
of recovery time, cells were counted hourly (5 hours total) to determine the growth rate.
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After 3 hours, samples were taken for cell diameter measurements and cell cycle
distribution analysis. Samples were fixed using fix solution (3.7% formaldehyde in
PBS). For cell cycle distribution, fixed yeast were then spun down (14000 rpm for 10
seconds) and resuspended in a 1:1000 dilution of DAPI. Diameters of unbudded cells
were measured using OpenLab 3.02 software from DIC images of cells. 89 wild-type
cells and 102 rps4ad cells were measured for cell diameter. If cells were not circular, the
long axis was measured. For cell cycle distribution analysis, four separate experiments
were conducted, each experiment counting 300 cells for each strain. Cells were split into
one of three categories, unbudded (GI), small to medium budded (S/G2), and large
budded (G2/M). DAPI, which stains nuclei, was used to assist in differentiating between
late S phase (medium bud) and G2/M phase cells (large bud).
Viability assay.
FSY 625 and SBY 561 were grown overnight in YPRaff (2% raffinose) media at 300.
Log phase cells were then induced with 2% galactose. At various time points, aliquots of
cells were taken and counted using a haemocytometer. Known numbers of cells were
then plated to YPD plates and grown for two days at 300. Cell viability was measured as
the number of cells able to form colonies on the YPD plates.
Immunoblots.
Standard procedures were followed for immunoblotting (Abruzzi et al., 2002; Solomon et
al., 1992). Antibody 345 was used against a-tubulin (Schatz et al., 1987) and antibody
206 was used against t3-tubulin (Bond et al., 1986). Anti-carboxypeptidase (CPY)
antibody was provided by H Ploegh. Band intensities were measured using blue
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fluorescence imaging (Storm System; Molecular Dynamics) and quantitated using
ImageQuant 1.2. Tubulin protein levels were normalized to CPY.
RNase Protection Assay.
Total yeast RNA was prepared from cells growing at log phase using a phenol extraction
procedure (Ausubel et al., 1989). Antisense RNA probes for TUB], TUB2, and CPY
mRNAs were obtained using the Maxiscript In Vitro Transcription Kit (Ambion). The
RPA1 1 kit from Ambion was used to perform the assay with between 5 and 20 ptg of
yeast RNA. Protected fragments were run on urea polyacrylamide denaturing gels. The
gels were dried and analyzed using phosphorimaging (Storm System; Molecular
Dynamics). Band intensities were quantitated using ImageQuant 1.2.
Gel filtration chromatography.
Wild-type and rps4aA cells were grown in YPD until mid-log phase (2*107 yeast per ml)
at 300. Approximately 1010 cells were prepared as previously described (Archer et al.,
1998), except that 10% glycerol was added to the lysis buffer. The cells were lysed using
a French press. A 0.5 ml volume of cell lysate was immediately injected into a Sephacryl
300S HR column (Amersham Biosciences) packed in MES buffer (80 mM
morpholineethanesulfonic acid, I mM MgCI2, 1 mM EGTA, 0.2 mM GTP [pH 6.85]) at
40. The column was run with MES buffer at 0.5 ml/min, and 1.0 ml fractions were
collected with a Bio-Rad Econo Pump and fraction collector. The column was calibrated
using blue dextran (void volume), ovalbumin, and BSA as sizing standards (Amersham
Biosciences).
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